0001079973-21-000818.txt : 20210820 0001079973-21-000818.hdr.sgml : 20210820 20210819174105 ACCESSION NUMBER: 0001079973-21-000818 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210820 DATE AS OF CHANGE: 20210819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marijuana Co of America, Inc. CENTRAL INDEX KEY: 0001078799 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 870426858 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27039 FILM NUMBER: 211191156 BUSINESS ADDRESS: STREET 1: 633 W. 5TH STREET STREET 2: SUITE 2826 CITY: LOS ANGELES STATE: CA ZIP: 90071 BUSINESS PHONE: (888) 777-4362 MAIL ADDRESS: STREET 1: 633 W. 5TH STREET STREET 2: SUITE 2826 CITY: LOS ANGELES STATE: CA ZIP: 90071 FORMER COMPANY: FORMER CONFORMED NAME: CONVERGE GLOBAL INC/CA DATE OF NAME CHANGE: 19990806 10-Q 1 mcoa_10q-063021v2.htm FORM 10-Q
0001078799 false 12/31 2021 Q2 0001078799 2021-01-01 2021-06-30 0001078799 2021-08-19 0001078799 2021-06-30 0001078799 2020-12-31 0001078799 us-gaap:PreferredClassAMember 2021-06-30 0001078799 us-gaap:PreferredClassAMember 2020-12-31 0001078799 us-gaap:PreferredClassBMember 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2020-12-31 0001078799 2021-04-01 2021-06-30 0001078799 2020-04-01 2020-06-30 0001078799 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2019-12-31 0001078799 MCOA:PreferredStockClassBMember 2019-12-31 0001078799 us-gaap:CommonStockMember 2019-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2019-12-31 0001078799 MCOA:StockSubcriptionsMember 2019-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001078799 us-gaap:RetainedEarningsMember 2019-12-31 0001078799 2019-12-31 0001078799 MCOA:PreferredStockClassAMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-01-01 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-01-01 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-01-01 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-06-30 0001078799 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-12-31 0001078799 MCOA:PreferredStockClassBMember 2020-12-31 0001078799 us-gaap:CommonStockMember 2020-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2020-12-31 0001078799 MCOA:StockSubcriptionsMember 2020-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001078799 us-gaap:RetainedEarningsMember 2020-12-31 0001078799 MCOA:PreferredStockClassAMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-01-01 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-01-01 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-01-01 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassAMember 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-06-30 0001078799 MCOA:SparrowtechIncMember 2009-10-01 2009-10-31 0001078799 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MinimumMember 2021-01-01 2021-06-30 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MaximumMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-03-31 0001078799 MCOA:OperatingSegmentMember 2021-04-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-03-31 0001078799 MCOA:OperatingSegmentMember 2020-04-01 2020-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-06-30 0001078799 us-gaap:LeaseAgreementsMember 2019-06-29 2019-07-02 0001078799 us-gaap:ComputerEquipmentMember 2021-06-30 0001078799 us-gaap:ComputerEquipmentMember 2020-12-31 0001078799 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001078799 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001078799 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001078799 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-03-16 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-11-06 0001078799 2017-01-01 2017-12-31 0001078799 2018-01-01 2018-03-31 0001078799 2018-04-01 2018-06-30 0001078799 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2016-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2016-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2016-12-31 0001078799 MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2017-01-01 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-01-01 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2017-12-31 0001078799 MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2018-01-01 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2018-01-01 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2018-12-31 0001078799 MCOA:InvestmentMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-01-01 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-01-01 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2019-09-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-10-01 2019-12-31 0001078799 MCOA:GlobalHempGroupMember 2019-10-01 2019-12-31 0001078799 MCOA:VivabudsMember 2019-10-01 2019-12-31 0001078799 MCOA:NaturalPlantMember 2019-10-01 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-01-01 2020-03-31 0001078799 MCOA:GlobalHempGroupMember 2020-01-01 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-03-31 0001078799 MCOA:InvestmentMember 2020-04-01 2020-06-30 0001078799 MCOA:GlobalHempGroupMember 2020-04-01 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-04-01 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-06-30 0001078799 MCOA:MoneyTracMember 2020-06-30 0001078799 MCOA:InvestmentMember 2020-07-01 2020-09-30 0001078799 MCOA:GlobalHempGroupMember 2020-07-01 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-09-30 0001078799 MCOA:MoneyTracMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-10-01 2020-12-31 0001078799 MCOA:GlobalHempGroupMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-12-31 0001078799 MCOA:MoneyTracMember 2020-12-31 0001078799 MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-01-01 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-03-31 0001078799 MCOA:MoneyTracMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-04-01 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-06-30 0001078799 MCOA:MoneyTracMember 2021-06-30 0001078799 2020-03-31 0001078799 2019-09-30 0001078799 2019-06-30 0001078799 2019-03-31 0001078799 2018-12-31 0001078799 2017-12-31 0001078799 MCOA:ConvertibleNotePayableElevenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableElevenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2020-12-31 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2021-06-30 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2020-12-31 0001078799 MCOA:LabrysMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-24 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2019-10-01 2019-12-31 0001078799 MCOA:OdysseyFundingLLCMember 2021-06-30 0001078799 MCOA:OdysseyFundingLLCMember 2020-12-31 0001078799 MCOA:PaladinAdvisorsLLCMember 2021-06-30 0001078799 MCOA:PaladinAdvisorsLLCMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2019-12-19 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember us-gaap:WarrantMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2021-03-30 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-01 2019-09-30 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember us-gaap:WarrantMember 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember us-gaap:WarrantMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2020-12-23 0001078799 MCOA:GWHoldingsGroupMember 2020-01-01 2020-01-06 0001078799 2021-02-24 2021-02-26 0001078799 us-gaap:PreferredClassAMember 2021-01-01 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockTwoMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockThreeMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFourMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFiveMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockSixMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockTwoMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockThreeMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFourMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFiveMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockSixMember 2020-01-01 2020-06-30 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

 

or

 

  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                          to                          

 

Commission file number: 000-27039

 

MARIJUANA COMPANY OF AMERICA, INC.

(Exact name of registrant as specified in its charter)

 

Utah   98-1246221
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
633 West Fifth Street, Suite 2826    
Los Angeles, CA   90071
(Address of principal executive offices)   (Zip Code)

 

(888) 777-4362

(Registrant’s telephone number, including area code)

 

1340 West Valley Parkway, Suite 205, Escondido CA 92029

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated Filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes    No 

 

The number of shares of the issuer’s common stock, $0.001 par value per share, outstanding at August 19, 2021 was 5,405,130,704.

 

 
 
 

 

 

 

    PAGE
PART I. FINANCIAL INFORMATION
      
  ITEM 1.  Financial Statements  4
      
     Condensed consolidated balance sheets as of June 30, 2021 (unaudited) and December 31, 2020 (audited)  4
      
     Condensed consolidated statements of operations for the three and six month ended June 30, 2021 and 2020 (unaudited)  5
      
     Condensed consolidated statement of stockholders’ deficit for the six months ended June 30, 2021 and 2020 (unaudited)  6
      
     Condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 (unaudited)  8
      
     Notes to condensed consolidated financial statements (unaudited)  9
      
  ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations  45
  ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk  53
  ITEM 4.  Controls and Procedures  53
         
PART II. OTHER INFORMATION   
      
  ITEM 1.  Legal Proceedings  54
  ITEM 1A.  Risk Factors  54
  ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds  55
  ITEM 3.  Defaults Upon Senior Securities  55
  ITEM 4.  Mine Safety Disclosures  55
  ITEM 5.  Other Information  55
  ITEM 6.  Exhibits  56
     SIGNATURES  57
    

 

2 
 
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, plans and objectives of management and markets for our common stock are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

 

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our most recent Annual Report on Form 10-K and any updates described in our Quarterly Reports on  Form 10-Q and Current Reports on Form 8-K as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the reports we file with the SEC, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors in our SEC reports, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

 

 

 

 

 

 

3 
 
 

 PART 1 – FINANCIAL INFORMATION

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS   

           
    Unaudited    Audited 
    June 30, 2021    Dec 31, 2020 
           
ASSETS          
Current assets:          
Cash  $179,811   $74,503 
Short-term investments   743,200    239,063 
Accounts receivable, net   47,570    8,640 
Inventory   203,898    103,483 
Prepaid insurance         55,783 
Other current assets   93,830    56,121 
  Total current assets   1,268,309    537,593 
           
Property and equipment, net   111,898    6,542 
           
Other assets:          
Long-term investments   2,232,899    1,552,001 
Right-of-use-assets         7,858 
Goodwill   2,989,803       
Security deposit   2,500    2,500 
           
Total assets   6,605,409    2,106,494 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities:          
Accounts payable   706,396    480,877 
Accrued compensation   9,000    79,214 
Accrued liabilities   136,108    401,461 
Notes payable, related parties   20,000    40,000 
Loans payable PPP Stimulus   35,500    35,500 
Convertible notes payable, net of debt discount of $1,122,225 and $808,980, respectively   497,775    1,426,894 
Loans payable - acquisition   100,000       
Contingent liability - acquisition   1,000,000       
Right-of-use liabilities - current portion         7,858 
Subscriptions payable   1,063,977    670,000 
Derivative liability   1,904,016    4,426,057 
  Total current liabilities   

5,472,772

    7,567,861 
           
Total liabilities   

5,472,772

    7,567,861 
           
Stockholders' deficit:          
Preferred stock, $0.001 par value, 50,000,000 shares authorized          
Class A preferred stock, $0.001 par value, 10,000,000 shares designated, 10,000,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020   10,000    10,000 
Class B preferred stock, $0.001 par value, 5,000,000 shares designated, 2,000,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020   2,000    2,000 
Common stock, $0.001 par value; 15,000,000,000 shares authorized; 5,068,524,855 and 3,136,774,861 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively   5,068,525    3,136,775 
Common stock to be issued, 266,164,070 and 11,892,411 shares, respectively   266,164    11,892 
Additional paid in capital   87,581,650    77,687,561 
Accumulated deficit   (91,795,702)   (86,309,595)
  Total stockholders' deficit   

1,132,637

    (5,461,367)
           
Total liabilities and stockholders' deficit  $6,605,409   $2,106,494 

 See the accompanying notes to these unaudited condensed consolidated financial statements

 

4 
 
 

 MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

                     
   For the three months ended  For the Six months ended
   June 30, 2021  June 30, 2020  June 30, 2021  June 30, 2020
REVENUES:            
Sales  $16,880   $77,827   $51,810   $156,474 
Related party sales        5,131         8,303 
Total Revenues   16,880    82,958    51,810    164,777 
                     
Cost of sales   3,301    39,187    28,481    73,392 
                     
Gross profit   13,579    43,771    23,329    91,385 
                     
OPERATING EXPENSES:                    
Depreciation   1,262    1,582    2,653    3,328 
Selling and marketing   155,212    74,212    262,761    200,667 
Payroll and related   132,257    95,644    270,402    196,843 
Stock-based compensation   139,000    536,452    158,900    542,767 
General and administrative   611,970    211,116    1,137,652    415,172 
  Total operating expenses   1,039,701    919,006    1,832,368    1,358,777 
                     
Net loss from operations   (1,026,122)   (875,235)   (1,809,039)   (1,267,392)
                     
OTHER INCOME (EXPENSES):                    
Interest expense, net   (891,783)   (881,945)   (1,992,745)   (1,772,096)
Impairment gain (loss) on joint ventures        7,048         (260,954)
Loss on equity investment   (394,194)   (7,048)   (394,194)   (133,893)
Gain (loss) on change in fair value of derivative liabilities   

696,729

    1,572,964    (1,629,289)   1,142,272 
Unrealized gain (loss) on trading securities   (115,997)        504,137    (13,945)
Loss on sale of trading securities        (2,603)        (2,603)
(Loss) gain on settlement of debt   (96,750)        (164,977)   3,490 
Total other income (expense)   (801,995)   688,416    (3,677,068)   (1,037,729)
                     
Net loss before income taxes   (1,828,117)   (186,819)   (5,486,107)   (2,305,121)
                     
Income taxes (benefit)                    
                     
NET INCOME (LOSS)  $(1,828,117)  $(186,819)  $(5,486,107)  $(2,305,121)
                     
                     
Loss per common share, basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.01)
                     
Weighted average number of common shares outstanding, basic and diluted (after stock-split)   4,837,346,227    245,000,528    4,465,632,479    185,851,674 

 See the accompanying notes to these unaudited condensed consolidated financial statements

5 
 
 

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

                                     
   Class A Preferred Stock  Class B Preferred Stock  Common Stock  Common Stock to be issued  Stock  Paid In  Accumulated   
   Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Subcriptions  Capital  Deficit  Total
Balance, December 31, 2019   10,000,000   $10,000         $      77,958,081   $77,958         $     $     $63,467,054   $(74,164,213)  $(10,609,201)
Common stock issued to settle amounts previously accrued                       8,333    8                  $6,692         6,700 
Common stock issued for services rendered                        44,658,333    44,658                   498,108         542,766 
Common stock issued in settlement of convertible notes payable and accrued interest   —                      270,547,861    270,549    43,994,720    43,995         1,216,928         1,531,472 
Converson of related party notes payable                       21,384,103    21,384                   29,229         50,613 
Common stock issued in exchange for exercise of warrants on a cashless basis   —                      51,054,214    51,054    1,000,000    1,000         375,446         427,500 
Common shares issued in settlement of legal case                       3,677,889    3,678                   952,573         956,251 
Reclassification of derivative liabilities to additional paid in capital                                                2,231,014         2,231,014 
Net loss   —            —            —            —                        (2,305,121)   (2,305,121)
Balance, June 30, 2020   10,000,000   $10,000         $      469,288,814   $469,289    44,994,720   $44,995   $     $68,777,044   $(76,469,334)  $(7,168,006)
                                                             

 

 

 

6 
 
 

 

 

 

                                     
   Class A Preferred Stock  Class B Preferred Stock  Common Stock  Common Stock to be issued  Stock  Paid In  Accumulated   
   Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Subcriptions  Capital  Deficit  Total
Balance, December 31, 2020   10,000,000   $10,000    2,000,000   $2,000    3,136,774,841   $3,136,775    11,892,411   $11,892   $     $77,687,561   $(86,309,595)  $(5,461,367)
Common stock issued to settle amounts previously accrued                       —                                        
Issuance of preferred stock to officer   —            —     $      —            —                      $         
Common stock issued for services rendered   —                      21,000,020    21,000    —                 119,900         140,900 
Common stock issued in settlement of convertible notes payable and accrued interest   —                      810,689,880    810,690    —                 930,184          1,740,874 
Issuance of common stock for settlement of liabilities   —                      3,027,031    3,027    (10,892,411)   (10,892)        16,488         8,623 
Issuance of common stock for settlement of liabilities – related parties                       22,500,000    22,500    —                 119,250         141,750 
Common stock issued in exchange for exercise of warrants on a cashless basis   —                      400,000,000    400,000    —                  (400,000)            
Sale of common stock   —                      632,597,599    632,598    —                 726,169          1,358,767 
Issuance of common stock for investments                       41,935,484    41,935                    608,065         650,000
Reclassification of derivative liabilities to additional paid in capital                                                5,975,670         5,975,670 
Debt discount from warrants issued with convertible notes payable                                                446,026         446,026 
Common stock issued for acquisition of business                                 265,164,070    265,164         1,352,337         1,617,501 
Net Loss   —            —            —            —                        (5,486,107)   (5,486,107)
Balance, June 30, 2021   10,000,000   $10,000    2,000,000   $2,000    5,068,524,855   $5,068,525    266,164,070   $266,164   $     $87,581,650   $(91,795,702)  $1,132,637 

 

 See the accompanying notes to these unaudited condensed consolidated financial statements

7 
 
 

 MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

           
   2021  2020
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $(5,486,107)  $(2,305,121)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of debt discount   744,783    1,028,931 
Depreciation and amortization   2,653    3,328 
Impairment loss on equity investment        260,954 
Loss on equity investment   394,194    133,895 
Loss (gain) on change in fair value of derivative liability   1,629,289    (1,142,272)
Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance   1,035,115    395,607 
Loss on share inducement and settlement of warrant liability         138,885 
Stock-based compensation   140,900    542,767 
Unrealized (gain) loss on trading securities   (504,137)   27,403 
Loss on settlement of liabilities   168,272       
Changes in operating assets and liabilities:          
Accounts receivable   1,361    9,752 
Inventories   (93,669)   (9,290)
Prepaid expenses and other current assets   37,309    (95,384)
Accounts payable   155,661    145,784 
Accrued expenses and other current liabilities   (67,264)   195,874 
Right-of-use assets   7,858    6,767 
Right-of-use liabilities   (7,858)   (6,885)
Net cash provided by (used in) operating activities   (1,841,640)   (669,005)
           
Cash flows from investing activities:          
Purchases of property and equipment   (107,934)   (1,271)
Payment to establish joint venture   (30,898)      
Acquisition of business   (150,607)      
Net cash provided by (used in) investing activities   (289,439)   (1,271)
           
Cash flows from financing activities:          
Proceeds from issuance of notes payable   1,508,250    442,000 
Proceeds from PPP loan payable         35,500 
Repayments of notes payable   (610,630)      
Repayments to related parties   (20,000)      
Proceeds from sale of common stock   1,358,767       
Net cash provided by (used in) financing activities   2,236,387    477,500 
           
Net increase (decrease) in cash   105,308    (192,776)
           
Cash at beginning of period   74,503    211,765 
           
Cash at end of period  $179,811   $18,989 
    —        
           
           
Supplemental disclosure of cash flow information:          
Cash paid for interest            
Cash paid for taxes            
           
Non cash financing activities:          
Common stock issued in settlement of convertible notes payable  $1,740,874   $1,531,471 
Reclassification of derivative liabilities to additional paid-in capital  $5,975,670   $2,231,014 
Common stock issued for investment  $650,000   $   
Common stock issued to settle liabilities  $8,623   $   
Common stock to be issued for acquisition of business  $1,617,501   $   
Common shares issued in settlement of legal case  $     $956,251 

 See the accompanying notes to these unaudited condensed consolidated financial statements

 

8 
 
 

  

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2021

(unaudited)

 

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Marijuana Company of America, Inc. (the “Company”) was incorporated under the laws of the State of Utah in October 1985 under the name Mormon Mint, Inc. The corporation was originally a startup company organized to manufacture and market commemorative medallions related to the Church of Jesus Christ of Latter Day Saints. On January 5, 1999, Bekam Investments, Ltd. acquired one hundred percent of the common shares of the Company and spun the Company off changing its name Converge Global, Inc. From August 13, 1999 until November 20, 2002, the Company focused on the development and implementation of Internet web content and e-commerce applications. In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties. From 2009 to 2014, we operated primarily in the mining exploration business.

In 2015, the Company changed its business model to a marketing and distribution company for medical marijuana. In conjunction with the change, the Company changed its name to Marijuana Company of America, Inc. At the time of the transition in 2015, there were no remaining assets, liabilities or operating activities of the mining business.

On September 21, 2015, the Company formed H Smart, Inc., a Delaware corporation as a wholly owned subsidiary for the purpose of operating the hempSMART™ brand.

On February 1, 2016, the Company formed MCOA CA, Inc., a California corporation as a wholly owned subsidiary to facilitate mergers, acquisitions and the offering of investments or loans to the Company.

On May 3, 2017, the Company formed Hempsmart Limited, a United Kingdom corporation as a wholly owned subsidiary for the purpose of future expansion into the European market.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries H Smart, Inc., Hempsmart Limited and MCOA CA, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements set forth in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2021 (the “Annual Report”).

Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, during the six months ended June 30, 2021, the Company incurred net losses from operations of $5,486,107 and used cash in operations of $1,841,640. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company's primary source of operating funds for the six months ended June 30, 2021 was from revenue generated from the issuance of convertible and non-convertible debt. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2021 and beyond as it continues to develop its direct sales and marketing programs; however, no assurance can be provided that the Company will not continue to experience losses in the future. The Company has stockholders' deficiencies as of June 30, 2021 and requires additional financing to fund future operations.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding; however, there can be no assurance that the Company will be successful in developing profitable operations or that it will be able to obtain financing on favorable terms, if at all. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

 

9 
 
 

 

 

NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Interim Financial Statements

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.

Identification of Our Contracts with Customers 

Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.

In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.

 

10 
 
 

 

Determination of the Price in Our Sales Contracts

The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.

Allocation of the Transaction Price of Our Sales Contracts

The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.

With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. 

Identifying the Performance Obligations in Our Sales Contracts

 

In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.

 

11 
 
 

 

Product Sales

Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.

Consulting Services

The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.

For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.  

The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605   to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Cash

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash   in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

12 
 
 

 

Accounts Receivable 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $0 and $0, respectively.

Inventories

Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.

Cost of Sales 

Cost of sales is comprised of cost of product sold, packaging, and shipping costs.

Stock-Based Compensation - Employees

The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  

The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  

If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. 

 

 

13 
 
 

 

 

  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. 

Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.

The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.

Stock-Based Compensation – Non Employees

Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.

 

14 
 
 

 

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.   
  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. 
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.

 

Earnings per Share

Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years.

 

15 
 
 

 

Investments 

The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).

Derivative Financial Instruments

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   

The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $168,780 and $44,659 for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.

Segment Information

ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.

16 
 
 

 

hempSMART

STATEMENT OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

 

                   
   For the three months ended 

6 Months

Ended

  For the three months ended 

6 Months

Ended

   March 31, 2021  June 30, 2021  June 30, 2021  March 31, 2020  June 30, 2020  June 30, 2020
                   
                   
Revenues  $34,872   $16,537   $51,409   $81,819   $82,958   $164,777 
                               
Cost of Goods Sold   25,032    3,301    28,333    34,205    39,187    73,392 
                               
Gross Profit   9,840    13,236    23,076    47,614    43,771    91,385 
                               
Expense                              
Stock Based Compensation                        17,850    17,850 
Selling and Marketing   97,812    150,881    248,693    101,897    74,356    176,253 
Payroll and Related expenses   53,947    54,864    108,811    18,749    32,113    50,862 
Depreciation Expense   1,391    1,391    2,782    1,746    1,582    3,328 
General and Admin Expenses   55,801    95,864    151,665    67,949    53,911    121,860 
Total Expense   208,951    303,000    511,951    190,341    179,812    370,153 
                               
Net Loss from Operations  $(199,111)  $(289,764)  $(488,875)  $(142,727)  $(136,041)  $(278,768)

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

 

17 
 
 

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has not recorded any unrecognized tax benefits.

 

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.

 

Recently Issued Accounting Pronouncements Adopted 

 

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

18 
 
 

 

NOTE 4 – OPERATING LEASE

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. ASU 2018-11, Topic 842   can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach on January 1, 2019. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced before the adoption date; initial direct costs for leases that commenced before the adoption date; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASU 2018-11, Leases, allowing it to account for its existing operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or, (iii) the accounting for indirect costs as defined in ASC 842.  

 

On May 31, 2021, the Company’s operating lease for its office space located at 1340 West Valley Parkway, Suite 205, Escondido, CA 92029 expired and, at that time, the Company fully amortized its right-of-use asset for such lease. On June 1, 2021, the Company entered into an office accommodation agreement whereby it may access a shared office space located at 633 West Fifth Street, Suite 2826, Los Angeles, CA 90071 on a month-to-month basis over a one-year term for a fee of $2,349 per month. In considering its qualitative disclosure obligations under ASC 842-20-50-3, the Company examined its office accommodation agreement for office space that has a fixed monthly fee with no variable payments and no options to extend. The office accommodation agreement creates no tenancy, leasehold, or other real property interest, other than a shared right-of-use. The office accommodation agreement does not provide for terms and conditions granting residual value guarantees by the Company, or any restrictions or covenants imposed for dividends or incurring additional financial obligations by the Company.

 

The Company determined under ASC 2018-11, Leases (Topic 842), due to the short-term nature of the office accommodation agreement, that such agreement met the criteria of ASC 842-20-25-2 and as such it is not necessary to capitalize the office accommodation agreement and fees will be recognized on a monthly straight-line basis. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

 

19 
 
 

 

 

NOTE 5 – PROPERTY, MACHINERY AND EQUIPMENT

Property and equipment as of June 30, 2021 and December 31, 2020 is summarized as follows:

          
  

June 30,

2021

 

December 31,

2020

Computer equipment  $23,784   $20,143 
Furniture and fixtures   5,407    5,140 
Machinery   104,102       
Subtotal   133,293    25,283 
Less accumulated depreciation   (21,395)   (18,741)
Property, machinery and equipment, net  $111,898   $6,542 

 

Property, machinery and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. On May 20, 2021, the Company purchased a new cannabis extraction machine which is to be leased to a cannabis distributor and manufacturer called Lynwood-MCOA joint venture. This joint venture is between Cannabis Global Inc. and the Company and pertains to the licensed cannabis operations of Natural Plant Extract of California Inc. in the city of Lynwood, CA. The lease payments are scheduled to commence during the third quarter of 2021.

 

Depreciation expense was $2,653 and $3,328 for the six months ended June 30, 2021 and 2020, respectively. 

 

NOTE 6 – INVESTMENTS 

Bougainville Ventures, Inc. Joint Venture

 

On March 16, 2017, the Company entered into a joint venture agreement with Bougainville Ventures, Inc. (“Bougainville”), a Canadian corporation, to (i) jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville's high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I-502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to, sales and marketing, agricultural procedures, operations, security and monitoring, processing and delivery, branding, capital resources and financial management; and (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through BV-MCOA Management, LLC, a limited liability company organized in the State of Washington on May 17, 2017.

 

Pursuant to the joint venture agreement, the Company committed to raise not less than $1,000,000 to fund joint venture operations, based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry.

 

The joint venture agreement provided that funding provided by the Company would contribute towards the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.

 

As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment from $1,000,000 to $800,000, and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.

 

20 
 
 

 

Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach of contract for non-payment. Bougainville also did not possess an agreement with a Tier 3 I-502 license holder to grow marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land, but did not deed the real property to the joint venture. Bougainville failed to pay delinquent property taxes to Okanogan County, and as a result, as further discussed below, to date, the property has not been deeded to the joint venture.

 

To clarify the respective contributions and roles of the parties, the Company offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville to enter into an amended and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.

 

On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of $800,000 contributed by the Company to the joint venture. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 I-502 cannabis license holder to grow cannabis on the real property; and (iii) that clear title to the real property associated with the Tier 3 I-502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed a lawsuit against Bougainville, BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2-0045324. The Company seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, the appointment of a receiver, the return to treasury of 15 million shares of restricted common stock issued by the Company to Bougainville and treble damages pursuant to the Consumer Protection Act. The Company has filed a lis pendens on the real property. The case is currently in litigation.

 

In connection with the joint venture agreement, the Company recorded a cash investment of $1,188,500 to the joint venture during 2017. This was comprised of a 49.5% ownership of BV-MCOA Management, LLC, and was accounted for using the equity method of accounting. The Company recorded an annual impairment in 2017 of $792,500, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $37,673 and $11,043 for the quarters ended March 31, 2018 and June 30, 2018, respectively, and recorded an annual impairment of $285,986 for the year ended December 31, 2018, at which time the Company determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation, as discussed above.

 

21 
 
 

 

Natural Plant Extract

 

On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. and its   subsidiaries (collectively, “NPE”), to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the parties terminated the joint venture and entered into a settlement and release agreement (the “Settlement Agreement”). In exchange for a complete release of all claims, the Company and NPE (1) agreed that the Company would reduce its interest in NPE from 20% to 5%; (2) the Company agreed to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement Agreement, and $25,000 no later than the fifth calendar day for each of the two months following execution of Settlement Agreement; and, (3) to retire the balance of the Company’s original valuation obligation from the material definitive agreement, representing a shortfall of $56,085, in a convertible promissory note, with terms allowing NPE to convert the note into shares of the Company’s common stock of at a 50% discount to the closing price of the Company’s common stock as of the maturity date. The note was satisfied in full during the year ended December 31, 2020.

 

As of the date of this filing, the Company owes $0 and is in compliance with the terms of the Settlement Agreement . On February 3, 2020, the Company issued NPE a convertible promissory note in the principal amount of $56,085. Additionally, as a result of the Settlement Agreement, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE.

 

Of the total amount due and payable by the Company with regards to the NPE joint venture agreement as of the date of this filing, the Company owes $75,000 and is in breach of the Settlement and Release of All Claims Agreement with NPE. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.

Brazilian Joint Ventures

 

On September 30, 2020, the Company entered into two joint venture agreements (the “Joint Venture Agreements”) with Marco Guerrero, a director of the Company (“Guerrero”) and related party, to form joint ventures in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America and to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of the joint venture entities in Uruguay and Brazil. The Brazilian joint venture, HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”), will be headquartered in São Paulo, Brazil. The Uruguayan joint venture, Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”), will be headquartered in Montevideo, Uruguay.

Pursuant to the Joint Venture Agreements, the Company acquired a 70% equity interest in both HempSmart Brazil and HempSmart Uruguay, with a minority 30% equity interest in both HempSmart Brazil and HempSmart Uruguay being held by newly formed entities controlled by Guerrero. Pursuant to the Joint Venture Agreements, the Company agreed to provide capital in the amount of $50,000 to both HempSmart Brazil and HempSmart Uruguay, for a total capital outlay obligation of $100,000. It is expected that the proceeds of the initial capital contribution will be used for contracting with third-party manufacturing facilities in Brazil and Uruguay and related infrastructure and employment of key personnel. As of June 30, 2021, the Company has not initiated the capital contribution but is pending to be done in the third quarter.

 

 

22 
 
 

 

The boards of directors of HempSmart Brazil and HempSmart Uruguay will consist of three directors, elected by the joint venture partners. Pursuant to the Joint Venture Agreements, the Company agreed to license, on a royalty-free basis, certain of its intellectual property regarding its existing products to HempSmart Brazil and HempSmart Uruguay to enable the joint ventures to manufacture and sell its products in Brazil, Uruguay, and for export to other Latin American countries, the United States, and globally in accordance with the terms of the Joint Venture Agreements.

 

In addition, as majority partner, in the event a joint venture is frustrated in its intent or purpose, the Company may trigger a compulsory buy-sell procedure pursuant to which the Company could pursue a sale of all or substantially all of the joint venture. Subject to certain exceptions, the joint venture partners may not transfer their interests in HempSmart Brazil and HempSmart Uruguay.  

 

Cannabis Global, Inc. 

 

Joint Venture

 

On May 12, 2021, the Company entered into a joint venture agreement with Cannabis Global, Inc. (“Cannabis Global”) pursuant to which the Company will invest up to $250,000 into a newly formed entity (“MCOA Lynwood”) and Cannabis Global, through Natural Plant Extracts of California, Inc. (“Natural Plant”), an entity in which Cannabis Global owns a majority interest, will operate a regulated and licensed laboratory to manufacture various cannabis products in the State of California. As of June 30, 2021, the Company has invested $115,000.

Share Exchange

 

On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis Global pursuant to which the Company issued 650,000,000 shares of its common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global common stock. In addition, the Company and Cannabis Global entered into a lock-up leak-out agreement which contains certain restrictions with respect to the sales of such securities.

Eco Innovation Group Inc. – Share Exchange

 

On February 26, 2021, the Company entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, par value $0.001, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”). For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. As of June 30, 2021, the Company owed ECOX and additional 64,621,893 with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to the shares to be issued.

Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month.

For a period of two years following the Effective Date, at the closing of each fiscal quarter, should the per-share closing price of the common shares of the same class as the Shares or the Exchange Shares, as quoted by the OTC Markets for the last day of the relevant fiscal quarter, decrease below original issuance value with the effect that the aggregate value of the Shares or the Exchange Shares at the fiscal quarter close would be lower than $650,000, then either MCOA, in the case of the Shares, or ECOX, in the case of the Exchange Shares, shall issue the other party the number of shares of common stock necessary to cause the aggregate value of the Shares or the Exchange Shares, as applicable, be $650,000 as of the end of the relevant fiscal quarter. The parties shall irrevocably instruct their respective transfer agents to reserve and maintain authorized and unissued common stock in a reserve account designated for the purpose of issuing such shares pursuant to this share exchange adjustment provision. Such share reserve accounts shall be maintained with a number of authorized and unissued common stock not less than three (3) times the number of Shares or Exchange Shares, as the case may be, that are issued pursuant to the Share Exchange Closing.

 

On February 24, 2021, the closing price of the Company’s common stock was $0.0155, so that the number of shares of Company common stock issuable to ECOX under the Share Exchange Agreement is 41,935,484. As a result of the transactions pursuant to the Share Exchange Agreement, the Company will have 4,179,073,945 shares of common stock outstanding, with the shares issued to ECOX pursuant to the Share Exchange Agreement representing 1.00% of the Company’s outstanding shares.

 

For the quarter ended June 30, 2021, the Company recorded a Loss on Equity Investment and corresponding increase in Subscriptions Payable of $394,194 to address the decline in the Company's stock price from the original issuance price of $.0155.

 

 

 

23 
 
 

 

 

 

 

 

MARIJUANA COMPANY OF AMERICA, INC.

INVESTMENT ROLL-FORWARD

AS OF JUNE 30, 2021

 

 

                                          
   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Beginning balance @12-31-16  $   $             $        $   $   $             $        $ 
                                                                       
Investments made during 2017   3,049,275    10,775              100,000         250,000    1,188,500    1,500,000                        
                                                                       
Quarter 03-31-17 equity method Loss                                                                    
                                                                       
Quarter 06-30-17 equity method Loss                                                                    
                                                                       
Quarter 09-30-17 equity method Loss   (375,000)                                 (375,000)                             
                                                                       
Quarter 12-31-17 equity method accounting   313,702                                  313,702                              
                                                                       
Impairment of Investment in 2017   (2,292,500)                                (792,500)   (1,500,000)                       
Balances as of 12/31/17  $695,477.00   $10,775.00   $   $   $100,000.00   $   $250,000.00   $334,702.00   $   $   $   $   $   $ 

 

 

24 
 
 

 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during 2018   986,654    986,654                                                            
                                                                       
Quarter 03-31-18 equity method Loss   (37,673)                                 (37,673)                             
                                                                       
Quarter 06-30-18 equity method Loss   (111,043)                                 (11,043)                             
                                                                       
Quarter 09-30-18 equity method Loss   (10,422)                  (10,422)                                            
                                                                       
Quarter 12-31-18 equity method Loss   (31,721)   (31,721)                                                          
                                                                       
Moneytrac investment reclassified to Short-Term investments   (250,000)                            (250,000)                       250,000         250,000 
                                                                       
Unrealized gains on trading securities - 2018                                                         560,000         560,000 
                                                                       
Impairment of investment in 2018   (933,195)   (557,631)             (89,578)             (285,986)                             
Balance @12-31-18  $408,077   $408,077   $   $   $   $   $   $   $   $   $   $810,000   $   $ 

 

 

 

25 
 
 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during quarter ended 03-31-19   129,040    129,040                                                             
                                                                       
Quarter 03-31-19 equity method Loss   (59,541)   (59,541)                                                            
                                                                       
Unrealized gains on trading securities - quarter ended 03-31-19                                                          (135,000)       $(135,000)
                                                                       
Balance @03-31-19  $477,576   $477,576   $   $   $   $   $   $   $   $   $   $675,000   $   $(135,000)
                                                                       
Investments made during quarter ended 06-30-19  $3,157,234   $83,646                                      $3,000,000   $73,588                
                                                                       
Quarter 06-30-19 equity method Income (Loss)  $(171,284)  ($141,870)                                     $(6,291)  $(23,123)               
                                                                       
Unrealized gains on trading securities - quarter ended 06-30-19  $                                                      (150,000)       $(150,000)
                                                                       
Balance @06-30-19  $3,463,526   $419,352   $   $   $   $   $   $   $   $2,993,709   $50,465   $525,000   $   $(285,000)

 

 

26 
 
 

 

 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
                                                                       
Investments made during quarter ended 09-30-19  $186,263                                                $186,263                
                                                                       
Quarter 09-30-19 equity method Income (Loss)  $122,863   $262,789                                      $(94,987)  $(44,939)               
                                                                       
Sale of trading securities during quarter ended 09-30-19                                                         $(41,667)       $(41,667)
                                                                       
Unrealized gains on trading securities - quarter ended 09-30-19  $                                                      (362,625)       $(362,625)
                                                                       
Balance @09-30-19  $3,772,652   $682,141   $   $   $   $   $   $   $   $2,898,722   $191,789   $120,708   $   $(689,292)

 

 

27 
 
 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during quarter ended 12-31-19  $392,226   $262,414                                           $129,812                
                                                                       
Quarter 12-31-19 equity method Income (Loss)  $(178,164)  $(75,220)                                     $(23,865)  $(79,079)               
Reversal of Equity method Loss for 2019  $272,285                                           $125,143   $147,142                
Impairment of investment in 2019  $(3,175,420)  $(869,335)                                     $(2,306,085)  $                
Loss on disposition of investment  $(389,664)                                               $(389,664)               
Sale of trading securities during quarter ended 12-31-19  $                                                     $(17,760)       $(17,760)
                                                                       
Unrealized gains on trading securities - quarter ended 12-31-19  $                                                      (75,545)       $(75,545)
Balance @12-31-19  $693,915   $  $   $   $   $   $   $   $   $693,915   $   $27,403   $   $(782,597)

 

 

28 
 
 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
                                                                       
Equity Loss for Quarter ended 03-31-20   126,845    126,845                                                             
                                                                       
Recognize Joint venture liabilities per JV agreement @03-31-20   394,848    394,848                                                             
                                                                       
Impairment of Equity Loss for Quarter ended 03-31-20   (521,692)   (521,692)                                                            
                                                                       
Unrealized gains on trading securities - quarter ended 03-31-19                                                          (13,945)       ($13,945)
Balance @03-31-20  $693,915   $   $   $   $   $   $   $   $   $693,915   $   $13,458   $   ($796,542)

 

 

29 
 
 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Equity Loss for Quarter ended 06-30-20   (7,048)   (7,048)                                                            
                                                                       
Impairment of Equity Loss for Quarter ended 06-30-20   7,048    7,048                                                             
                                                                       
Sales of of trading securities - quarter ended 06-30-20                                                          (13,458)       ($13,458)
Balance @06-30-20  $693,915   $   $   $   $   $   $   $   $   $693,915   $   $   $0   ($810,000)
                                                                       
Global Hemp Group trading securities issued   650,000        $650,000                                           $185,000   $185,000      
                                                                       
Investment in Cannabis Global                                                                     
                                                                       
Balance @09-30-20  $1,343,915   $   $650,000   $   $   $   $   $   $   $693,915   $   $185,000   $185,000   ($810,000)
                                                                       
Unrealized gain on Global Hemp Group securities - 4th Quarter 2020                                                         $54,064   $54,064      
                                                                       
Unrealized gains on Cannabis Global Inc securities - 4th Quarter 2020   208,086        $208,086                                                        
Balance @12-31-20  $1,552,001   $   $858,086   $   $   $   $   $   $   $693,915   $   $239,064   $239,064   ($810,000)
                                                                       
Investment in ECOX   650,000             $650,000                                      $620,133   $620,133      
                                                                       
Balance @03-31-21  $2,202,001   $   $858,086   $650,000   $   $   $   $   $   $693,915   $0   $859,197   $859,197   ($810,000)
                                                                       
Investments made during quarter ended 06-30-21   30,898                       $30,898                                         
                                                                       
Unrealized gain on Global Hemp Group securities - 2nd quarter 2021                                                         ($115,997)  ($115,997)     
                                                                       
Balance @06-30-21  $2,232,899   $   $858,086   $650,000   $   $30,898   $   $   $   $693,915   $   $743,200   $743,200   ($810,000)

 

 

 

30 
 
 

 

                   
  06-30-20 03-31-20 12-31-19 09-30-19 06-30-19 03-31-19 12-31-18 12-31-17    
This includes balances for: Note (h) Note (g) Note (f) Note (e) Note (d) Note (c) Note (b) Note (a)    
      - Debt obligation of JV 478,494 394,848 - 1,633,872 1,778,872 128,522 289,742 1,500,000  
      - Convertible NP, net of discount 2,784,044 3,040,324 3,193,548 2,688,555 2,149,170 1,536,271 1,132,668 394,555  
      - Long term debt - - - - - - - 172,856  
Total Debt balance 3,262,538 3,435,172 3,193,548 4,322,427 3,928,042 1,664,793 1,422,410 2,067,411  

 

NOTE 7 – NOTES PAYABLE, RELATED PARTY

As of June 30, 2021 and December 31, 2020, the Company’s officers and directors have provided advances and incurred expenses on behalf of the Company as such have been evidenced by the issuance of notes to such officers and directors. The notes are unsecured, due on demand and accrue interest at a rate of 5% per annum. The balance due to Notes Payable Related Party as of June 30, 2021 and December 31, 2020 was $20,000 and $40,000 respectively. These notes are payable to the estate of Charles Larsen.

NOTE 8 – CONVERTIBLE NOTES PAYABLE

During the six months ended June 30, 2021, the Company issued an aggregate of 810,689,880 shares of its common stock in settlement of issued convertible notes payable and accrued interest.  

For the six months ended June 30, 2021 and June 30, 2020, the Company recorded amortization of debt discounts of $744,783 and $1,028,931, respectively, as a charge to interest expense.

Convertible notes payable are comprised of the following:

      
   June 30,  December 31,
   2021  2020
Lender  (Unaudited)  (Audited)
Convertible note payable - Power Up Lending Group  $     $35,000 
Convertible note payable - Crown Bridge Partners  $35,000   $172,500 
Convertible note payable – Labrys  $537,500   $   
Convertible note payable - GS Capital Partners LLC  $     $143,500 
Convertible note payable – Geneva Roth  $     $33,500 
Convertible note payable - Robert L. Hymers III  $185,000   $70,000 
Convertible note payable – Dutchess Capital  $135,000   $10,000 
Convertible note payable – Redstart Holdings  $     $109,000 
Convertible note payable - GW Holdings  $     $98,175 
Convertible note payable - St. George/Bucktown  $727,500   $1,160,726 
Total  $1,620,000   $1,832,401 
Less debt discounts  $(1,122,225)  $(405,507)
Net  $497,775   $1,426,894 
Less current portion  $(497,775)  $(1,426,894)
Long term portion  $     $   

 

 

31 
 
 

 

Convertible Note Payable-Labrys

In June 2021, the Company issued a convertible promissory note in the aggregate principal amount of $537,500 to Labrys Funds, LP (“Labrys”). The promissory note accrues interest at 12% per annum, is due one year from the issuance date and includes an original issuance discount in the aggregate amount of $53,750. The Company also paid $33,750 in deferred financing fees and received $450,000 of net proceeds. The note is convertible at any time at a conversion price of $0.005 per share. The Company also issued a five-year warrants to purchase up to 76,349,431 shares of its common stock to Labrys, at an exercise price of $0.00704 per share. In addition, the Company issued five-year warrants to purchase up to 76,349,431 shares of its common stock to an investment banker for services, which warrants have an exercise price of $0.008448 per share. The aggregate debt discount of $533,526 is being amortized to interest expense over the respective terms of the note.

The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. The Company is prohibited from effecting an exercise of the warrant to the extent that, as a result of such exercise, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the note. Accrued interest on the note was $5,375 as of June 30, 2021.

Convertible Notes Payable-Power Up Lending

From July 1 through September 12, 2019, the Company issued four convertible promissory notes in the aggregate principal amount of $294,000 to Power Up Lending Group Ltd. (“Power Up”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date and include an original issuance discount in the aggregate amount of $12,000. The notes are convertible at any time at a conversion price equal to 61% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the date of conversion. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the notes should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $169,202 is being amortized to interest expense over the respective terms of the notes.

The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.

As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $0 and $35,000 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $1,167, respectively, of accrued interest on the notes.

 

 

32 
 
 

 

Convertible Notes Payable-Crown Bridge Partners

From October 1 through December 31, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $225,000 to Crown Bridge Partners LLC (“Crown Bridge”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date and include an original issuance discount in aggregate amount of $22,500. Interest accrues from the issuance date, but interest shall not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 60% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the conversion date. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $88,674 was being amortized to interest expense over the respective terms of the notes. The Company also issued a warrants to purchase up to 519,230 shares of the Company’s common stock with an initial exercise price of $0.26, with reset provisions based on issuances of common stock subsequent to the issuance date. Due to the reset provision, the exercise option of these warrants is also accounted for as a derivative liability. See Note 10.

The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.

As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $35,000 and $172,500 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed accrued interest of $0 and $6,500 on the notes, respectively.

Convertible Notes Payable-Odyssey Funding LLC

On October 30, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $250,000 to Odyssey Funding LLC (“Odyssey”). The promissory notes accrue interest at a rate of 12% per annum, were due one year from the respective issuance date and include an original issuance discount in an aggregate amount of $12,500. Interest accrues from the issuance date, but interest does not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 55% the average of the two lowest trading prices of the Company’s common stock as quoted on the OTC Markets or such other exchange where the Company's shares are then traded, for the 20 trading days prior to the conversion date.

As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $207,650 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company an aggregate of $0 and $0 of principal, respectively. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the notes, respectively  .

Convertible Notes Payable - Paladin Advisors LLC

On October 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $75,000 to Paladin Advisors, LLC (“Paladin”). The promissory notes accrue interest at a rate of 8% per annum and were due six months from the respective issuance date of each note. Pursuant to the notes, Paladin has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 45% discount to the lowest closing bid of the 10 day trading period prior to the date of conversion.

 

33 
 
 

 

The aggregate debt discount of $46,721 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $0 and $0 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the notes  , respectively.

Convertible Notes Payable-GS Capital Partners LLC

On December 19, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $173,000 to GS Capital Partners LLC (“GS Capital”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date, and include an original issuance discount in an aggregate amount of $15,000. Pursuant to the notes, GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the notes into shares of the Company's common stock at a conversion price equal to 62% of the lowest trading price of the Company's common stock as reported on the OTC Markets or such other exchange on which the Company’s shares are then traded, for the 20 trading days prior to the date of conversion.

As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $166,193 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $143,500 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $$2,789 in accrued interest on the notes  , respectively.

Convertible Notes Payable-St. George Investments

On November 1, 2017, the Company issued a secured convertible promissory note in the principal amount of $601,420 to St. George Investments LLC (“St. George”). The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on September 10, 2018 and includes an original issue discount of $59,220. The promissory note was funded on November 11, 2017 for $542,200, net of the original issue discount and transaction costs. As of September 30, 2019, the Company owed $417,890 of principal and $38,378 of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate. On December 20, 2017, the Company issued a secured convertible promissory note in the principal amount of up to $1,655,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on October 27, 2018 and includes an original issue discount of $155,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. The promissory note was funded in nine tranches of  $300,000; $200,000; $200,000; $400,000; $75,000; $150,000; $85,000; $120,000 and $70,000, resulting in aggregate net proceeds of $1,500,000. The Company received aggregate net proceeds of $1,200,000 and $300,000 during the years ended December 31, 2018 and 2017, respectively. As an investment incentive, the Company issued five-year warrants to purchase up to 1,100,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 5,274,146 total warrants.

The promissory note is convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 20% prepayment premium. The note is secured by a trust deed of certain assets of the Company. “Market Capitalization” means the total outstanding shares of common stock multiplied by the stock price published on OTC Markets.

On November 5, 2018, $250,000 of principal and accrued interest was assigned to John Fife as an individual with all the terms and conditions of the original note issued to St. George. On March 21, 2019, $150,959 of principal and $4,963 of accrued interest along with $160,454 of derivative liabilities valued as of the respective conversion date were converted into an aggregate of 394,460 shares of the Company’s common stock.

During the nine months ended September 30, 2019, $550,000 of principal, $122,694 of accrued interest and $441,394 of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of 1,710,897 shares of the Company’s common stock, resulting in a gain on debt settlement of $21,586. As of September 30, 2019, the Company owed $0 of principal and $0 of accrued interest on these convertible promissory notes. Although these notes were in default until they were repaid, the lender did not enforce the default interest rate.

 

34 
 
 

 

On August 28, 2018, the Company issued a secured convertible promissory note in the amount of $1,128,518 (including overfunding of $23,518) to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on June 30, 2019, and includes an original issue discount of $100,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the year ended December 31, 2018, the Company received aggregate net proceeds of $825,000. During the nine months ended September 30, 2019, an additional $218,518 was funded under this note resulting in net proceeds of $198,518.

As an investment incentive to St. George, the Company issued St. George five-year warrants to purchase up to 750,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. The aggregate fair value of the issued warrants was $1,588,493. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $1,114,698 is being amortized to interest expense over the respective term of each tranche.   As of June 30, 2020, the warrants had an exercise price of $0.0085 for 3,750,000 total warrants.

The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion rate will be 60% of the three lowest closing trade prices during the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory notes include certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

During the nine months ended September 30, 2019, $1,000,859 of principal and $840,299 of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of 4,475,543 shares of the Company’s common stock, resulting in a loss on debt settlement of $612,034. As of September 30, 2019, the Company owed $828,518 of principal and $28,138 of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate.

On January 29, 2019, the Company issued a secured convertible promissory note in the principal amount of $2,205,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on December 5, 2019, and includes an original issue discount of $200,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in eight tranches totaling $1,406,482, resulting in aggregate net proceeds of $1,276,482. As an investment incentive to St. George, the Company issued to St. George five-year warrants to purchase up to 1,500,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 7,500,000 total warrants. The aggregate fair value of the issued warrants was $999,838. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense.

 

35 
 
 

 

The promissory notes  are convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

On March 25, 2019, the Company issued a secured convertible promissory note in the principal amount of $580,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on January 24, 2020 and includes an original issue discount of $75,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in the amount of $580,000 resulting in net proceeds of $500,000. As an investment incentive, the Company issued five-year warrants to purchase up to 375,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 1,875,000 total warrants. The aggregate fair value of the issued warrants was $258,701. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $483,966 is being amortized to interest expense over the term of the note.

The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

The Company entered into five convertible note agreements with Bucktown Capital, LLC, an affiliated entity of St. George in fiscal year 2020 and during the six months ended June 30, 2021. The notes have total principal due of $727,500, bear interest at 8% per annum. The notes mature between December 2021 and March 2022. The notes are convertible at fixed prices, with $225,000 of principal convertible at $0.002 per share, $80,000 convertible at $0.003 per share, and $422,500 convertible at $0.005 per share.

As of June 30, 2021 and December 31, 2020, the Company owed $727,500 and $1,160,726 of principal, respectively, on these notes. As of June 30, 2021 and December 31, 2020, the Company owed $24,042 and $350,525 of accrued interest on the above notes, respectively.

Convertible Notes Payable - Robert L. Hymers III

On December 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $96,552.70 to Robert L. Hymers III (“Hymers”) in satisfaction of funds owed to Mr. Hymers from his consulting contract with the Company for past services rendered and completed. The promissory notes accrue interest at a rate of 10% per annum, and are were six months from the respective issuance date of the note along with accrued and unpaid interest. Hymers has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 50% discount to the lowest closing bid price of the Company’s common stock during the 15 day trading period prior to the date of conversion. The aggregate debt discount of $92,332 is being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $185,000 and $70,000 of principal, respectively, to Hymers.  As of June 30, 2021 and December 31, 2020, the Company owed $3,125 and $1,005 in accrued interest on the notes  , respectively.

Convertible Notes Payable – Natural Plant Extract

On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. (“NPE”) to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the Company terminated the joint venture.

Definitive Agreement

Pursuant to the agreement with NPE, the Company agreed to acquire 20% (equal to 200,000 shares of NPE) of NPE’s authorized shares in exchange for the payment of $2,000,000 and $1,000,000 worth of the Company’s restricted common stock. The Company agreed to form a joint venture with NPE incorporated in California under the name “Viva Buds, Inc.” for the purpose of operating a California licensed cannabis distribution business pursuant to California law legalizing THC psychoactive cannabis for recreational and medicinal use.

36 
 
 

 

 

The Company’s payment obligations were governed by a stock purchase agreement which required the Company to make the following payments: 

a. Deposit of $350,000 within 5 days of the execution of the agreement;

b. Deposit of $250,000 payable within 30 days of the execution of the agreement;

c. Deposit of $400,000 within 60 days of the execution of the agreement;

d. Deposit of $500,000 within 75 days of the execution of the agreement; and

e. Deposit of $500,000 within 90 days of the execution of the agreement.

The Company made its initial payment pursuant to this schedule, but otherwise failed to comply with the payment schedule and was in breach of contract.

Settlement and Release of All Claims Agreement

On February 3, 2020, the Company and NPE entered into a Settlement and Release of All Claims Agreement. In exchange for a universal release of all claims, the Company and NPE (i) agreed to reduce the Company’s interest in NPE from 20% to 5%; (ii) agreed that the Company would to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement and Release of All Claims Agreement, and $25,000 no later than the 5th calendar day for each of the two months following execution of Settlement and Release of All Claims Agreement; and, (iii) agreed to retire the balance of the Company’s original valuation obligation from the agreement, representing a shortfall of $56,085.15, in a convertible promissory note, with terms allowing NPE to convert the note into the Company’s common stock at a 50% discount to the closing price of the Company’s common stock as of the maturity date.

Of the total amount due and payable by the Company as of the date of this filing, the Company owes $50,000, and is in breach of the Settlement and Release of All Claims Agreement. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.

Convertible Note Payable – GW Holdings Group

On January 6, 2020, the Company entered into a convertible promissory note in the amount of $57,750 with GW Holdings Group, LLC (“GW”). GW has the option, beginning on the six month anniversary of the date of issuance, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a conversion price equal to 40% discount of the lowest trading price for the 15 trading days prior to the date of the conversion. The note accrues interest at a rate of 10% per annum and include a $5,250 original issue discount such that the price of the note was $57,750. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $98,175 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $818 in accrued interest on the note  , respectively.

Convertible Note Payable – Jefferson Capital

On January 20, 2020, the Company issued a convertible promissory note to Jefferson Capital, LLC (“Jefferson”) with note matured on January 20, 2021. Jefferson has the right to convert any or all of the note into common stock of the Company at a conversion price equal to (i) 60% of the lowest trading price of the Company’s common stock during the 20 trading day period prior to the issue date of the note or (ii) 60% multiplied by the market price, meaning the lowest trade price for the Company’s common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note.

 

37 
 
 

 

Convertible Note Payable – BHP Capital

On January 21, 2021, the Company issued a convertible promissory note in the principal amount of $37,625to BHP Capital NY, Inc. (“BHP”). The Company agreed to pay simple interest on the outstanding principal amount of the note at a rate of 10% per annum. All amounts owed pursuant to the note are convertible, in whole or in part, into shares of the Company’s common stock at BHP’s option at the lower of (i) the lowest price at which the Company has issued stock; or (ii) the market price, defined as 60% of the lowest trading price for the Company’s common stock during the 20 trading day period ending on the last trading day prior to the conversion date. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest   on the note.

Convertible Notes Payable – LG Capital

On March 2, 2020, the Company entered issued a convertible promissory note in the principal amount of $50,000 to LG Capital Funding, LLC (“LG Capital”) which note matured on March 2, 2021. The note accrues interest at a rate of 8% per annum. LG Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a price per share of equal to 55% of the lowest trading price of the Company’s common stock as quoted on the OTC Markets for the 20 trading days prior to the date of conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note  .

Convertible Debt Summary:  

The Company has identified the embedded derivatives related to the above described notes and warrants. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the note and to fair value as of each subsequent reporting date.

At June 30, 2021, the Company determined the aggregate fair value of embedded derivatives to be $1,904,016. The fair values were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 128.2% to 169.0%, (3) weighted average risk-free interest rate of 0.16% to 0.18%, (4) expected life of 0.05 to 2.7 years, (5) conversion prices of $0.00185 to $0.00333 and (6) the Company's common stock price of $0.0044 per share as of June 30, 2020.

For the six months ended June 30, 2021, the Company recorded a gain on the change in fair value of derivative liabilities of $1,347,646 and a loss of $1,035,115 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense. For the six months ended June 30, 2020, the Company recorded a gain on change in fair value of derivative liabilities of $1,142,272, a loss of $395,607 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense, and amortization of debt discounts of $1,028,931 as a charge to interest expense.

Paycheck Protection Program Loan

 

During the quarter ended June 30, 2020, the Company's wholly owned subsidiary, H Smart Inc., received a $35,500 loan as part of the Paycheck Protection Program (“PPP”) offered by the Small Business Administration.

 

The Company has elected to account for the PPP loan pursuant to FASB ASC 470, Debt, or as a government grant by analogy to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance.

 

Following the guidance in ASC 470, the Company has recognized the entire loan amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company will not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.

For purposes of derecognizing the liability, ASC 470 refers to the extinguishment guidance in ASC 405, Liabilities.

38 
 
 

 

Based on that guidance, the loan would remain recorded as a liability until either of the following criteria are met:

· The Company has been legally released from being the primary obligor under the liability.

  · The Company pays the lender and is relieved of its obligation for the liability.

Because the Company will not be legally released from being the primary obligor of the PPP loan until forgiveness is actually granted, income from the extinguishment of the loan would only be recognized once the Company's application for forgiveness is approved. If the forgiveness application is approved, any resulting amount forgiven would be recognized and separately disclosed in the income statement as a gain on extinguishment.

Subscriptions Payable

On September 30, 2020, the Company entered into a share exchange agreement (“Share Exchange Agreement”) with Cannabis Global, Inc. (“CBGL”) dated September 30, 2020, to acquire the number of shares of CBGL’s common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement.  For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000.

On February 26, 2021, the Company entered into a share exchange agreement (“ECOX Share Exchange Agreement”) with Eco Innovation Group, Inc. (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the ECOX Share Exchange Agreement.  For both parties, the ECOX Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the ECOX Share Exchange Agreement to fall below $650,000. Based on the value of ECOX shares in the market as of June 30, 2021, the Company recorded a value for additional shares owed to ECOX pursuant to the ECOX Share Exchange Agreement of $329,572 as a subscription agreement along with a loss from equity investment of $391,194. As of June 30, 2021 41,935,484 shares of the Company’s common stock have been issued. As a result, the balance of subscriptions payable as of June 30, 2021 and December 31, 2020 was $999,355 and $670,000, respectively.

NOTE 9 – STOCKHOLDERS’ DEFICIT

Preferred Stock

The Company is authorized to issue 50,000,000 shares of $0.001 par value preferred stock (“Series A Preferred Stock”) as of June 30, 2021 and December 31, 2020 of which 10,000,000 shares are outstanding as of June 30, 2021. As of June 30, 2021 and December 31, 2020, the Company is authorized to issue 5,000,000 shares of Class B Preferred Stock of which 2,000,000 shares are issued and outstanding as of June 30, 2021.

 

 

 

39 
 
 

 

Each share of Class A Preferred Stock is entitled to 100 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.

 

Each share of Class B Preferred Stock is entitled to 1,000 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.

Common stock

The Company is authorized to issue 15,000,000,000 shares of $0.001 par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $0.001 par value common stock. As of June 30, 2021, and December 31, 2020, the Company had 5,068,524,855 and 3,136,774,861 shares of common stock issued and outstanding, respectively. As of August 19, 2021, there were 5,405,130,704 shares of the Company’s common stock issued and outstanding.

During the six months ended June 30, 2021, the Company issued an aggregate of 21,000,020 shares of its common stock for services with an estimated fair value of $140,900.

During the six months ended June 30, 2021, the Company issued an aggregate of 810,689,880 shares of its common stock, including 153,227,150 related to warrants accounted for as liabilities, in settlement of convertible notes payable, accrued interest of $1,677,373, and reclassified derivative liabilities of $5,975,670 to additional paid in capital in connection with the conversions.

During the six months ended June 30, 2021, the Company issued a net amount of 3,027,031 shares of its common stock in settlement of liabilities with an estimated fair value of $8,623, which included 10,892,411 related to shares to be issued as of December 31, 2020, and the cancellation of 8,755,714 shares for previous settlements, and 890,334 new shares issued for settlement of accounts payable.  

During the six months ended June 30, 2021, the Company issued 22,500,000 of its common stock upon the settlement of related party notes payable and accounts payable with an estimated fair value of $141,750.

During the six months ended June 30, 2021, the Company issued 400,000,000 of its common stock upon the exercise of warrants on a cash basis, including warrant liabilities with an estimated value of $63,500.

During the six months ended June 30, 2021, the Company sold 632,597,599 of its common stock for an aggregate value of $1,358,767.

During the six months ended June 30, 2021, the Company issued 41,935,484 of its common stock with a value of $650,000 and will issue an additional 64,621,893 shares for investments with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to these additional shares during the three months ended June 30, 2021.

The Company is authorized to issue 15,000,000,000 shares of $0.001 par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $0.001 par value common stock. As of June 30, 2020 and December 31, 2019, the Company had 469,288,934 and 77,958,081 shares of common stock issued and outstanding, respectively.

During the six months ended June 30, 2020, the Company issued an aggregate of 8,333 shares of its common stock to settle amounts previously accrued with an estimated fair value of $6,700.

During the six months ended June 30, 2020, the Company issued an aggregate of 44,658,333 shares of its common stock for services with an estimated fair value of $542,766.

During the six months ended June 30, 2020, the Company issued an aggregate of 270,547,861 shares of its common stock in settlement of convertible notes payable, accrued interest and embedded derivative liabilities of an aggregate of $1,531,471.

During the six months ended June 30, 2020, the Company issued 21,384,103 of its common stock upon the conversion of related party notes payable with an estimated fair value of $50,613.

During the six months ended June 30, 2020, the Company issued 51,054,214 shares of its common stock upon the exercise of warrants on a cashless basis.

During the six months ended June 30, 2020, the Company issued 3,677,889 shares of its common stock in settlement of a legal case with an estimated fair value of $956,251.

On January 17, 2020, the Company entered into an amendment of an existing convertible promissory note issued to Paladin. The Company authorized the issuance of a warrant to purchase up to 5,750,000 shares of the Company’s common stock, which warrant could be exercised on a cashless basis. This warrant was exercised during the three months ended June 30, 2020.

Options

As of June 30, 2021, the Company has no outstanding stock options.

 

40 
 
 

 

Warrants

The following table summarizes the stock warrant activity for the three months ended June 30, 2021:

                               
    Shares  

Weighted-Average

Exercise Price

 

Weighted Average

Remaining

Contractual Term

 

Aggregate

Intrinsic Value

Outstanding at December 31, 2020     293,054,702     $ 0.0011       2.22     $ 1,023,306  
Granted     79,785,156     0.0071       5.00           
Increase due to reset provision     (9,722,222 )   0.004       2.41           
Exercised     (194,788,035 )     0.004       1.66       1,427,826    
Outstanding at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  
Exercisable at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  

 

Certain warrants issued to debt holders have reset provisions whereby upon subsequent issuances of common stock at a price below the current exercise price, the number of warrants increase and the exercise price is reduced to the new price. The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $0.0061 as of June 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

NOTE 10 — FAIR VALUE MEASUREMENT

ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

41 
 
 

 

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of June 30, 2021 and December 31, 2020, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in Note 3. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 3 are that of volatility and market price of the underlying common stock of the Company.

As of June 30, 2021 and December 31, 2020, the Company did not have any derivative instruments that were designated as hedges.

The derivative liability as of June 30, 2021 and December 31, 2020, in the amount of $1,904,016 and $4,426,057, respectively, have a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended June 30, 2021:

     
  

Debt

Derivative

Balance, January 1, 2021  $4,426,057 
Increase resulting from initial issuance of additional convertible notes payable   1,824,340 
Decreases resulting from conversion of convertible notes payable   (5,975,670)
Decreases resulting from payoff of convertible notes payable   (649,961)
Loss from change in fair value included in earnings   2,279,250 
Balance, June 30, 2021  $1,904,016 

 

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. During the period ended June 30, 2021, the Company’s stock price decreased significantly from initial valuations. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 11 — RELATED PARTY TRANSACTIONS

The Company’s current officers and stockholders advanced funds to the Company for travel related   to business meetings and due diligence with respect to acquisition targets and working capital purposes. As of June 30, 2021 and December 31, 2020, the balance due to officers for travel and working capital purposes was $0 and $0, respectively.

As of June 30, 2021 and December 31, 2020, accrued compensation due to officers and executives included as accrued compensation was $9,000 and $79,214, respectively.

 

42 
 
 

 

Related party sales contributed $0 and $5,131 to revenues for the three months ended June 30, 2021 and 2020, respectively, while related party sales contributed $0 and $8,303 to revenues for the six months ended June 30, 2021 and 2020, respectively. Related party sales are comprised of sales of the Company’s hempSMART products to the Company’s directors, officers, employees, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.

 

NOTE 12 – ACQUISITION 

On June 29, 2021, the Company, cDistro Merger Sub, Inc., a Nevada corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and cDistro, Inc., a privately-held Nevada corporation engaged in the hemp and CBD product distribution business (“cDistro”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger Sub merged with and into cDistro on June 30, 2021, with cDistro becoming a wholly-owned subsidiary of the Company and the surviving corporation in the merger (the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

 

Contingent Consideration - Earnout Agreement

 

In connection to the Merger, the Company and the securityholder of cDistro (the “cDistro Stockholder”) entered into an earnout agreement dated June 29, 2021 (the “Earnout Agreement”), whereby the Company agreed to issue additional shares of its common stock to the cDistro Stockholder as compensation for the Merger conditioned upon the achievement of certain gross revenue milestones. If cDistro meets revenue targets of $600,000 per quarter, up to a total of $2,400,000 of revenue, the Company will issue shares worth $250,000 upon the achievement each quarterly revenue target, with the number of shares to be issued at each payout date calculated based on the lessor of 220,970,059 shares of common stock or a 30% discount to the average close price of the Company’s common stock for the 20-day period immediately preceding the payout date of the earnout. In accordance with ASC 805, the Company accounts for this earnout agreement as contingent consideration based on the number of shares calculated as owed as of each quarter end, with changes in value to be recorded in earnings each reporting period.

 

Leak-Out Agreement

 

On June 29, 2021, in connection with the Merger and the Earnout Agreement, the cDistro Stockholder entered into a Lock-Up and Leak-Out Agreement with the Company pursuant to which, among other thing, such stockholder agreed to certain restrictions regarding the resale of the common stock issued pursuant to the Merger for a period of six months from the date of the Merger.

 

Employment Agreement

 

On June 29, 2021, in connection with the Merger, the Company and the Chief Executive Officer of cDistro entered into an employment agreement, pursuant to which that employee will serve as cDistro’s Chief Executive Officer for a three-year term.

 

The acquisition of cDistro is being accounted for as a business combination under ASC 805. The Company is continuing to gather evidence to evaluate what identifiable intangible assets were acquired, such as a customer list, and the fair value of each, and expects to finalize the fair value of the acquired assets within one year of the acquisition date. 

 

The aggregate preliminary fair value of consideration for the cDistro acquisition was as follows

 

     
   Amount
Cash, net of cash acquired of $99,393  $250,607 
Contingent Consideration - Earnout Agreement   1,000,000 
265,164,070 shares of common stock (not issued as of June 30, 2021)   1,617,501 
Total preliminary consideration transferred  $2,868,108 

 

During the three months ended June 30, 2021, the Company has paid $250,000 of the cash consideration.

 

43 
 
 

 

The following information summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed at the acquisition date:

     
Accounts Receivable  $40,291 
 Inventory   6,746 
 Other Assets   19,310 
 Goodwill   2,989,803 
 Accounts payable   (181,042)
 other accrued liabilities   (7,000)
 Net assets acquired  $2,868,108 

Unaudited Pro Forma Financial Information

 

The following table sets forth the pro-forma consolidated results of operations for the three and six months ended June 30, 2021 and 2020 as if the cDistro acquisition occurred on January 1, 2020. The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the acquisitions had taken place on the dates noted above, or of results that may occur in the future.

            
   Three months ended June 30,  Six months ended June 30,
   2021  2020  2021  2020
Revenue  $290,196   $152,402   $444,239   $234,221 
Operating loss   (1,067,780)   (965,158)   (1,855,860)   (1,357,315)
Net loss   (1,869,775)   (276,742)   (5,532,928)   (2,395,044)
 Net loss per common share  $(0.00)  $(0.00)  $(0.00)  $(0.01)
Weighted Average common shares outstanding   5,102,510,297    510,164,598    4,730,796,549    451,015,744 
                     

NOTE 13 – SUBSEQUENT EVENTS 

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

 

44 
 
 

 

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and results of operations together with and our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

We are focused on the research and development of (i) various species of hemp; (ii) beneficial uses of hemp and hemp derivatives; (iii) indoor and outdoor cultivation methods for hemp; (iv) technology used for cultivation and harvesting of different species of hemp, including, but not limited to, lighting, venting, irrigation, hydroponics, nutrients and soil; (v) different industrial hemp derived cannabinoids (“CBD”) and the possible health benefits thereof; and (vi) new and improved methods of hemp cannabinoid extraction omitting or eliminating the delta-9 tetrahydrocannabinol “THC” molecule.

  

Specifically, we develop and sell consumer products that include industrial hemp derived, non-psychoactive CBD as an ingredient, under the brand name “hempSMART™” through our wholly-owned subsidiary, H Smart, Inc. In addition, we provide consulting services to licensed cannabis and/or hemp operators with respect to financial accounting and bookkeeping and real property management. Our business also includes making selected investments and entering into joint ventures with start-up businesses in the legalized cannabis and hemp industries.

 

Our Products

 

hempSMART™

 

Our consumer products containing hemp and CBD are sold through our wholly-owned subsidiary H Smart, Inc. under the brand name hempSMART™. Our current hempSMART™ products offerings include the following:

 

  • hempSMART Brain™ a proprietary patented and formulated personal care consumer product encapsulated with enriched non-psychoactive industrial hemp derived CBD. This encapsulation is combined with other high quality, proprietary natural ingredients to compliment CBD to support the brain.

  • hempSMART Pain™ capsules formulated with 10mg of full spectrum, non-psychoactive CBD per serving, derived from industrial hemp, which along with a proprietary blend of other natural ingredients, are intended to deliver an all-natural formulation for the temporary relief of minor discomfort associated with physical activity.
  • hempSMART Pain Cream™ each container is formulated with 300mg of full spectrum non-psychoactive CBD derived from industrial hemp. This product contains a synergistic combination of natural botanicals and full spectrum hemp extract featuring CBD, cannabigerol, also known as CBG, and a broad range of terpenes. Our proprietary blend of Ayurvedic herbs along with menthol, cayenne pepper extract, rosemary oil, aloe gel, white willow bark, arnica, wintergreen extract and tea tree oil, is intended to provide an immediate cooling and soothing sensation. This topical product is formulated to help reduce minor discomfort and promote muscle relaxation on the areas to which it is applied.

  • hempSMART Drops™ full spectrum hemp CBD oil tincture drops available in 250mg and 500mg bottles, enriched with non-psychoactive industrial hemp derived CBD, and available in four different flavors (lemon, mint, orange and strawberry). These drops are free of the THC isolate.

 

45 
 
 

 

  • hempSMART Pet Drops™ for cats and dogs, formulated with 250mg of full spectrum non-psychoactive CBD derived from industrial hemp. This product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, fractionated coconut oil, and a rich bacon flavor.

  • hempSMART Face™ a nourishing facial moisturizer combines full spectrum CBD from hemp with a unique blend of Ayurvedic herbs and botanicals. This facial moisturizer is designed to refresh, replenish and restore skin, providing long lasting hydration and balance.

  • hempSMART Drink Mix, an industrial hemp based powderized premium CBD drink made with organic CBD infused with honey to be mixed with any beverage of preference.

Our Consulting Services

 

In addition to selling our hempSMART™ products, we also provide certain services to licensed cannabis and/or hemp operators. Our services include the following:

 

Financial Accounting and Bookkeeping

 

We provide financial accounting, bookkeeping and reporting protocols in order to allow licensed cannabis and/or hemp operators in those states where cannabis has been legalized for medicinal and/or recreational use, to report, collect, verify and state effective financial records and disclosure. We provide a comprehensive accounting strategy based on best accounting practices.

 

Real Property Management Consulting

 

Our property management consulting services consist of providing planning, budgeting, acquisition, accounting and management services to licensed cannabis and/or hemp operators in those states where cannabis and/or hemp has been legalized for medicinal and/or recreational use and who are searching for real property to conduct operations.

 

We have not yet entered into any engagements for such services and have not generated any revenue related to such services.

 

cDistro Acquisition

 

On June 29, 2021, we acquired cDistro, Inc. which is engaged in the hemp and CBD product distribution business. Specifically, cDistro distributes high quality hemp-derived cannabinoid products on its website, www.cdistro.com.cDistro (retail services/wholesale pricing) offers the CBD brands along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America. We work exclusively with select manufacturers to deliver retail service at wholesale. 

46 
 
 

Current Joint Ventures and Investments

 

Joint Ventures in Brazil and Uruguay

 

On September 30, 2020, we entered into two joint venture agreements with Marco Guerrero, our director, to form joint venture operations in Brazil and Uruguay to produce, manufacture, market and sell our hempSMART™ products in Latin America and to develop and sell hempSMART™ products globally.

 

Cannabis Global, Inc. 

 

Joint Venture

 

On May 12, 2021, we entered into a joint venture agreement with Cannabis Global, Inc. (“Cannabis Global”) pursuant to which we will invest up to $250,000 into a newly formed entity (“MCOA Lynwood”) and Cannabis Global, through Natural Plant Extracts of California, Inc., an entity in which Cannabis Global owns a majority interest, will operate a regulated and licensed laboratory to manufacture various cannabis products in the State of California. As of June 30, 2021, we have invested $158,000.

 

Share Exchange

 

On September 30, 2020, we entered into a securities exchange agreement with Cannabis Global pursuant to which we issued 650,000,000 shares of our common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global common stock. In addition, we and Cannabis Global entered into a lock-up leak-out agreement which contains certain restrictions with respect to the sales of such securities.

 

Joint Venture Subject to Ongoing Dispute

 

On March 16, 2017, we entered into a joint venture agreement with Bougainville Ventures, Inc. (“Bougainville”) to, among other things, engage in the development and promotion of products in the legalized cannabis industry in Washington State. We believe that some of the funds we paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds and that Bougainville misrepresented certain material facts in the joint venture agreement. As a result of the foregoing, on September 20, 2018, we filed suit against Bougainville, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court. See Part II, Item 1 - Legal Proceedings. 

 

Results of Operations

Three Months Ended June 30, 2021 Compared to Three Months Ended June 30, 2020

 

Revenues

 

Total revenues for the three months ended June 30, 2021 and 2020, were $16,880 and $82,958, respectively, a decrease of $66,078. This decrease is attributable to our new eCommerce sales platform as well as the slowing of the general market demand for our products and services due to the COVID-19 pandemic. Changes to our sales strategy include the rebranding of hempSMART’s products.

 

The following table identifies a comparison of our sales of products during the three months ended June 30, 2021 and 2020, respectively: 

 

       
Products  June 30, 2021  June 30, 2020
Body Lotion  $403   $1,297 
Brain   270    9,558 
Drink Mix   24    2,052 
Drops   10,352    38,908 
Face Moisturizer   89    6,436 
Pain Capsules & cDistro products (2021 only)   342    2,548 
Pain Cream   4,668    17,058 
Pet Drops   732    5,101 
Totals  $16,880   $82,958 

 

47 
 
 

 

Related Party Sales 

 

Related party sales contributed $0 and $5,131 to revenues for the three months ended June 30, 2021 and 2020, respectively. Related party sales are comprised of sales of our hempSMART products to our directors, officers, employees, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.

 

Costs of Sales

 

Costs of sales primarily consist of inventory cost and overhead, manufacturing, packaging, warehousing, shipping, and direct labor costs directly attributable to our hempSMART products. For the three months ended June 30, 2021 and 2020, our total costs of sales were $3,301 and $39,187, respectively, a decrease of $35,886. The decrease in costs of sales is due to a decline in sales as a result of the COVID-19 pandemic.

 

Gross Profit

 

For the three months ended June 30, 2021 and 2020, gross profit was $13,579 and $43,771, respectively, a decrease of $30,192. This decrease was primarily attributed to new pricing and promotions associated with our sales restructuring and new sales strategies, along with the effects of the COVID-19 pandemic during the three months ended June 30, 2021. As a result, the gross margins were 80.4% and 56.2% for the three months ended June 30, 2021 and 2020, respectively.

 

Selling and Marketing Expenses

For the three months ended June 30, 2021 and 2020, selling and marketing expenses were $155,212 and $74,212, respectively, an increase of $81,014. The increase is due primarily to the effects of the restructuring of our sales team and new sales strategies deployed during the three months ended June 30, 2021, as compared to June 30, 2020. These increases were mainly attributable to advertising/promotions of $33,769 and digital media of $47,245. The changes to the sales strategy implemented during the quarter ended June 30, 2021 included rebranding of hempSMART’s products.

Payroll and Related Expenses

For the three months ended June 30, 2021 and 2020, payroll and related expenses were $132,257 and $95,644, respectively, an increase of $36,613. This increase is attributed to an increase in headcount during the three months ended June 30, 2021, as compared to June 30, 2020.

Stock-based Compensation

For the three months ended June 30, 2021 and 2020, stock-based compensation was $139,000 and $536,452, respectively, a decrease of $397,452. This decrease was due to less shares issued to our officers and vendors during the three months ended June 30, 2021, as our cash position was higher as compared to the three-month period ended June 30, 2020.

General and Administrative Expenses

General and administrative expenses increased to $611,970 for the three months ended June 30, 2021 as compared to $211,116 for the three months ended June 30, 2020. General and administrative expenses include research and development, building rent, utilities, legal fees, office supplies, subscriptions, and office equipment. The increase of $400,854 during the three months ended June 30, 2021 is primarily attributed to increased legal fees of $162,510 related to acquisition costs and SEC filings, $87,901 for investor relations as we expanded our investor/stockholder communications, $24,750 in additional audit fees related to potential acquisition projects, $18,843 in director and officer liability insurance as rates were increased during the period due to cannabis industry risk assessments, $36,688 in travel attributed to investor and marketing events, as well as our events, $16,818 in bank fees due to wire transfers relating to payments to an investor, marketing and operation vendors, $10,000 in board fees as directors were paid in cash instead of stock, $9,527 in research and development expenses related to development of future products and $19,729 in shipping costs related to implementation and transfer of inventory to our outsourced logistics warehouse in the United States and Europe.

 

48 
 
 

Gain on Change in Fair Value of Derivative Liabilities

During the three months ended June 30, 2021 and 2020, we issued convertible promissory notes and warrants with an embedded derivative, all requiring us to adjust to reflect the fair value of the derivatives each reporting period, and mark to market as a non-cash adjustment to our current period operations. This resulted in gains of $696,729 and $1,572,964 change in fair value of derivative liabilities for the three months ended June 30, 2021 and 2020, respectively.

Loss on Equity Investment

During the three months ended June 31, 2021 and 2020, we adjusted the carrying value of our investment for our pro rata share of equity investment of $394,194 and $7,048, respectively.

Loss on Settlement of Debt

During the three months ended June 30, 2021 and 2020, we realized a loss on settlement of debt of $96,750 and $0, respectively.

Interest Expense

Interest expense during the three months ended June 30, 2021 was $891,783 compared to $881,945 for the three months ended June 30, 2020. Interest expense primarily consists of interest incurred on our convertible and non-convertible debt. The debt discounts amortization incurred during the three months ended June 30, 2021 and 2020 was $433,073 and $592,338, respectively.

Net Loss

Our net loss for the three months ended June 30, 2021 and 2020 was $1,828,117 and $186,819, respectively, an increase of $1,641,298. The net loss of $1,828,117 for the three months ended June 30, 2021 represents 10,830% of total revenues for the period. The net loss of $186,819 for the three months ended June 30, 2020, represents 225.2% of total revenues for the period.

Six Months Ended June 30, 2021 Compared to Six Months Ended June 30, 2020

 

Revenues

 

Total revenues for the six months ended June 30, 2021 and 2020 were $51,810 and $164,777, respectively, a decrease of $112,967. The decrease in total revenues of hempSMART™ products was due to the decrease in volume of sales as a result of the COVID-19 pandemic and our new eCommerce sales platform.

 

 

The following table identifies our product offerings and the revenues related to these products for the six months ended June 30, 2021 and 2020, respectively:

 

       
Products  June 30, 2021  June 30, 2020
Body Lotion  $1,067   $2,452 
Brain   361    19,674 
Drink Mix   167    2,052 
Drops   29,716    86,132 
Face Moisturizer   2,793    7,309 
Pain Capsules & cDistro products (2021 only)   343    3,646 
Pain Cream   16,423    31,906 
Pet Drops   940    11,606 
Totals  $51,810   $164,777 

 

49 
 
 

 

Related Party Sales 

 

Related party sales contributed $0 and $8,303 to revenues for the six months ended June 30, 2021 and 2020, respectively. Related party sales are comprised of sales of our hempSMART products to our directors, officers, employees, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.

 

Costs of Sales

 

Costs of sales, include the costs of product development, manufacturing, testing, packaging, storage and sale. For the six months ended June 30, 2021 and 2020, costs of sales were $28,481 and $73,392, respectively, a decrease of $44,911. The decrease was a result of decreased growth in the marketing and selling of our hempSMART™ products.

 

Gross Profit

 

For the six months ended June 30, 2021 and 2020, gross profit was $23,329 and $91,385, respectively, a decrease of $68,056. This decrease was primarily attributed to our new sales platform and new   sales pricing and promotions, along with the effects of the COVID-19 pandemic during the six months ended June 30, 2021. As a result, our gross margins were 45.0% and 58.4% for the six months ended June 30, 2021 and 2020, respectively.

 

Selling and Marketing Expenses

For the six months ended June 30, 2021 and 2020, selling and marketing expenses were $262,761 and $200,667, respectively, an increase of $62,094. This increase was attributed to our investment in social media advertising in support of our new eCommerce program promoting our rebranded hempSMART products.

Payroll and Related Expenses

 

For the six months ended June 30, 2021 and 2020, payroll and related expenses was $270,402 and $196,843, respectively, an increase of $73,559. This increase is attributed to additional head counts created during the six months ended June 30, 2021 as compared to the six months ended June 30, 2020.

Stock-based Compensation

For the six months ended June 30, 2021 and 2020, stock-based compensation was $158,900 and $542,767, respectively, a decrease of $383,867. This decrease is attributed to our improved cash position during the six months ended June 30, 2021 as compared to the six months ended June 30, 2020.

General and Administrative Expenses

General and administrative expenses increased to $1,137,652 for the six months ended June 30, 2021 compared to $415,172 for the six months ended June 30, 2020. General and administrative expenses include research and development, building rent, utilities, legal fees, office supplies, subscriptions, and office equipment. The increase of $722,480 during six months ended June 30, 2021 were primarily attributed to $23,016 in bank fees related to wire transfer fees, $46,000 in board of director fees due to renegotiated rates during the six months ended June 30, 2021, $114,132 in consulting fees related to services for medical advisory and strategic planning, $41,550 of additional fees paid for director and officer liability insurance as rates were increased dramatically by insurance carriers due to cannabis industry risk assessments, $149,720 more in investor relations during the six months ended June 30, 2021 as we expanded our investor/stockholder communications, $297,469 of additional legal consulting fees which were related to various lawsuits, SEC filings and international work related to the formation of our new subsidiaries in Brazil and Uruguay.

Loss/Gain on Change in Fair Value of Derivative Liabilities

During the six months ended June 30, 2021 and 2020, we issued convertible promissory notes and warrants with an embedded derivative, all requiring us to adjust to the fair value of the derivatives each reporting period, and mark to market as a non-cash adjustment to our current period operations. This resulted in a loss of $1,629,289 and a gain of $1,142,272 change in fair value of derivative liabilities for the six months ended June 30, 2021 and 2020, respectively.

50 
 
 

 

Loss on Equity Investment

During the six months ended June 30, 2021 and 2020, we adjusted the carrying value of our investment for our pro rata share of equity investment of $394,194 and $133,893, respectively.

Loss/Gain on Settlement of Debt

During the six months ended June 30, 2021 and 2020, we realized a loss on settlement of debt of $164,977 and a gain of $3,409, respectively. These were related to the payoffs of settlement agreements made in the ordinary course of our business during the six months ended June 30, 2021 and 2020, respectively.

Interest Expense

Interest expense during the six months ended June 30, 2021 and 2020 was $1,992,745 and $1,772,096, respectively. Interest expense primarily consists of interest incurred on our convertible and non-convertible debt. The debt discounts amortization during the six months ended June 30, 2021 and 2020 was $744,783 and $1,028,931, respectively.

Net Loss

Our net loss for the six months ended June 30, 2021 and 2020 was $5,486,107 and $2,305,121, respectively, an increase of $3,180,986. The net loss of $5,486,107 for the six months ended June 30, 2021 represents 10,589% of total revenues for the period. The net loss of $2,305,121 for the six months ended June 30, 2020, represents 1,390% of total revenues for the period.

Liquidity and Capital Resources

We have generated a net loss from continuing operations for the six months ended June 30, 2021 of $5,486,107 and used $1,841,640 cash for operations. As of June 30, 2021, we had total assets of $6,605,409, which short-term investments of $743,200, inventory of $203,898, and other current assets of $93,830. The other current assets consisted of $93,830 in advances to our new Brazilian operations, a $12,500 non-trade receivable due from a brokerage firm and advance payments to vendors.

During the six months ended June 30, 2021 and 2020, we met our capital requirements through a combination of loans, sales of equity and convertible debt instruments; however, we will need to secure additional external funding in order to continue our operations. Our primary internal sources of liquidity were provided by an increase in proceeds from the issuance of notes payable of $1,508,250 and sale of our common stock for gross proceeds of $1,358,767 for the six months ended June 30, 2021 as compared to an increase in proceeds from the issuance of note payables of $442,000 and a government loan due to COVID-19 of $35,500 for the six months ended June 30, 2020. Our ability to rely upon external financing arrangements to fund operations is not certain, and this may limit our ability to secure future funding from external sources without changes in terms requested by counterparties, changes in the valuation of collateral, and associated risk, each of which is reasonably likely to result in our liquidity decreasing in a material way. We intend to utilize cash on hand, loans and other forms of financing such as the sale of additional equity and debt securities and other credit facilities to conduct our ongoing business, and to also conduct strategic business development and implementation of our business plans generally. However, we may be unable to raise additional funds when needed on favorable terms, or at all, which may have a negative impact on our financial condition and could force us to curtail or cease our operations.

Cash Flows from Operating Activities

For the six months ended June 30, 2021, we used cash in operating activities of $1,841,640. For the six months ended June 30, 2020, we used cash in operating activities of $669,005. This decrease of $1,172,635 is due primarily to loss for the period which was offset by stock-based compensation and continued implementation of our business plans, operations, management, personnel and professional services.

 

51 
 
 

Cash Flows from Investing Activities

During the six months ended June 30, 2021, we used $289,439 in investing activities related to purchase of equipment and property of $107,934, $30,898 to establish a joint venture and $150,607 in the acquisition of a new business. During the six months ended June 30, 2020, we used $1,271 related to our purchase of property and equipment.

Cash Flows from Financing Activities

During the six months ended June 30, 2021, cash provided by financing activities was $2,236,387 as a result of our receipts of funds from the issuance of notes payable of $1,508,250 and sale of our common stock of $1,358,767, along with repayments of notes payable of $610,630 and repayments of related party notes of $20,000. During the six months ended June 30, 2020, cash provided by financing activities was $477,500 as a result of our receipt of funds from the issuance of notes payable of $442,000 and a government loan due to COVID-19 of $35,500.

Our business plans have not generated significant revenues and as of the date of this filing are not sufficient to generate adequate amounts of cash to meet our needs for cash. Our primary source of operating funds in 2021 and 2020 has been proceeds from the sale of our common stock and the issuance of convertible debt and non-convertible debt. We have experienced net losses from operations since inception, but expect these conditions to improve in 2021 and beyond as we develop direct sales and marketing programs. We had stockholders' deficiencies at June 30, 2021 and require additional financing to fund future operations. As of the date of this filing, and due to the early stages of operations, we have insufficient sales data to evaluate the amounts and certainties of cash flows, as well as whether there has been material variability in historical cash flows.

We currently do not have sufficient cash and liquidity to meet our anticipated working capital for the next twelve months. Historically, we have financed our operations primarily through private sales of our common stock and debt. If our sales goals for our hempSMART™ products do not materialize as planned, and we are not able to achieve profitable operations at some point in the future, we may have insufficient working capital to maintain our operations as we presently intend to conduct them or to fund our expansion, marketing, and product development plans. There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all.

Off Balance Sheet Arrangements; Commitments and Contractual Obligations

As of June 30, 2021, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources nor did we have any commitments or contractual obligations. 

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Note 1 to the condensed consolidated financial statements describes the significant accounting policies and methods used in the preparation of the condensed consolidated financial statements. Estimates are used for, among other things, contingencies and taxes. Actual results could differ materially from those estimates. The following critical accounting policies are impacted significantly by judgments, assumptions, and estimates used in the preparation of the condensed consolidated financial statements.

Stock-Based Compensation

 

We account for employee and non-employee compensation in accordance with Accounting Standards Codification 718-10-30 of the Financial Accounting Standards Board. See Note 3 - “Summary of Significant Accounting Policies” set forth in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is set forth in Note 3 to the condensed consolidated financial statements included elsewhere in this Quarterly Report.

JOBS Act

 

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to opt out of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition periods for complying with new or revised accounting standards is irrevocable.

 

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

COVID-19:

 

The COVID-19 global pandemic has been unprecedented and unpredictable and is likely to continue to result in significant national and global economic disruption, which may adversely affect our business. Based on the Company’s current assessment, however, the Company does not expect any material impact on its long-term strategic plans, its operations, or its liquidity due to the worldwide spread of COVID-19. However, the Company is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, suppliers, and industry. 

 

52 
 
 

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We are required to maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2021, our disclosure controls and procedures were not effective due to material weaknesses. Management has identified the following material weaknesses: our ability to prepare our financial statements in a timely manner and inadequate segregation of duties consistent with control objectives. In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we plan to create a new controller position and hire a controller in order to segregate duties within the accounting department consistent with control objectives. In addition, we also intend to increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us and we are able to find a qualified person to fill such roll.   This includes hiring a competent director of corporate reporting to help ensure that the Company meets its filing deadlines in a more timely manner.

 

Changes in Internal Control

 

There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

53 
 
 

 

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may become involved in various lawsuits and legal proceedings. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Except as set forth herein, we are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results. 

 

On September 20, 2018, we filed suit against Bougainville Ventures, Inc. (“Bougainville”), BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court. We previously entered into a joint venture agreement with Bougainville on March 16, 2017, as amended on November 6, 2017.

 

We and Bougainville originally agreed to a joint venture with the goal of participating in the legalized cannabis business in Washington State. We intended to organize and operate a cannabis growth and cultivation business on land owned by Bougainville in Oroville, Washington. Furthermore, we agreed to finance the joint venture with a cash payment of $800,000 and issued Bougainville 15 million shares of our common stock. Bougainville represented that it would provide the real property for the joint venture, computer controlled greenhouses and agricultural facilities and, as landlord, oversight of the operations of a cannabis licensee holding a I-502 cannabis license. Bougainville represented that the property was I-502 compliant, and that it had a lease payment arrangement with an I-502 license holder to operate on the land. Bougainville agreed to vend  clear title to the real property associated with the I-502 licensee to the joint venture within 30 days of the final payment by us. Despite our compliance, in full with our financial obligations, Bougainville did not and has not transferred the real property to the joint venture. We determined that Bougainville did not own the real property, misappropriated funds paid into the joint venture for its own purposes and did not have an agreement with a licensed I-502 operator.

 

Pursuant to our complaint, we are seeking legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the registrant, for the appointment of a receiver, the return to treasury of the 15 million shares of common stock issued to Bougainville, and, for treble damages pursuant to the Consumer Protection Act in Washington State. We have filed a lis pendens on the real property.

 

We recently served process on the defendants and the case is currently in litigation. The case is currently set for trial on January 22, 2022.

ITEM 1A. RISK FACTORS.

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2020 (“Annual Report”). There have been no material changes in our risk factors from those previously disclosed in our Annual Report. You should carefully consider the risks described in our Annual Report, which could materially affect our business, financial condition or future results. The risks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

 

54 
 
 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the quarter ended June 30, 2021, the Company issued the following securities:

On April 1, 2021, the Company issued 56,883,314 shares of its common stock upon the conversion of a convertible note.

On April 22, 2021, the Company issued 20,000,000 shares of its common stock to the Company’s Chief Executive Officer as consideration for services.

On June 9, 2021, the Company issued 8,445,314 shares of its common stock upon the conversion of a convertible note.

On June 9, 2021, the Company issued 84,456,280 shares of its common stock upon the conversion of a convertible note.

On June 9, 2021, the Company issued 60,325,556 shares of its common stock upon the conversion of a convertible note.

On June 10, 2021, the Company issued 17,566,093 shares of its common stock upon the conversion of a convertible note.

On June 23, 2021, the Company issued 18,274,353 shares of its common stock upon the conversion of a convertible note.

On June 25, 2021, the Company issued 22,500,000 shares of its common stock to a consultant in settlement of accrued compensation.

The foregoing issuances were exempt from registration under Section 4(a)(2) of the Securities Act

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

ITEM 5. OTHER INFORMATION.

 

None.

 

55 
 
 

 

ITEM 6. EXHIBITS.

 

Exhibit
No.
  Description
     
2.1   Agreement and Plan of Merger, dated June 29, 2021, by and among Marijuana Company of America, Inc., cDistro Merger Sub, Inc. and cDistro, Inc. (Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2021)
     
10.1+   First Amendment to Executive Employment Agreement, dated April 27, 2021, by and between the Company and Jesus Quintero (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2021)  
     
10.2   Joint Venture Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2021)
     
10.3  

Form of Earnout Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2021)

 

     
10.4   Form of Lock-Up and Leak-Out Agreement (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2021)
     
10.5   Form of Stock Purchase Agreement (Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2021)
     
10.6+   Form of Employment Agreement (Incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2021)
     
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline  XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 is formatted in Inline XBRL

 

 

* Filed herewith.

 

+ Indicates a management contract or any compensatory plan, contract or arrangement.

 

 

 

56 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MARIJUANA COMPANY OF AMERICA, INC.
     
Date:  August 19, 2021 By: /s/ Jesus Quintero
    Jesus Quintero,
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial and Accounting Officer)
     

 

 

 

 

 

57 
 
 

 

EX-31.1 2 ex31x1.htm EXHBIT 31.1

 

EXHIBIT 31.1

 

RULE 13a-14(a)/15d-14(a) CERTIFICATION

 

I, Jesus M. Quintero, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2021 of Marijuana Company of America, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.       The registrant’s other certifying officer(s) and I are responsible for establishing for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  1. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,
  1. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  1. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.       The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  1. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

August 19, 2021

 

  /s/ Jesus M. Quintero
  Jesus M. Quintero
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

EX-31 3 ex31x2.htm EXHIBIT 31.2

 

 EXHIBIT 31.2

 

RULE 13a-14(a)/15d-14(a) CERTIFICATION

 

I, Jesus M. Quintero, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2021 of Marijuana Company of America, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.       The registrant’s other certifying officer(s) and I are responsible for establishing for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  1. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,
  1. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  1. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.       The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  1. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

August 19, 2021

 

  /s/ Jesus M. Quintero
  Jesus M. Quintero, Chief Financial Officer
  (Principal Financial and Accounting Officer)

  

 

EX-32.1 4 ex32x1.htm EXHBIIT 32.1

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Marijuana Company of America, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Jesus M. Quintero, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.       The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

August 19, 2021

 

  /s/ Jesus M. Quintero
  Jesus M. Quintero
  Chief Executive Officer
  (Principal Executive Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

EX-32.2 5 ex32x2.htm EXHBIT 32.2

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Marijuana Company of America, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Jesus M. Quintero, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.       The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

August 19, 2021

 

  /s/ Jesus M. Quintero
  Jesus M. Quintero
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 

EX-101.SCH 6 mcoa-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - OPERATING LEASE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - FAIR VALUE MEASUREMENT link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - STOCKHOLDERS’ DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - FAIR VALUE MEASUREMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - OPERATING LEASE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NOTES PAYABLE, RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - STOCKHOLDERS' DEFICIT (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - FAIR VALUE MEASUREMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - ACQUISITION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - ACQUISITION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mcoa-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 mcoa-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 mcoa-20210630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Preferred Class A [Member] Preferred Class B [Member] Equity Components [Axis] Preferred Stock Class A [Member] Preferred Stock Class B [Member] Common Stock [Member] Common Stock To Be Issued [Member] Stock Subcriptions [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncash or Part Noncash Acquisitions by Unique Description [Axis] Sparrowtech, Inc. [Member] Long-Lived Tangible Asset [Axis] Property, Plant and Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Segments [Axis] Operating Segment [Member] Other Commitments [Axis] Lease Agreements [Member] Computer Equipment [Member] Furniture and Fixtures [Member] Machinery and Equipment [Member] Investment, Name [Axis] Joint Venture Agreement With Bougainville Ventures Inc [Member] Investment Type [Axis] Investments [Member] Investment Secondary Categorization [Axis] Global Hemp Group [Member] Benihemp [Member] Money Trac [Member] Bougainville Ventues [Member] Stock Option Plan [Member] Short-term Investments [Member] Cannabis [Member] E C O X [Member] Lynwood [Member] Natural Plant [Member] Vivabuds [Member] Global Hemp [Member] Short-term Debt, Type [Axis] Convertible Notes Payable - Power Up Lending Group [Member] Convertible Notes Payable - Crown Bridge Partners [Member] Convertiblenotepayable Labrys [Member] Convertible Notes Payable - GS Capital Partners LLC [Member] Convertible Note Payable Geneva Roth [Member] Convertible Notes Payable - Robert Hymers III [Member] Convertible Promissory Notes - October 30, 2019, Odyssey Funding LLC [Member] Convertible Note Payable Redstart H L D G S [Member] Convertible Note Payable G W Holdings [Member] Convertible Promissory Notes - October 23, 2019, Paladin Advisors LLC [Member] Related Party Transaction [Axis] Labrys [Member] Power Up Lending [Member] Convertible Promissory Notes From October 01 Through December 31, 2019 - Crown Bridge Partners [Member] Secured Convertible Promissory Notes March 25, 2019 - St George Investments [Member] Odyssey Funding L L C [Member] Paladin Advisors L L C [Member] Convertible Promissory Notes - December 19, 2019, GS Capital Partners LLC [Member] Secured Convertible Promissory Notes August 28, 2018 - St George Investments [Member] Award Type [Axis] Warrant [Member] Secured Convertible Promissory Notes January 29, 2019 - St George Investments [Member] Convertible Promissory Notes - December 23, 2019, Robert L. Hymers III [Member] G W Holdings Group [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Common Stock Four [Member] Common Stock Five [Member] Common Stock Six [Member] Liability Class [Axis] Derivative Financial Instruments, Liabilities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Related Party [Axis] Officers And Executives [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Short-term investments Accounts receivable, net Inventory Prepaid insurance Other current assets   Total current assets Property and equipment, net Other assets: Long-term investments Right-of-use-assets Goodwill Security deposit Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable Accrued compensation Accrued liabilities Notes payable, related parties Loans payable PPP Stimulus Convertible notes payable, net of debt discount of $1,122,225 and $808,980, respectively Loans payable - acquisition Contingent liability - acquisition Right-of-use liabilities - current portion Subscriptions payable Derivative liability   Total current liabilities Total liabilities Stockholders' deficit: Preferred stock, $0.001 par value, 50,000,000 shares authorized Common stock, $0.001 par value; 15,000,000,000 shares authorized; 5,068,524,855 and 3,136,774,861 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively Common stock to be issued, 266,164,070 and 11,892,411 shares, respectively Additional paid in capital Accumulated deficit   Total stockholders' deficit Total liabilities and stockholders' deficit Statement [Table] Statement [Line Items] Convertible note payable, net of debt discount Preferred stock, par value per share Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock to be issued Income Statement [Abstract] REVENUES: Sales Related party sales Total Revenues Cost of sales Gross profit OPERATING EXPENSES: Depreciation Selling and marketing Payroll and related Stock-based compensation General and administrative   Total operating expenses Net loss from operations OTHER INCOME (EXPENSES): Interest expense, net Impairment gain (loss) on joint ventures Loss on equity investment Gain (loss) on change in fair value of derivative liabilities Unrealized gain (loss) on trading securities Loss on sale of trading securities (Loss) gain on settlement of debt Total other income (expense) Net loss before income taxes Income taxes (benefit) NET INCOME (LOSS) Loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted (after stock-split) Beginning balance, value Beginning Balance, shares Common stock issued to settle amounts previously accrued Issuance of preferred stock to officer Common stock issued to settle amounts previously accrued, shares Common stock issued for services rendered Common stock issued for services rendered, shares Common stock issued in settlement of convertible notes payable and accrued interest Common stock issued in settlement of convertible notes payable and accrued interest, shares Issuance of common stock for settlement of liabilities Issuance of common stock for setlement of liabilities, shares Issuance of common stock for settlement of liabilities – related parties Converson of related party notes payable, Shares Common stock issued in exchange for exercise of warrants on a cashless basis Common stock issued in exchange for exercise of warrants on a cashless basis, shares Sale of common stock Sale of common stock, shares Issuance of common stock for investments Issuance of common stock for investments, shares Common shares issued in settlement of legal case Common stock issued in settlement of legal case, shares Reclassification of derivative liabilities to additional paid in capital Debt discount from warrants issued with convertible notes payable Common stock issued for acquisition of business Common stock issued for acquisition of business, Shares Net Loss Ending balance, value Ending Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of debt discount Depreciation and amortization Impairment loss on equity investment Loss on equity investment Loss (gain) on change in fair value of derivative liability Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance Loss on share inducement and settlement of warrant liability Stock-based compensation Unrealized (gain) loss on trading securities Loss on settlement of liabilities Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Accounts payable Accrued expenses and other current liabilities Right-of-use assets Right-of-use liabilities Net cash provided by (used in) operating activities Cash flows from investing activities: Purchases of property and equipment Payment to establish joint venture Acquisition of business Net cash provided by (used in) investing activities Cash flows from financing activities: Proceeds from issuance of notes payable Proceeds from PPP loan payable Repayments of notes payable Repayments to related parties Proceeds from sale of common stock Net cash provided by (used in) financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for taxes Non cash financing activities: Common stock issued in settlement of convertible notes payable Reclassification of derivative liabilities to additional paid-in capital Common stock issued for investment Common stock issued to settle liabilities Common stock to be issued for acquisition of business Common shares issued in settlement of legal case Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS AND BASIS OF PRESENTATION GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Leases [Abstract] OPERATING LEASE Property, Plant and Equipment [Abstract] PROPERTY, MACHINERY AND EQUIPMENT Investments, All Other Investments [Abstract] INVESTMENTS Notes Payable Related Party NOTES PAYABLE, RELATED PARTY Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ DEFICIT Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENT Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Business Combination and Asset Acquisition [Abstract] ACQUISITION Subsequent Events [Abstract] SUBSEQUENT EVENTS Interim Financial Statements Revenue Recognition Identification of Our Contracts with Customers Product Sales Consulting Services Use of Estimates Cash Concentrations of Credit Risk Accounts Receivable Allowance for Doubtful Accounts Inventories Cost of Sales Stock-Based Compensation - Employees Stock-Based Compensation – Non Employees Earnings per Share Property and Equipment Investments Derivative Financial Instruments Fair Value of Financial Instruments Advertising Segment Information Income Taxes Recent Accounting Pronouncements Segment Information Schedule of Property and Equipment Schedule of Investment Roll Forward Schedule of Convertible Notes Payable Summarizes the Stock Warrant Activity Summary of Changes in Fair Value of Derivative Liabilities Schedule of aggregate preliminary fair value Schedule summarizes the preliminary allocation of the fair values Schedule of pro-forma consolidated results of operations Noncash or Part Noncash Acquisitions [Table] Noncash or Part Noncash Acquisitions [Line Items] Merger description of Sparrowtech, Inc Net losses from operations Net cash used cash in operations SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items] Revenues Cost of Goods Sold Gross Profit Expense Stock Based Compensation Selling and Marketing Payroll and Related expenses Depreciation Expense General and Admin Expenses Total Expense Net Loss from Operations Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Allowance for doubtful accounts Depreciation calculation method Estimatied useful lives Advertising cost Unrecognized tax benefits Other Commitments [Table] Other Commitments [Line Items] Monthly rent Property and equipment, gross Less accumulated depreciation Property and equipment, net Depreciation expense Investment Income [Table] SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items] Investment, Beginning balance Investments made Equity method Loss Equity method Loss Equity method Loss Equity method Loss Equity method Loss Impairment of Investment Investment, Beginning balance Investments made Investment, Ending balance Unrealized gains on trading securities Sale of trading securities Reversal of Equity method Loss Loss on disposition of investment Recognize Joint venture liabilities per JV agreement Unrealized gain on Global Hemp Group securities       - Debt obligation of JV       - Convertible NP, net of discount       - Long term debt Total Debt balance Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Total committed amount to raise for joint ventures Cash investment Annual impairment Equity losse Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Total Less debt discounts Net Less current portion Long term portion Accrued interest Debt principal amount Convertible promissory note face value Convertible promissory note interest rate Convertible promissory note conversion terms Convertible promissory note payment terms Convertible promissory note original issue discount Debt discount Convertible notes payable Accrued interest Legal, accounting and other transaction costs with respect to convertible promissory note Convertible promissory note overfunding Warrants issued for debt as an investment incentive Fair value of issued warrants Shares issued for settlement of debt, value Derivative liabilities portion of debt converted into common stock Shares issued for settlement of debt, shares Gain (loss) on debt settlement Gross proceeds from convertible promissory note Net proceeds from convertible promissory notes Exercisable price Convertible promissory note due date description Outstanding at Beginning of Period Outstanding at Beginning of Period Outstanding at Beginning of Period Outstanding at Beginning of Period Granted Granted Granted, years Granted Increase due to reset provision Increase due to reset provision, years Increase due to reset provision Exercised Exercised Exercised Exercised Outstanding at End of Period Outstanding at End of Period Exercisable at End of Period Outstanding at End of Period Exercisable at End of Period Exercisable at End of Period [custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3] Exercisable at End of Period Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock voting rights Common Stock, Par or Stated Value Per Share Common Stock, Shares, Outstanding Sale of common stock, value Common stock, description Common Stock, Shares Authorized Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Balance at beginning Increase resulting from initial issuances of additional convertible notes payable Decreases resulting from conversion or payoff of convertible notes payable Decreases resulting from payoff of convertible notes payable Loss due to change in fair value included in earnings Balance at end Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Note payable Related party sales contributed Cash, net of cash acquired of $99,393 Contingent Consideration - Earnout Agreement 265,164,070 shares of common stock (not issued as of June 30, 2021) Total preliminary consideration transferred Revenue Operating loss Net loss  Net loss per common share Weighted Average common shares outstanding Accounts Receivable  Inventory  Other Assets  Goodwill  Accounts payable  other accrued liabilities  Net assets acquired Cash Paid Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Interest Expense ImpairmentOfJointVenture DerivativeLossOnDerivatives TradingSecuritiesRealizedLos Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Domestic Shares, Outstanding LossOnEquityInvestment Unrealized Gain (Loss) on Derivatives Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation UnrealizedGainLossOnTradingSecurities GainLossOnSettlementOfDebt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Noncurrent Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentToEstablishJointVenture Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect CommonSharesIssuedInSettlementOfLegalCase Cash and Cash Equivalents, Policy [Policy Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Investments [Default Label] GainLossOnInvestments2 EquityMethodAccounting EquityMethodAccounting1 GainLossOnInvestment Convertible Debt, Current Interest Payable, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised Cancellation of JV debt obligation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Induced Conversion of Convertible Debt Expense BusinessAcquisitionAccountsReceivable EX-101.PRE 10 mcoa-20210630_pre.xml XBRL PRESENTATION FILE XML 11 mcoa_10q-063021v2_htm.xml IDEA: XBRL DOCUMENT 0001078799 2021-01-01 2021-06-30 0001078799 2021-08-19 0001078799 2021-06-30 0001078799 2020-12-31 0001078799 us-gaap:PreferredClassAMember 2021-06-30 0001078799 us-gaap:PreferredClassAMember 2020-12-31 0001078799 us-gaap:PreferredClassBMember 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2020-12-31 0001078799 2021-04-01 2021-06-30 0001078799 2020-04-01 2020-06-30 0001078799 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2019-12-31 0001078799 MCOA:PreferredStockClassBMember 2019-12-31 0001078799 us-gaap:CommonStockMember 2019-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2019-12-31 0001078799 MCOA:StockSubcriptionsMember 2019-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001078799 us-gaap:RetainedEarningsMember 2019-12-31 0001078799 2019-12-31 0001078799 MCOA:PreferredStockClassAMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-01-01 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-01-01 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-01-01 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-06-30 0001078799 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-12-31 0001078799 MCOA:PreferredStockClassBMember 2020-12-31 0001078799 us-gaap:CommonStockMember 2020-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2020-12-31 0001078799 MCOA:StockSubcriptionsMember 2020-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001078799 us-gaap:RetainedEarningsMember 2020-12-31 0001078799 MCOA:PreferredStockClassAMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-01-01 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-01-01 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-01-01 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassAMember 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-06-30 0001078799 MCOA:SparrowtechIncMember 2009-10-01 2009-10-31 0001078799 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001078799 srt:MinimumMember us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001078799 srt:MaximumMember us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-03-31 0001078799 MCOA:OperatingSegmentMember 2021-04-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-03-31 0001078799 MCOA:OperatingSegmentMember 2020-04-01 2020-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-06-30 0001078799 us-gaap:LeaseAgreementsMember 2019-06-29 2019-07-02 0001078799 us-gaap:ComputerEquipmentMember 2021-06-30 0001078799 us-gaap:ComputerEquipmentMember 2020-12-31 0001078799 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001078799 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001078799 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001078799 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-03-16 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-11-06 0001078799 2017-01-01 2017-12-31 0001078799 2018-01-01 2018-03-31 0001078799 2018-04-01 2018-06-30 0001078799 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2016-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2016-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2016-12-31 0001078799 MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-01-01 2017-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-12-31 0001078799 MCOA:GlobalHempMember us-gaap:ShortTermInvestmentsMember 2017-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2017-12-31 0001078799 MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-01-01 2018-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2018-12-31 0001078799 MCOA:InvestmentMember 2019-01-01 2019-03-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-01-01 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-01-01 2019-03-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-03-31 0001078799 MCOA:GlobalHempMember us-gaap:ShortTermInvestmentsMember 2019-03-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001078799 MCOA:GlobalHempMember us-gaap:ShortTermInvestmentsMember 2019-06-30 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-09-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-10-01 2019-12-31 0001078799 MCOA:GlobalHempGroupMember 2019-10-01 2019-12-31 0001078799 MCOA:VivabudsMember 2019-10-01 2019-12-31 0001078799 MCOA:NaturalPlantMember 2019-10-01 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-01-01 2020-03-31 0001078799 MCOA:GlobalHempGroupMember 2020-01-01 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-03-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0001078799 MCOA:InvestmentMember 2020-04-01 2020-06-30 0001078799 MCOA:GlobalHempGroupMember 2020-04-01 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-04-01 2020-06-30 0001078799 MCOA:MoneyTracMember us-gaap:ShortTermInvestmentsMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-06-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:MoneyTracMember 2020-06-30 0001078799 MCOA:InvestmentMember 2020-07-01 2020-09-30 0001078799 MCOA:GlobalHempGroupMember 2020-07-01 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-07-01 2020-09-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:MoneyTracMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-10-01 2020-12-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-10-01 2020-12-31 0001078799 MCOA:GlobalHempGroupMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2020-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-12-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:MoneyTracMember 2020-12-31 0001078799 MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-01-01 2021-03-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-03-31 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:MoneyTracMember 2021-03-31 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2021-04-01 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-04-01 2021-06-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:GlobalHempGroupMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:CannabisMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:ECOXMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:BenihempMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:LynwoodMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:MoneyTracMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:BougainvilleVentuesMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:GateCResearchMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:NaturalPlantMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:VivabudsMember MCOA:InvestmentMember 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-06-30 0001078799 MCOA:GlobalHempMember MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:MoneyTracMember 2021-06-30 0001078799 2020-03-31 0001078799 2019-09-30 0001078799 2019-06-30 0001078799 2019-03-31 0001078799 2018-12-31 0001078799 2017-12-31 0001078799 MCOA:ConvertibleNotePayableElevenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableElevenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2020-12-31 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2021-06-30 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2020-12-31 0001078799 MCOA:LabrysMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-24 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2019-10-01 2019-12-31 0001078799 MCOA:OdysseyFundingLLCMember 2021-06-30 0001078799 MCOA:OdysseyFundingLLCMember 2020-12-31 0001078799 MCOA:PaladinAdvisorsLLCMember 2021-06-30 0001078799 MCOA:PaladinAdvisorsLLCMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2019-12-19 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-28 0001078799 us-gaap:WarrantMember MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2021-03-30 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-01 2019-09-30 0001078799 us-gaap:WarrantMember MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-25 0001078799 us-gaap:WarrantMember MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2020-12-23 0001078799 MCOA:GWHoldingsGroupMember 2020-01-01 2020-01-06 0001078799 2021-02-24 2021-02-26 0001078799 us-gaap:PreferredClassAMember 2021-01-01 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockTwoMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockThreeMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFourMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFiveMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockSixMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockTwoMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockThreeMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFourMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFiveMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockSixMember 2020-01-01 2020-06-30 0001078799 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2020-12-31 0001078799 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-01-01 2021-06-30 0001078799 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2020-12-31 iso4217:USD shares iso4217:USD shares pure 0001078799 false --12-31 2021 Q2 10-Q true 2021-06-30 false 000-27039 MARIJUANA COMPANY OF AMERICA, INC. UT 98-1246221 633 West Fifth Street Suite 2826 Los Angeles CA 90071 (888) 777-4362 Yes Yes Non-accelerated Filer true true true false 5405130704 179811 74503 743200 239063 47570 8640 203898 103483 55783 93830 56121 1268309 537593 111898 6542 2232899 1552001 7858 2989803 2500 2500 6605409 2106494 706396 480877 9000 79214 136108 401461 20000 40000 35500 35500 1122225 808980 497775 1426894 100000 1000000 7858 1063977 670000 1904016 4426057 5472772 7567861 5472772 7567861 0.001 0.001 50000000 50000000 0.001 0.001 10000000 10000000 10000000 10000000 10000000 10000000 0.001 0.001 5000000 5000000 2000000 2000000 2000000 2000000 0.001 0.001 15000000000 15000000000 5068524855 5068524855 3136774861 3136774861 5068525 3136775 266164070 11892411 266164 11892 87581650 77687561 -91795702 -86309595 1132637 -5461367 6605409 2106494 16880 77827 51810 156474 5131 8303 16880 82958 51810 164777 3301 39187 28481 73392 13579 43771 23329 91385 1262 1582 2653 3328 155212 74212 262761 200667 132257 95644 270402 196843 139000 536452 158900 542767 611970 211116 1137652 415172 1039701 919006 1832368 1358777 -1026122 -875235 -1809039 -1267392 891783 881945 1992745 1772096 -7048 260954 -394194 -7048 -394194 -133893 -696729 -1572964 1629289 -1142272 -115997 504137 -13945 2603 2603 -96750 -164977 3490 -801995 688416 -3677068 -1037729 -1828117 -186819 -5486107 -2305121 -1828117 -186819 -5486107 -2305121 -0.00 -0.00 -0.00 -0.01 4837346227 245000528 4465632479 185851674 10000000 10000 77958081 77958 63467054 -74164213 -10609201 8333 8 6692 6700 44658333 44658 498108 542766 270547861 270549 43994720 43995 1216928 1531472 21384103 21384 29229 50613 51054214 51054 1000000 1000 375446 427500 3677889 3678 952573 956251 2231014 2231014 -2305121 -2305121 10000000 10000 469288814 469289 44994720 44995 68777044 -76469334 -7168006 10000000 10000 2000000 2000 3136774841 3136775 11892411 11892 77687561 -86309595 -5461367 21000020 21000 119900 140900 810689880 810690 930184 1740874 3027031 3027 -10892411 -10892 16488 8623 22500000 22500 119250 141750 400000000 400000 -400000 632597599 632598 726169 1358767 41935484 41935 608065 650000 5975670 5975670 446026 446026 265164070 265164 1352337 1617501 -5486107 -5486107 10000000 10000 2000000 2000 5068524855 5068525 266164070 266164 87581650 -91795702 1132637 -5486107 -2305121 744783 1028931 2653 3328 260954 -394194 -133895 -1629289 1142272 1035115 395607 0 138885 140900 542767 504137 -27403 -168272 -0 -1361 -9752 93669 9290 -37309 95384 155661 145784 -67264 195874 -7858 -6767 -7858 -6885 -1841640 -669005 107934 1271 30898 -0 -150607 0 -289439 -1271 1508250 442000 0 35500 610630 -0 20000 -0 1358767 0 2236387 477500 105308 -192776 74503 211765 179811 18989 1740874 1531471 5975670 2231014 650000 8623 1617501 956251 <p id="xdx_80F_eus-gaap--NatureOfOperations_zR0uEbqjIsUk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 1 – <span id="xdx_821_zLiTVd2hHboi">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Marijuana Company of America, Inc. (the “Company”) was incorporated under the laws of the State of Utah in October 1985 under the name Mormon Mint, Inc. The corporation was originally a startup company organized to manufacture and market commemorative medallions related to the Church of Jesus Christ of Latter Day Saints. On January 5, 1999, Bekam Investments, Ltd. acquired one hundred percent of the common shares of the Company and spun the Company off changing its name Converge Global, Inc. From August 13, 1999 until November 20, 2002, the Company focused on the development and implementation of Internet web content and e-commerce applications. <span id="xdx_903_eus-gaap--NoncashOrPartNoncashAcquisitionDescription_c20091001__20091031__us-gaap--NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis__custom--SparrowtechIncMember" title="Merger description of Sparrowtech, Inc">In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties.</span> From 2009 to 2014, we operated primarily in the mining exploration business.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In 2015, the Company changed its business model to a marketing and distribution company for medical marijuana. In conjunction with the change, the Company changed its name to Marijuana Company of America, Inc. At the time of the transition in 2015, there were no remaining assets, liabilities or operating activities of the mining business.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On September 21, 2015, the Company formed H Smart, Inc., a Delaware corporation as a wholly owned subsidiary for the purpose of operating the hempSMART™ brand.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On February 1, 2016, the Company formed MCOA CA, Inc., a California corporation as a wholly owned subsidiary to facilitate mergers, acquisitions and the offering of investments or loans to the Company.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On May 3, 2017, the Company formed Hempsmart Limited, a United Kingdom corporation as a wholly owned subsidiary for the purpose of future expansion into the European market.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries H Smart, Inc., Hempsmart Limited and MCOA CA, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements set forth in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2021 (the “Annual Report”).</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020.</p> In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties. <p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z4sPsmCiwXHf" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 2 – <span id="xdx_821_zWGfcoG6heh9">GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, during the six months ended June 30, 2021, the Company incurred net losses from operations of $<span id="xdx_903_ecustom--OperatingLoss_pp0p0_c20210101__20210630_z3OBS6teykF3" title="Net losses from operations">5,486,107</span> and used cash in operations of $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20210101__20210630_zGZt5ECY8hc9" title="Net cash used cash in operations">1,841,640</span>. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company's primary source of operating funds for the six months ended June 30, 2021 was from revenue generated from the issuance of convertible and non-convertible debt. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2021 and beyond as it continues to develop its <span style="background-color: white">direct sales and marketing programs</span>; however, no assurance can be provided that the Company will not continue to experience losses in the future. The Company has stockholders' deficiencies as of June 30, 2021 and requires additional financing to fund future operations.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding; however, <span style="background-color: white">there can be no assurance that the Company will be successful in developing profitable operations or that it will be able to obtain financing on favorable terms, if at all. </span>The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.</p> 5486107 -1841640 <p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_znJyNn5NyEJa" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 –<span id="xdx_824_z2WKVjcJI751">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_847_ecustom--InterimFinancialStatementsPolicyTextBlock_zDFJbmwpcWTj" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zmLtoQbxukyb">Interim Financial Statements</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zxjmY1AK31Pe" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zPs9xn1u1SXb">Revenue Recognition</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.</p> <p id="xdx_841_ecustom--IdentificationOurContractswithCustomersTextBlock_zM61mgclVF26" style="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zIF4Dzuy2Wnd">Identification of Our Contracts with Customers</span></span></span><span style="font-size: 8pt"> </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Determination of the Price in Our Sales Contracts</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Allocation of the Transaction Price of Our Sales Contracts</span></i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Recognition of Revenue when the Performance Obligation is Satisfied</span></i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Identifying the Performance Obligations in Our Sales Contracts</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_ecustom--ProductSalesPolicyTextBlock_zhtlGwypt2R5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zkW1G55EuZIf">Product Sales</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.</p> <p id="xdx_841_ecustom--ConsultingServicesPolicyTextBlock_zqRn0lNqcaP5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zlAaZ7PILdg6">Consulting Services</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.</span><span style="font-size: 8pt">  </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605</span><span style="font-size: 8pt">  </span> <span style="font-size: 10pt">to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.</span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zc1C8GtvZpS6" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zJvLAIbwIPMf">Use of Estimates</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p> <p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSbQ6bDdXge8" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zqGVs0g61TOi">Cash</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.</p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z2opAuNRRBKe" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zscNpgXHS93j">Concentrations of Credit Risk</span></span></p> <p style="font: 12pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash </span><span style="font-size: 8pt">  </span><span style="font-size: 10pt">in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.</span></p> <p id="xdx_84B_eus-gaap--ReceivablesPolicyTextBlock_zbMWrotWG5Gk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zHRQXjjVBAAf">Accounts Receivable</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.</p> <p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zRUjxMn7vBhi" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zUMgrqXPpFnf">Allowance for Doubtful Accounts</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20210630_pp0p0" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20201231_pp0p0" title="Allowance for doubtful accounts">0</span>, respectively.</p> <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zj3lzjC3u2pb" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zr4R9BTDPX67">Inventories</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.</p> <p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z1rdmVLUNZu5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zgQUQJktRr27">Cost of Sales</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Cost of sales is comprised of cost of product sold, packaging, and shipping costs.</p> <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJCiacJ2P4Be" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222"><span style="text-decoration: underline"><span id="xdx_865_zqjMc94XTv9f">Stock-Based Compensation - Employees</span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><span style="font-size: 10pt; color: #222222">The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6</span><span style="font-size: 8pt"/><span style="font-size: 10pt; color: #222222">, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222">The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="width: 1%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="width: 94%; padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected term of share options and similar instruments</i>. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. </span></td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; width: 5%"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; width: 1%"> </td> <td style="padding-bottom: 12pt; text-align: justify; width: 94%"><span style="font-size: 10pt; color: #222222"><i>Expected volatility of the entity’s shares and the method used to estimate it</i>.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected annual rate of quarterly dividends</i>.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Risk-free rate(s)</i>. An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222">The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.</p> <p id="xdx_840_ecustom--StockBasedCompensationNonEmployeesTextBlock_zlDLykWKAtji" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222"><span style="text-decoration: underline"><span id="xdx_862_zD0D173wWCyj">Stock-Based Compensation – Non Employees</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222"><i><span style="text-decoration: underline">Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="width: 1%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="width: 97%; padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected term of share options and similar instruments</i>: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. </span><span style="font-size: 8pt; color: black">  </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected volatility of the entity’s shares and the method used to estimate it</i>.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected annual rate of quarterly dividends</i>.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Risk-free rate(s)</i>. An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.</span></td></tr> </table> <p style="font: 11pt/106% Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGPIYd81yId" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zO7oW3gX90Sd">Earnings per Share</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.</p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0BJ1NpIEek7" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zF1y4i1BEhFb">Property and Equipment</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentDepreciationMethods_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember" title="Depreciation calculation method">straight-line method</span> over their estimated useful lives of <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zPnmYvZfgCKf" title="Estimatied useful lives">3</span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zX7d6cM8d5Na" title="Estimatied useful lives">5</span> years.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zckljGXu6cxk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zaTPr3acjhhh">Investments</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).</p> <p id="xdx_84C_eus-gaap--DerivativesReportingOfDerivativeActivity_z80LTdY6LHJj" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_z0nZ3GzOiIUd">Derivative Financial Instruments</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.</p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmwtsupt0yL3" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zwSMPo5a9QMl">Fair Value of Financial Instruments</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.</p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zcSmULDCdd46" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_z9BeqGPmdq07">Advertising</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $<span id="xdx_901_eus-gaap--AdvertisingExpense_c20210101__20210630_pp0p0" title="Advertising cost">168,780 </span>and $<span id="xdx_903_eus-gaap--AdvertisingExpense_c20200101__20200630_pp0p0" title="Advertising cost">44,659 </span>for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.</p> <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYOdCAM9Rusd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="text-decoration: underline"><span id="xdx_867_zpcKpSvke687">Segment Information</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>hempSMART</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENT OF OPERATIONS</b></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020</b></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zpVSCNDmjwNb" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zSnR5jPjW3cl" style="display: none">Segment Information</span></span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_49D_20210101__20210331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zG7wgCiQeIEd" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_497_20210401__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z65CC2r0hqJj" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_495_20210101__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_ztglHcNdZeC2" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_490_20200101__20200331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zQUdktSCvX7l" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200401__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z7yNHdlGzi01" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200101__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zyhNlzEvjYzk" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,872</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">16,537</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51,409</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">81,819</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82,958</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">164,777</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost of Goods Sold</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,032</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,301</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28,333</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,205</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">39,187</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">73,392</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gross Profit</span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9,840</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,236</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">23,076</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">47,614</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,771</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">91,385</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_z4zqZTuPgC81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zm1OnaqK5gP" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock Based Compensation</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">—</span>  </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z6HWEb4V1XNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Selling and Marketing</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97,812</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">150,881</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">248,693</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">101,897</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">74,356</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">176,253</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--PayrollAndRelatedExpenses_zPtbejd8mxF" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Payroll and Related expenses</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,947</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54,864</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">108,811</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,749</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">32,113</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">50,862</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--Depreciation_zRcA5MexKVDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,782</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,746</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,328</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_zJhzbm5jd9U1" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">General and Admin Expenses</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">55,801</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">95,864</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">151,665</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">67,949</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,911</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">121,860</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingExpenses_zLPrhAGKkxb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total Expense</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">208,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">303,000</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">511,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">190,341</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">179,812</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">370,153</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperations_zTw5PeRLoqF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net Loss from Operations</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(199,111</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(289,764</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(488,875</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(142,727</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(136,041</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(278,768</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"/> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zMVwiNwDV4rk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zQqhHG8clcm1">Income Taxes</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has <span id="xdx_901_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20210630_zIUajj2Usw1" title="Unrecognized tax benefits"><span id="xdx_902_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20201231_zno1Y0GiZK2l" title="Unrecognized tax benefits">no</span></span>t recorded any unrecognized tax benefits.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z80YElqjMm61" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86F_zAJmnUv6ixE6">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Recently Issued Accounting Pronouncements Not Yet Adopted</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"/></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt; background-color: white"><i>Recently Issued Accounting Pronouncements Adopted</i></span><span style="font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><i><span style="text-decoration: underline">Accounting for Income Taxes</span></i> In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes (Topic 740)</i>. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202</span>1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Equity Securities, Equity-method Investments and Certain Derivative</span></i><span style="text-decoration: underline">s</span> In January 2020, the FASB issued ASU 2020-01, <i>Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</i>. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"/></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"/> <p id="xdx_847_ecustom--InterimFinancialStatementsPolicyTextBlock_zDFJbmwpcWTj" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zmLtoQbxukyb">Interim Financial Statements</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zxjmY1AK31Pe" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zPs9xn1u1SXb">Revenue Recognition</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.</p> <p id="xdx_841_ecustom--IdentificationOurContractswithCustomersTextBlock_zM61mgclVF26" style="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zIF4Dzuy2Wnd">Identification of Our Contracts with Customers</span></span></span><span style="font-size: 8pt"> </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Determination of the Price in Our Sales Contracts</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Allocation of the Transaction Price of Our Sales Contracts</span></i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><i><span style="text-decoration: underline">Recognition of Revenue when the Performance Obligation is Satisfied</span></i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Identifying the Performance Obligations in Our Sales Contracts</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_ecustom--ProductSalesPolicyTextBlock_zhtlGwypt2R5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zkW1G55EuZIf">Product Sales</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.</p> <p id="xdx_841_ecustom--ConsultingServicesPolicyTextBlock_zqRn0lNqcaP5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zlAaZ7PILdg6">Consulting Services</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.</span><span style="font-size: 8pt">  </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605</span><span style="font-size: 8pt">  </span> <span style="font-size: 10pt">to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.</span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zc1C8GtvZpS6" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zJvLAIbwIPMf">Use of Estimates</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p> <p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSbQ6bDdXge8" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zqGVs0g61TOi">Cash</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.</p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z2opAuNRRBKe" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zscNpgXHS93j">Concentrations of Credit Risk</span></span></p> <p style="font: 12pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash </span><span style="font-size: 8pt">  </span><span style="font-size: 10pt">in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.</span></p> <p id="xdx_84B_eus-gaap--ReceivablesPolicyTextBlock_zbMWrotWG5Gk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zHRQXjjVBAAf">Accounts Receivable</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.</p> <p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zRUjxMn7vBhi" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zUMgrqXPpFnf">Allowance for Doubtful Accounts</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20210630_pp0p0" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20201231_pp0p0" title="Allowance for doubtful accounts">0</span>, respectively.</p> 0 0 <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zj3lzjC3u2pb" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zr4R9BTDPX67">Inventories</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.</p> <p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z1rdmVLUNZu5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zgQUQJktRr27">Cost of Sales</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Cost of sales is comprised of cost of product sold, packaging, and shipping costs.</p> <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJCiacJ2P4Be" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222"><span style="text-decoration: underline"><span id="xdx_865_zqjMc94XTv9f">Stock-Based Compensation - Employees</span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white"><span style="font-size: 10pt; color: #222222">The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6</span><span style="font-size: 8pt"/><span style="font-size: 10pt; color: #222222">, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222">The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="width: 1%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="width: 94%; padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected term of share options and similar instruments</i>. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. </span></td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; width: 5%"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; width: 1%"> </td> <td style="padding-bottom: 12pt; text-align: justify; width: 94%"><span style="font-size: 10pt; color: #222222"><i>Expected volatility of the entity’s shares and the method used to estimate it</i>.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected annual rate of quarterly dividends</i>.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Risk-free rate(s)</i>. An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white; color: #222222">Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222">The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.</p> <p id="xdx_840_ecustom--StockBasedCompensationNonEmployeesTextBlock_zlDLykWKAtji" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222"><span style="text-decoration: underline"><span id="xdx_862_zD0D173wWCyj">Stock-Based Compensation – Non Employees</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white; color: #222222"><i><span style="text-decoration: underline">Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="width: 1%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt"> </td> <td style="width: 97%; padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected term of share options and similar instruments</i>: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. </span><span style="font-size: 8pt; color: black">  </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected volatility of the entity’s shares and the method used to estimate it</i>.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-bottom: 12pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Expected annual rate of quarterly dividends</i>.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. </span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt; color: #222222">•</span></td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"> </td> <td style="padding-right: 5.4pt; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt; color: #222222"><i>Risk-free rate(s)</i>. An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.</span></td></tr> </table> <p style="font: 11pt/106% Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGPIYd81yId" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zO7oW3gX90Sd">Earnings per Share</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.</p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0BJ1NpIEek7" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zF1y4i1BEhFb">Property and Equipment</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentDepreciationMethods_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember" title="Depreciation calculation method">straight-line method</span> over their estimated useful lives of <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zPnmYvZfgCKf" title="Estimatied useful lives">3</span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zX7d6cM8d5Na" title="Estimatied useful lives">5</span> years.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> straight-line method P3Y P5Y <p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zckljGXu6cxk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zaTPr3acjhhh">Investments</span></span> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).</p> <p id="xdx_84C_eus-gaap--DerivativesReportingOfDerivativeActivity_z80LTdY6LHJj" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_z0nZ3GzOiIUd">Derivative Financial Instruments</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.</p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmwtsupt0yL3" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zwSMPo5a9QMl">Fair Value of Financial Instruments</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.</p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zcSmULDCdd46" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_z9BeqGPmdq07">Advertising</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $<span id="xdx_901_eus-gaap--AdvertisingExpense_c20210101__20210630_pp0p0" title="Advertising cost">168,780 </span>and $<span id="xdx_903_eus-gaap--AdvertisingExpense_c20200101__20200630_pp0p0" title="Advertising cost">44,659 </span>for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.</p> 168780 44659 <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYOdCAM9Rusd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="text-decoration: underline"><span id="xdx_867_zpcKpSvke687">Segment Information</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>hempSMART</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENT OF OPERATIONS</b></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020</b></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zpVSCNDmjwNb" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zSnR5jPjW3cl" style="display: none">Segment Information</span></span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_49D_20210101__20210331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zG7wgCiQeIEd" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_497_20210401__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z65CC2r0hqJj" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_495_20210101__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_ztglHcNdZeC2" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_490_20200101__20200331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zQUdktSCvX7l" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200401__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z7yNHdlGzi01" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200101__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zyhNlzEvjYzk" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,872</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">16,537</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51,409</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">81,819</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82,958</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">164,777</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost of Goods Sold</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,032</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,301</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28,333</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,205</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">39,187</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">73,392</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gross Profit</span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9,840</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,236</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">23,076</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">47,614</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,771</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">91,385</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_z4zqZTuPgC81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zm1OnaqK5gP" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock Based Compensation</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">—</span>  </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z6HWEb4V1XNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Selling and Marketing</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97,812</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">150,881</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">248,693</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">101,897</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">74,356</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">176,253</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--PayrollAndRelatedExpenses_zPtbejd8mxF" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Payroll and Related expenses</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,947</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54,864</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">108,811</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,749</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">32,113</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">50,862</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--Depreciation_zRcA5MexKVDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,782</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,746</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,328</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_zJhzbm5jd9U1" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">General and Admin Expenses</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">55,801</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">95,864</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">151,665</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">67,949</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,911</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">121,860</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingExpenses_zLPrhAGKkxb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total Expense</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">208,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">303,000</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">511,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">190,341</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">179,812</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">370,153</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperations_zTw5PeRLoqF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net Loss from Operations</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(199,111</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(289,764</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(488,875</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(142,727</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(136,041</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(278,768</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"/> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zpVSCNDmjwNb" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zSnR5jPjW3cl" style="display: none">Segment Information</span></span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_49D_20210101__20210331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zG7wgCiQeIEd" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_497_20210401__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z65CC2r0hqJj" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_495_20210101__20210630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_ztglHcNdZeC2" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_490_20200101__20200331__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zQUdktSCvX7l" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200401__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_z7yNHdlGzi01" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" id="xdx_496_20200101__20200630__us-gaap--StatementBusinessSegmentsAxis__custom--OperatingSegmentMember_zyhNlzEvjYzk" style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="7" style="color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended</span></td><td style="font-family: Ariel; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Ariel; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">6 Months</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Ended</span></p></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2021</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">March 31, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 30, 2020</span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,872</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">16,537</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51,409</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">81,819</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82,958</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 2%; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">164,777</span></td><td style="width: 1%; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost of Goods Sold</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,032</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,301</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28,333</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,205</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">39,187</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">73,392</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gross Profit</span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9,840</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,236</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">23,076</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">47,614</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">43,771</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">91,385</span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_z4zqZTuPgC81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zm1OnaqK5gP" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock Based Compensation</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">—</span>  </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span> </td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,850</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z6HWEb4V1XNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Selling and Marketing</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97,812</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">150,881</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">248,693</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">101,897</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">74,356</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">176,253</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--PayrollAndRelatedExpenses_zPtbejd8mxF" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Payroll and Related expenses</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,947</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54,864</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">108,811</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,749</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">32,113</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">50,862</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--Depreciation_zRcA5MexKVDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation Expense</span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,391</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,782</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,746</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,328</span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_zJhzbm5jd9U1" style="vertical-align: bottom; background-color: White"> <td style="color: #333333; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">General and Admin Expenses</span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">55,801</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">95,864</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">151,665</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">67,949</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">53,911</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">121,860</span></td><td style="padding-bottom: 1pt; color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingExpenses_zLPrhAGKkxb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total Expense</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">208,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">303,000</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">511,951</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">190,341</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">179,812</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">370,153</span></td><td style="padding-bottom: 1pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #333333; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="color: #333333; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperations_zTw5PeRLoqF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #333333; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net Loss from Operations</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(199,111</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(289,764</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(488,875</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(142,727</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(136,041</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="color: #333333; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; color: #333333; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(278,768</span></td><td style="padding-bottom: 2.5pt; color: #333333; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> </table> 34872 16537 51409 81819 82958 164777 25032 3301 28333 34205 39187 73392 9840 13236 23076 47614 43771 91385 17850 17850 97812 150881 248693 101897 74356 176253 53947 54864 108811 18749 32113 50862 1391 1391 2782 1746 1582 3328 55801 95864 151665 67949 53911 121860 208951 303000 511951 190341 179812 370153 -199111 -289764 -488875 -142727 -136041 -278768 <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zMVwiNwDV4rk" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zQqhHG8clcm1">Income Taxes</span></span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has <span id="xdx_901_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20210630_zIUajj2Usw1" title="Unrecognized tax benefits"><span id="xdx_902_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20201231_zno1Y0GiZK2l" title="Unrecognized tax benefits">no</span></span>t recorded any unrecognized tax benefits.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0 0 <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z80YElqjMm61" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86F_zAJmnUv6ixE6">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Recently Issued Accounting Pronouncements Not Yet Adopted</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"/></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt; background-color: white"><i>Recently Issued Accounting Pronouncements Adopted</i></span><span style="font-size: 8pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><i><span style="text-decoration: underline">Accounting for Income Taxes</span></i> In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes (Topic 740)</i>. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202</span>1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Equity Securities, Equity-method Investments and Certain Derivative</span></i><span style="text-decoration: underline">s</span> In January 2020, the FASB issued ASU 2020-01, <i>Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</i>. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"/></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"/> <p id="xdx_802_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBbHucnjhgu7" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 4 – <span id="xdx_82B_z1TeojRNKcO8">OPERATING LEASE</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. ASU 2018-11, Topic 842</span><span style="font-size: 8pt">  </span> <span style="font-size: 10pt">can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We adopted this standard using a modified retrospective approach on January 1, 2019. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced before the adoption date; initial direct costs for leases that commenced before the adoption date; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The Company elected the package of practical expedients permitted under ASU 2018-11, Leases, allowing it to account for its existing operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or, (iii) the accounting for indirect costs as defined in ASC 842.</span><span style="font-size: 8pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 31, 2021, the Company’s operating lease for its office space located at 1340 West Valley Parkway, Suite 205, Escondido, CA 92029 expired and, at that time, the Company fully amortized its right-of-use asset for such lease. On June 1, 2021, the Company entered into an office accommodation agreement whereby it may access a shared office space located at 633 West Fifth Street, Suite 2826, Los Angeles, CA 90071 on a month-to-month basis over a one-year term for a fee of $<span id="xdx_900_eus-gaap--OperatingLeasesRentExpenseMinimumRentals_c20190629__20190702__us-gaap--OtherCommitmentsAxis__us-gaap--LeaseAgreementsMember_pp0p0" title="Monthly rent">2,349</span> per month. In considering its qualitative disclosure obligations under ASC 842-20-50-3, the Company examined its office accommodation agreement for office space that has a fixed monthly fee with no variable payments and no options to extend. The office accommodation agreement creates no tenancy, leasehold, or other real property interest, other than a shared right-of-use. The office accommodation agreement does not provide for terms and conditions granting residual value guarantees by the Company, or any restrictions or covenants imposed for dividends or incurring additional financial obligations by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company determined under ASC 2018-11, Leases (Topic 842), due to the short-term nature of the office accommodation agreement, that such agreement met the criteria of ASC 842-20-25-2 and as such it is not necessary to capitalize the office accommodation agreement and fees will be recognized on a monthly straight-line basis. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.</p> <p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0"> </p> 2349 <p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zPg1Zq5ucska" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 5 – <span id="xdx_82F_zCiSCpEfiUX">PROPERTY, MACHINERY AND EQUIPMENT</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Property and equipment as of June 30, 2021 and December 31, 2020 is summarized as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxxOkTCDlPjb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BD_zxiDknLkFZHa" style="display: none">Schedule of Property and Equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Computer equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Property and equipment, gross">23,784</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Property and equipment, gross">20,143</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Furniture and fixtures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Property and equipment, gross">5,407</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Property and equipment, gross">5,140</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Machinery</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Property and equipment, gross">104,102</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_d0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zYWtISxpBVOd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Property and equipment, gross">—  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: justify">Subtotal</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Property and equipment, gross">133,293</td><td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Property and equipment, gross">25,283</td><td style="font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zaWfDcZRYZA" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less accumulated depreciation">(21,395</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zT1U2rODd1Fl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less accumulated depreciation">(18,741</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Property, machinery and equipment, net</td><td style="font-size: 10pt"><b> </b></td> <td style="font-size: 10pt; text-align: left"><b>$</b></td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p0_c20210630_zPXPmgP3ygG7" style="font-size: 10pt; text-align: right" title="Property and equipment, net"><b>111,898</b></td><td style="font-size: 10pt; text-align: left"><b> </b></td><td style="font-size: 10pt"><b> </b></td> <td style="font-size: 10pt; text-align: left"><b>$</b></td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p0_c20201231_zhGGN6XD1Dtg" style="font-size: 10pt; text-align: right" title="Property and equipment, net"><b>6,542</b></td><td style="font-size: 10pt; text-align: left"><b> </b></td></tr> </table> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Property, machinery and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. On May 20, 2021, the Company purchased a new cannabis extraction machine which is to be leased to a cannabis distributor and manufacturer called Lynwood-MCOA joint venture. This joint venture is between Cannabis Global Inc. and the Company and pertains to the licensed cannabis operations of Natural Plant Extract of California Inc. in the city of Lynwood, CA. The lease payments are scheduled to commence during the third quarter of 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Depreciation expense was $<span id="xdx_90F_eus-gaap--Depreciation_c20210101__20210630_pp0p0" title="Depreciation expense">2,653</span> and $<span id="xdx_902_eus-gaap--Depreciation_c20200101__20200630_pp0p0" title="Depreciation expense">3,328</span> for the six months ended June 30, 2021 and 2020, respectively.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxxOkTCDlPjb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BD_zxiDknLkFZHa" style="display: none">Schedule of Property and Equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Computer equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Property and equipment, gross">23,784</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Property and equipment, gross">20,143</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Furniture and fixtures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Property and equipment, gross">5,407</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="font-size: 10pt; text-align: right" title="Property and equipment, gross">5,140</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Machinery</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Property and equipment, gross">104,102</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_d0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zYWtISxpBVOd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Property and equipment, gross">—  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: justify">Subtotal</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Property and equipment, gross">133,293</td><td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="font-size: 10pt; font-weight: bold; text-align: right" title="Property and equipment, gross">25,283</td><td style="font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zaWfDcZRYZA" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less accumulated depreciation">(21,395</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zT1U2rODd1Fl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less accumulated depreciation">(18,741</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Property, machinery and equipment, net</td><td style="font-size: 10pt"><b> </b></td> <td style="font-size: 10pt; text-align: left"><b>$</b></td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p0_c20210630_zPXPmgP3ygG7" style="font-size: 10pt; text-align: right" title="Property and equipment, net"><b>111,898</b></td><td style="font-size: 10pt; text-align: left"><b> </b></td><td style="font-size: 10pt"><b> </b></td> <td style="font-size: 10pt; text-align: left"><b>$</b></td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_pp0p0_c20201231_zhGGN6XD1Dtg" style="font-size: 10pt; text-align: right" title="Property and equipment, net"><b>6,542</b></td><td style="font-size: 10pt; text-align: left"><b> </b></td></tr> </table> 23784 20143 5407 5140 104102 0 133293 25283 21395 18741 111898 6542 2653 3328 <p id="xdx_80B_eus-gaap--InvestmentsAndOtherNoncurrentAssetsTextBlock_zgjsQFhiFKIl" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 6 – <span id="xdx_824_zsHvQXT7Pfyl">INVESTMENTS</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><span style="text-decoration: underline">Bougainville Ventures, Inc. Joint Venture</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On March 16, 2017, the Company entered into a joint venture agreement with Bougainville Ventures, Inc. (“Bougainville”), a Canadian corporation, to (i) jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville's high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I-502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to, sales and marketing, agricultural procedures, operations, security and monitoring, processing and delivery, branding, capital resources and financial management; and (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through BV-MCOA Management, LLC, a limited liability company organized in the State of Washington on May 17, 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant to the joint venture agreement, the Company committed to raise not less than $<span id="xdx_90B_eus-gaap--OtherCommitment_c20170316__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JointVentureAgreementWithBougainvilleVenturesIncMember_pp0p0" title="Total committed amount to raise for joint ventures">1,000,000</span> to fund joint venture operations, based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The joint venture agreement provided that funding provided by the Company would contribute towards the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment from $1,000,000 to $<span id="xdx_909_eus-gaap--OtherCommitment_c20171106__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JointVentureAgreementWithBougainvilleVenturesIncMember_pp0p0" title="Total committed amount to raise for joint ventures">800,000</span>, and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach of contract for non-payment. Bougainville also did not possess an agreement with a Tier 3 I-502 license holder to grow marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land, but did not deed the real property to the joint venture. Bougainville failed to pay delinquent property taxes to Okanogan County, and as a result, as further discussed below, to date, the property has not been deeded to the joint venture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">To clarify the respective contributions and roles of the parties, the Company offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville to enter into an amended and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of $800,000 contributed by the Company to the joint venture. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 I-502 cannabis license holder to grow cannabis on the real property; and (iii) that clear title to the real property associated with the Tier 3 I-502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed a lawsuit against Bougainville, BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2-0045324. The Company seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, the appointment of a receiver, the return to treasury of 15 million shares of restricted common stock issued by the Company to Bougainville and treble damages pursuant to the Consumer Protection Act. The Company has filed a lis pendens on the real property. The case is currently in litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">In connection with the joint venture agreement, the Company recorded a cash investment of $<span id="xdx_903_ecustom--CashInvestment_c20170101__20171231_zMxbiA08llRk" title="Cash investment">1,188,500</span> to the joint venture during 2017. This was comprised of a 49.5% ownership of BV-MCOA Management, LLC, and was accounted for using the equity method of accounting. The Company recorded an annual impairment in 2017 of $<span id="xdx_906_ecustom--AnnualImpairment_c20170101__20171231_zRipdNY5pSRe" title="Annual impairment">792,500</span>, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $<span id="xdx_90B_ecustom--EquityLosse_c20180101__20180331_zGUo5GOl67N2" title="Equity losse">37,673</span> and $<span id="xdx_908_ecustom--EquityLosse_c20180401__20180630_zZ9ZPepsHCdd">11,043</span> for the quarters ended March 31, 2018 and June 30, 2018, respectively, and recorded an annual impairment of $<span id="xdx_90B_ecustom--EquityLosse_c20180101__20181231_zS63N691WiKh">285,986</span> for the year ended December 31, 2018, at which time the Company determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation, as discussed above.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><span style="text-decoration: underline">Natural Plant Extract</span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. and its</span><span style="font-size: 8pt">   </span><span style="font-size: 10pt">subsidiaries (collectively, “NPE”), to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the parties terminated the joint venture and entered into a settlement and release agreement (the “Settlement Agreement”). In exchange for a complete release of all claims, the Company and NPE (1) agreed that the Company would reduce its interest in NPE from 20% to 5%; (2) the Company agreed to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement Agreement, and $25,000 no later than the fifth calendar day for each of the two months following execution of Settlement Agreement; and, (3) to retire the balance of the Company’s original valuation obligation from the material definitive agreement, representing a shortfall of $56,085, in a convertible promissory note, with terms allowing NPE to convert the note into shares of the Company’s common stock of at a 50% discount to the closing price of the Company’s common stock as of the maturity date. The note was satisfied in full during the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">As of the date of this filing, the Company owes $0 and is in compliance with the terms of the Settlement Agreement</span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">. On February 3, 2020, the Company issued NPE a convertible promissory note in the principal amount of $56,085. Additionally, as a result of the Settlement Agreement, the Company became liable to pay NPE its 5% portion</span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Of the total amount due and payable by the Company with regards to the NPE joint venture agreement as of the date of this filing, the Company owes $75,000 and is in breach of the Settlement and Release of All Claims Agreement with NPE. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline">Brazilian Joint Ventures</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">On September 30, 2020, the Company entered into two joint venture agreements (the “Joint Venture Agreements”) with Marco Guerrero, a director of the Company (“Guerrero”) and related party, to form joint ventures in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America and to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of the joint venture entities in Uruguay and Brazil. The Brazilian joint venture, HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”), will be headquartered in São Paulo, Brazil. The Uruguayan joint venture, Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”), will be headquartered in Montevideo, Uruguay.</span></p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Pursuant to the Joint Venture Agreements, the Company acquired a 70% equity interest in both HempSmart Brazil and HempSmart Uruguay, with a minority 30% equity interest in both HempSmart Brazil and HempSmart Uruguay being held by newly formed entities controlled by Guerrero. Pursuant to the Joint Venture Agreements, the Company agreed to provide capital in the amount of $50,000 to both HempSmart Brazil and HempSmart Uruguay, for a total capital outlay obligation of $100,000. It is expected that the proceeds of the initial capital contribution will be used for contracting with third-party manufacturing facilities in Brazil and Uruguay and related infrastructure and employment of key personnel. As of June 30, 2021, the Company has not initiated the capital contribution but is pending to be done in the third quarter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The boards of directors of HempSmart Brazil and HempSmart Uruguay will consist of three directors, elected by the joint venture partners. Pursuant to the Joint Venture Agreements, the Company agreed to license, on a royalty-free basis, certain of its intellectual property regarding its existing products to HempSmart Brazil and HempSmart Uruguay to enable the joint ventures to manufacture and sell its products in Brazil, Uruguay, and for export to other Latin American countries, the United States, and globally in accordance with the terms of the Joint Venture Agreements.</p> <p style="font: 7pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In addition, as majority partner, in the event a joint venture is frustrated in its intent or purpose, the Company may trigger a compulsory buy-sell procedure pursuant to which the Company could pursue a sale of all or substantially all of the joint venture. Subject to certain exceptions, the joint venture partners may not transfer their interests in HempSmart Brazil and HempSmart Uruguay.</span><span style="font-size: 8pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Cannabis</span></span><span style="text-decoration: underline"><span style="font-size: 8pt"> </span><span style="font-size: 10pt">Global, Inc.</span></span><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Joint Venture</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On May 12, 2021, the Company entered into a joint venture agreement with Cannabis Global, Inc. (“Cannabis Global”) pursuant to which the Company will invest up to $250,000 into a newly formed entity (“MCOA Lynwood”) and Cannabis Global, through Natural Plant Extracts of California, Inc. (“Natural Plant”), an entity in which Cannabis Global owns a majority interest, will operate a regulated and licensed laboratory to manufacture various cannabis products in the State of California. As of June 30, 2021, the Company has invested $115,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Share Exchange</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis Global pursuant to which the Company issued 650,000,000 shares of its common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global common stock. In addition, the Company and Cannabis Global entered into a lock-up leak-out agreement which contains certain restrictions with respect to the sales of such securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Eco Innovation Group Inc. – Share Exchange</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On February 26, 2021, the Company entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, par value $0.001, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”). For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. As of June 30, 2021, the Company owed ECOX and additional 64,621,893 with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to the shares to be issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white">For a period of two years following the Effective Date, at the closing of each fiscal quarter, should the per-share closing price of the common shares of the same class as the Shares or the Exchange Shares, as quoted by the OTC Markets for the last day of the relevant fiscal quarter, decrease below original issuance value with the effect that the aggregate value of the Shares or the Exchange Shares at the fiscal quarter close would be lower than $650,000, then either MCOA, in the case of the Shares, or ECOX, in the case of the Exchange Shares, shall issue the other party the number of shares of common stock necessary to cause the aggregate value of the Shares or the Exchange Shares, as applicable, be $650,000 as of the end of the relevant fiscal quarter. The parties shall irrevocably instruct their respective transfer agents to reserve and maintain authorized and unissued common stock in a reserve account designated for the purpose of issuing such shares pursuant to this share exchange adjustment provision. Such share reserve accounts shall be maintained with a number of authorized and unissued common stock not less than three (3) times the number of Shares or Exchange Shares, as the case may be, that are issued pursuant to the Share Exchange Closing.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white">On February 24, 2021, the closing price of the Company’s common stock was $0.0155, so that the number of shares of Company common stock issuable to ECOX under the Share Exchange Agreement is 41,935,484. As a result of the transactions pursuant to the Share Exchange Agreement, the Company will have 4,179,073,945 shares of common stock outstanding, with the shares issued to ECOX pursuant to the Share Exchange Agreement representing 1.00% of the Company’s outstanding shares.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white">For the quarter ended June 30, 2021, the Company recorded a Loss on Equity Investment and corresponding increase in Subscriptions Payable of $394,194 to address the decline in the Company's stock price from the original issuance price of $.0155.</p> <p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>MARIJUANA COMPANY OF AMERICA, INC.</b></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>INVESTMENT ROLL-FORWARD</b></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>AS OF JUNE 30, 2021</b></p> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--InvestmentTableTextBlock_zafwAW189did" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENTS (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_zpQ2MJcJsG9f" style="display: none">Schedule of Investment Roll Forward</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Beginning balance @12-31-16</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zyXiweYCx9qf" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zwI9FizLy3Vc" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z8ZHF8zuxtk7" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zbmhY8r1QZVd" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_z0NHDQzXOad6" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zpZfJvKb9ra1" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zOmZw0L9oDN3" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1041">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zDSY1dSaVlM5" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during 2017</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Investments made">3,049,275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_pp0p0" style="text-align: right" title="Investments made">10,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_pp0p0" style="text-align: right" title="Investments made">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="text-align: right" title="Investments made">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="text-align: right" title="Investments made">1,188,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_pp0p0" style="text-align: right" title="Investments made">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="text-align: right" title="Investments made"><span style="-sec-ix-hidden: xdx2ixbrl1056">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="text-align: right" title="Investments made"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 03-31-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1060">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--GainLossOnInvestments1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z4ErmVvzrFni" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1062">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 06-30-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--GainLossOnInvestments1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zVKf2kzC5gOc" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--GainLossOnInvestments2_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z9KAcZQ7U38k" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 09-30-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--EquityMethodAccounting_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Equity method accounting">(375,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EquityMethodAccounting_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="text-align: right" title="Equity method accounting">(375,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--EquityMethodAccounting_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zIyhPiLDGhLc" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1072">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 12-31-17 equity method accounting</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zLoYQXG1Ibhh" style="text-align: right" title="Equity method accounting">313,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zcQVgW8f3Nal" style="text-align: right" title="Equity method accounting">313,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z2uLfIjargSe" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1078">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Impairment of Investment in 2017</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(2,292,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1082">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(792,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(1,500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1088">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1090">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balances as of 12/31/17</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zWkfgEsdqst7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance">695,477.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zwLgsT8ocJcd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,775.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_znioWtTn1qQc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zUVglKag2ub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z1oRTlk6jbK4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance">100,000.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_z5x7UKug8LHc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zDkNlBAmAUZc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">250,000.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zUqPYfxODEEk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">334,702.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zd0fpZyB2RN5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_z2Th0UAeYX7d" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zAMqcwRb8964" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zfcv9wjARs3i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zJukKLIgrN2l" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zaSPipjZiQI2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during 2018</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--InvestmentsMade_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z5z1hC6kP1Wj" style="text-align: right" title="Investment, Beginning balance">986,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--InvestmentsMade_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zxFjC7QYEqfi" style="text-align: right" title="Investment, Beginning balance">986,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--Investment_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zpjSVHvz45Lb" style="text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1119">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 03-31-18 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--GainLossOnInvestment_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zvKSKjvcO353" style="text-align: right" title="Investments made">(37,673</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--GainLossOnInvestment_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zk8yMhPkH8la" style="text-align: right" title="Investments made">(37,673</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--GainLossOnInvestment_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zd9biMkAtb1l" style="text-align: right" title="Investments made"><span style="-sec-ix-hidden: xdx2ixbrl1125">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 06-30-18 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GainLossOnInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zea4SPGNNwfg" style="text-align: right" title="Equity method Loss">(111,043</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GainLossOnInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zeqnP0pS3TZe" style="text-align: right" title="Equity method Loss">(11,043</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GainLossOnInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zHQLmkvOxgzf" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1131">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 09-30-18 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--GainLossOnInvestments1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zldO6SLuHxu3" style="text-align: right" title="Equity method Loss">(10,422</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--GainLossOnInvestments1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zkjkDc5yxnLk" style="text-align: right" title="Equity method Loss">(10,422</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--GainLossOnInvestments1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zrqh0SV3sxxg" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1137">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 12-31-18 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--GainLossOnInvestments2_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z38U51RTzsza" style="text-align: right" title="Equity method Loss">(31,721</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--GainLossOnInvestments2_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zirguz4JFotd" style="text-align: right" title="Equity method Loss">(31,721</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--GainLossOnInvestments2_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zwY1vrtoUKke" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1143">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--GainLossOnInvestments2_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zjkcFSAYv4Al" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1145">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Moneytrac investment reclassified to Short-Term investments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EquityMethodAccounting_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zfVqtCwwK79i" style="text-align: right" title="Equity method Loss">(250,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--EquityMethodAccounting_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zwaaVnudd6Ml" style="text-align: right" title="Equity method Loss">(250,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EquityMethodAccounting_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zrqsHq0dE3ti" style="text-align: right" title="Equity method Loss">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--EquityMethodAccounting_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zkQ4LIcKpHh3" style="text-align: right" title="Equity method Loss">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized gains on trading securities - 2018</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--EquityMethodAccounting1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zElvFTC45dC" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1155">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EquityMethodAccounting1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zaVEwbVdwwf5" style="text-align: right" title="Equity method Loss">560,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EquityMethodAccounting1_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zgah0uXSTNue" style="text-align: right" title="Equity method Loss">560,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Impairment of investment in 2018</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ImpairmentOfInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zjZc9NKU0Qk4" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(933,195</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ImpairmentOfInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zahpnyGcWMg6" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(557,631</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ImpairmentOfInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z6BALIMgclRf" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(89,578</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ImpairmentOfInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zUxzUuSDStt2" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(285,986</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ImpairmentOfInvestments_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zkdhAkXPzhL5" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1169">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @12-31-18</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zS4UYOTrJvCf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">408,077</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_ztPJUbAyl4Jc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">408,077</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_ziSYekGqMtG4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zcdrZeywOdwg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zMfxvXQj16hi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1175">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iE_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zmgCXqyn0Y9l" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zlpNF4BtCHK7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1178">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zfhMCUFGsZJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1180">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z9HlVnqpsyJl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_z0oslihTUuz7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zxPo1HRy7Xc6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1183">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zpghXUJQ9NT7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zIEvo2RbLUV4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zmSLhZDLv5ml" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Investments made during quarter ended 03-31-19</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--InvestmentsMade_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="width: 1%; text-align: right" title="Investments made">129,040</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--InvestmentsMade_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_z4hFkL6f6GX4" style="width: 1%; text-align: right" title="Investment, Beginning balance">129,040</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 03-31-19 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zYB3dwb7fqr9" style="text-align: right" title="Equity method Loss">(59,541</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GainLossOnInvestments_pp0p0_c20190101__20190331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zHvrz0P2lBa4" style="text-align: right" title="Investments made">(59,541</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on trading securities - quarter ended 03-31-19</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ImpairmentOfInvestments_c20190101__20190331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(135,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ImpairmentOfInvestments_c20190101__20190331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(135,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @03-31-19</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zocoqWMo6mQ6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Beginning balance">477,576</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zgOfxkB5bld7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Beginning balance">477,576</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zgUb5FwDfG31" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zkPWXoHariY1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1208">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zmpb59G1o5n8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zFHlCvxHnEig" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zkJC4SZrcm17" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zf0QtOetuV1e" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z8HfOKU7qt2i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1213">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zLmeuISYnJMe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_z71qVCcJsAO2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zz7cxANqvIdb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Beginning balance">675,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zpov1rrvfyA5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--Investment_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_z5y4XubvfLW" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Beginning balance">(135,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during quarter ended 06-30-19</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--InvestmentsMade_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z1Yb2xamFOOh" style="text-align: right" title="Investments made">3,157,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--InvestmentsMade_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zNFkXCi1SFWd" style="text-align: right" title="Investments made">83,646</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--InvestmentsMade_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_z20yiObmcUvj" style="text-align: right">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--InvestmentsMade_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zYpH7DBphAVd" style="text-align: right">73,588</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 06-30-19 equity method Income (Loss)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--GainLossOnInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z50jRv4yoree" style="text-align: right" title="Equity method Loss">(171,284</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">($</td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zHnLnQv4o46a" style="text-align: right" title="Equity method Loss">141,870</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zBotRkvWDmI6" style="text-align: right">(6,291</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--GainLossOnInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zg1p3wX56uy2" style="text-align: right">(23,123</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on trading securities - quarter ended 06-30-19</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z0PvivPngB3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Unrealized gains on trading securities"><span style="-sec-ix-hidden: xdx2ixbrl1234">—</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ImpairmentOfInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zUrYZmo8tUah" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ImpairmentOfInvestments_pp0p0_c20190401__20190630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_ztH7Gg4lIWFb" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @06-30-19</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z8gy5UR0mwUg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,463,526</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zjvMORrkPXWc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">419,352</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zyoXCw7nD0Pe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zczNyCqiTEYk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_ziy6f1KXsoB1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zyLRYurt8Nx1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zJt9ZG4xAr9g" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zAXdWoblPE1d" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z9LzD7nmiczc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zOJKUBjq5ri" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Beginning balance">2,993,709</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zOhogn4J6v71" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">50,465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zqiKpPPPBQDi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">525,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_z37HeZBXAxb4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--Investment_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zuTYzCNPsuV5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(285,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <p style="margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; width: 44%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during quarter ended 09-30-19</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--InvestmentsMade_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zKYV1DOhUAtf" style="font-weight: bold; text-align: right">186,263</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentsMade_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zO2BkcYxPRR3" style="text-align: right">186,263</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 09-30-19 equity method Income (Loss)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zsoG3l8fINaj" style="font-weight: bold; text-align: right">122,863</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GainLossOnInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zU81K02xPNj2" style="text-align: right">262,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--GainLossOnInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zOpG249kIpef" style="text-align: right">(94,987</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GainLossOnInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_z0yamAYU1jQ1" style="text-align: right">(44,939</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sale of trading securities during quarter ended 09-30-19</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--SaleOfTradingSecurities_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zbgq71UcS2Xg" style="text-align: right" title="Sale of trading securities">(41,667</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--SaleOfTradingSecurities_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zgoHJMYciQIk" style="text-align: right">(41,667</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on trading securities - quarter ended 09-30-19</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zrPNClC7g4pf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">—</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ImpairmentOfInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zyr958sSf4Wh" style="border-bottom: Black 1pt solid; text-align: right">(362,625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ImpairmentOfInvestments_pp0p0_c20190701__20190930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zNREokQ9K0Kl" style="border-bottom: Black 1pt solid; text-align: right">(362,625</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @09-30-19</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zGag1Giw78Rl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,772,652</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zUAM3ZzzoKj1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">682,141</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zxHOuv3GlcXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zaDY4uvpeT1c" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zyIgwfzpJXFf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_z0mQNidzWhA2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zL7jhl1H8bN" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_z920b2oTYZCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z8fbBvcs1q0a" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1279">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zBTJcW3WF1O7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,898,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zDZB0bVX3YV8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">191,789</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zjREzVmWtci9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">120,708</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zqpbG9sUfyHl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--Investment_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zHJ2O71WWwgj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(689,292</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Investments made during quarter ended 12-31-19</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentsMade_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zEjX4ZQPfo43" style="width: 1%; text-align: right">392,226</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentsMade_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zEKHvQxO14Z3" style="width: 1%; text-align: right">262,414</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InvestmentsMade_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--VivabudsMember_z7yJTdUXO7F3" style="width: 1%; text-align: right">129,812</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 12-31-19 equity method Income (Loss)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--GainLossOnInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zZuV0P7DOMT7" style="text-align: right">(178,164</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--GainLossOnInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zaFvCWw546i4" style="text-align: right">(75,220</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--GainLossOnInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--NaturalPlantMember_zkyKJ5br9aBi" style="text-align: right">(23,865</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--GainLossOnInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--VivabudsMember_zHf3sRU5YcTf" style="text-align: right">(79,079</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reversal of Equity method Loss for 2019</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ReversalOfEquityMethodLoss_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zR1Vv3vqthN8" style="text-align: right" title="Reversal of Equity method Loss">272,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ReversalOfEquityMethodLoss_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--NaturalPlantMember_zOSmxKRMOaqj" style="text-align: right" title="Reversal of Equity method Loss">125,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ReversalOfEquityMethodLoss_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--VivabudsMember_zWnKgs6t4zE4" style="text-align: right" title="Reversal of Equity method Loss">147,142</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impairment of investment in 2019</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zQWstbvBN4He" style="text-align: right">(3,175,420</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ImpairmentOfInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zZ53G31yDR3c" style="text-align: right">(869,335</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--NaturalPlantMember_ztNDyhNdkEC7" style="text-align: right">(2,306,085</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ImpairmentOfInvestments_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--VivabudsMember_zEJdxMRJWavd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">—</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on disposition of investment</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--LossOnDispositionOfInvestment_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zmJ2Y0WlQuE9" style="text-align: right" title="Loss on disposition of investment">(389,664</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--LossOnDispositionOfInvestment_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--VivabudsMember_zwrGJcIqBuYk" style="text-align: right" title="Loss on disposition of investment">(389,664</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sale of trading securities during quarter ended 12-31-19</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--EquityMethodAccounting1_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z7w21g4us5E8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--EquityMethodAccounting1_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z2ze2m1j0pKd" style="text-align: right">(17,760</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--EquityMethodAccounting1_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zZzYOnVco69g" style="text-align: right">(17,760</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on trading securities - quarter ended 12-31-19</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zcZhBoQkU9B4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">—</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zQh2KxLfbdsi" style="border-bottom: Black 1pt solid; text-align: right">(75,545</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20191001__20191231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zNHfuSlZC1V2" style="border-bottom: Black 1pt solid; text-align: right">(75,545</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @12-31-19</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zya1JlHgxsKa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zw3B4gYPDzw2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1316">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"/><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zVMydwU8iF7f" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zcbE0Oyv6rci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zz4tGSlaTeB7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1319">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zYxqVRRL9vQ8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1320">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_z9XEGvDxe4wl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zX1pqKTSYWm" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zWB735kiAtCh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zIEsXolkRcve" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zTr5KNY2MYLe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zRFrWkJtSOX3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">27,403</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zCNUjBEfW4jd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--Investment_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zkfT6zr7vZld" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(782,597</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <p style="margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; width: 44%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 1%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 1%"> </td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity Loss for Quarter ended 03-31-20</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GainLossOnInvestments_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zDFMqzTVjUlj" style="text-align: right">126,845</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GainLossOnInvestments_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zI1Re2gRhj33" style="text-align: right">126,845</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Recognize Joint venture liabilities per JV agreement @03-31-20</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--RecognizeJointVentureLiabilitiesPerJvAgreement_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zdC3rHN6Xjdb" style="text-align: right" title="Recognize Joint venture liabilities per JV agreement">394,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--RecognizeJointVentureLiabilitiesPerJvAgreement_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zXLu6QqnBcah" style="text-align: right" title="Recognize Joint venture liabilities per JV agreement">394,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impairment of Equity Loss for Quarter ended 03-31-20</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ImpairmentOfInvestments_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zwpcLosNVzk1" style="text-align: right">(521,692</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ImpairmentOfInvestments_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zBOTxk4Lr8ol" style="text-align: right">(521,692</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on trading securities - quarter ended 03-31-19</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zw0ImPEFyMRe" style="border-bottom: Black 1pt solid; text-align: right">(13,945</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">($</td><td id="xdx_984_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20200101__20200331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zI9xvm6pUy0a" style="border-bottom: Black 1pt solid; text-align: right">13,945</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @03-31-20</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zMuRaRcvByse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zjZefA2Oobw4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1342">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zo6qmgii8Vlh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zIkIaA0QUEjh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zDtm8sOiUZtj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zj5SGyywW5Fk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zOwgAlgHglP1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zTN7dMXp9UOa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zw7h7AS4mZOa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zNvuRXIPCNB1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zWMQ2Nn143oh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zk1gp4E2x0al" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,458</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zccecyGvrfWa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zSxn3U0cPBr7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">796,542</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <p style="margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Equity Loss for Quarter ended 06-30-20</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--GainLossOnInvestments_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zpZvpbv0C85a" style="width: 1%; text-align: right">(7,048</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zHqPClAKnYwf" style="width: 1%; text-align: right">(7,048</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold; text-align: right"> </td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impairment of Equity Loss for Quarter ended 06-30-20</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ImpairmentOfInvestments_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zCmRR4H3La9i" style="text-align: right">7,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ImpairmentOfInvestments_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zWrk6MOdSF6" style="text-align: right">7,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Sales of of trading securities - quarter ended 06-30-20</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--EquityMethodAccounting1_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z9VmvxvSOoq8" style="border-bottom: Black 1pt solid; text-align: right">(13,458</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">($</td><td id="xdx_989_ecustom--EquityMethodAccounting1_pp0p0_c20200401__20200630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zZMFCvDqUBi4" style="border-bottom: Black 1pt solid; text-align: right">13,458</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @06-30-20</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zjQeF0ATX68d" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zJmeW1EjGmji" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zovyeNuVCgNh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zmYVgpfD3TCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zx3UbSUhgfmi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_z9zzF5sbPrUj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zNAndVvVDIc8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1369">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_znBMbxHJxsVl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zWBQwv72pFxf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zEzwcoX7w5J5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_z0CHRZbzoPx3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zVGrgrRGoWP8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1374">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zoNOdRbBnJi2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--MoneyTracMember_zS72T62xAKQg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Global Hemp Group trading securities issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--GainLossOnInvestments_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zAmv6pXE1h5d" style="text-align: right">650,000</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--GainLossOnInvestments_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zla5dj3wOgbi" style="text-align: right">650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--GainLossOnInvestments_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zpTfZbHbAb45" style="font-weight: bold; text-align: right">185,000</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--GainLossOnInvestments_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_z9V4JUsiPyWj" style="text-align: right">185,000</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in Cannabis Global</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ImpairmentOfInvestments_pp0p0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z6XU1wjakEOh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1381">—</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @09-30-20</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zGQS9H4VHdlg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,343,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zoZQ4yTPtOA1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zkbDyibtpKAc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">650,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zwWuQral7Ixl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zKatjn7pe56i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zM2cGNS9FGz5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1387">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_z6ssEPkLX3h9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zFxrD9lu29hi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zl5IJBtVvDe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1390">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zk64pXleIig1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zgJZIP0VlRYb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zQGa63l0WKAg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">185,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zhcNZpE5Pfw7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">185,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--MoneyTracMember_zZXPoXmpPSE1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized gain on Global Hemp Group securities - 4th Quarter 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--UnrealizedGainOnGlobalHempGroupSecurities_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zfPzgfvAJnnj" style="font-weight: bold; text-align: right" title="Unrealized gain on Global Hemp Group securities">54,064</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--UnrealizedGainOnGlobalHempGroupSecurities_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zXgP2Co6XJFk" style="text-align: right" title="Unrealized gain on Global Hemp Group securities">54,064</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized gains on Cannabis Global Inc securities - 4th Quarter 2020</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zSgNrYSiuERe" style="border-bottom: Black 1pt solid; text-align: right">208,086</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--GlobalHempGroupMember_zx2DMj246pC5" style="border-bottom: Black 1pt solid; text-align: right">208,086</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @12-31-20</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zOFHkP3eyW1h" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,552,001</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zMFAmcxfSDGg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1403">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zIylcYmGWVwb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">858,086</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zYoJojCnnajb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z4zlqKnzs0s4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1406">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zrMxS1weUmkf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_z1SBgd0v7Gb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zMuJNLd6Sypd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z5TpLFiMItji" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zTsNRHQs7Ahj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_ziVCqBLoTkIf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z6Y6kDs0TZ21" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">239,064</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zS7Dsw0s6Rmj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">239,064</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--MoneyTracMember_zrCO7tYCiKZ9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investment in ECOX</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ImpairmentOfInvestments_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zJXqaEvvIhB1" style="text-align: right">650,000</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfInvestments_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_z5f57aLKtLJ2" style="text-align: right">650,000</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ImpairmentOfInvestments_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_ztj4n3qfNtBa" style="font-weight: bold; text-align: right">620,133</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--ImpairmentOfInvestments_pp0p0_c20210101__20210331__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_z0p355UmsaAa" style="font-weight: bold; text-align: right">620,133</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @03-31-21</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zeyha4peSty7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,202,001</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zx61ZTlzz5kg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1421">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_zYnZeYohx68j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">858,086</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zP6UDXqQVgn6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">650,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zrfRYAjKzci8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zfDudCO61Xkf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1425">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zrJqCHrlkMCg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1426">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zaMY4sPJ2ZN2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1427">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zoFanGW4pZTj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zKKqDmqTOrA9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zLZ7X7aFYbV7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zQQ1JwxVVPZi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">859,197</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_ztpTX8725zPg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">859,197</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--MoneyTracMember_zJQNio0lIuJ9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during quarter ended 06-30-21</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ImpairmentOfInvestments_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_z7OLH4JHmU17" style="text-align: right">30,898</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ImpairmentOfInvestments_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_zXxDRFuxan79" style="text-align: right">30,898</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized gain on Global Hemp Group securities - 2nd quarter 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">($</td><td id="xdx_983_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zQ5bHVnEqJt5" style="font-weight: bold; text-align: right">115,997</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">($</td><td id="xdx_981_ecustom--UnrealizedGainsOnTradingSecurities_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zOfCVgIdAHU5" style="font-weight: bold; text-align: right">115,997</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance @06-30-21</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zNWLSWDc3JWa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,232,899</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zWrKbHv8UmPk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_z6hKZeEN0sua" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">858,086</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zxOzvJEq4KL7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">650,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_zhfIAJtyHcC8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_z1EG4FVmN9fb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">30,898</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zULvqN6u3GQ4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_z41HoEEfPBDe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1445">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_z6uY5MRFtRs9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_zqi14qVe3eKi" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">693,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_z9upz0j9Fmuk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zV7ZsX4w6Qb4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">743,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zwWvKUYO6dth" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">743,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">($</td><td id="xdx_989_eus-gaap--Investments_iE_pp0p0_c20210401__20210630__us-gaap--InvestmentTypeAxis__custom--MoneyTracMember_zESAmaiq3eL8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">810,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_49A_20200630_zgcW4opuvi6" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_49C_20200331_zXVcqjewsKH4" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_492_20191231_zhdr7cELsNa5" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_497_20190930_zaBgXUKti1T" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_49D_20190630_zomaV5QQgH16" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_497_20190331_zaHSh0SnoVWc" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_492_20181231_zgoGZZSZkKOd" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_493_20171231_zV4Mqstr1bNe" style="white-space: nowrap; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>06-30-20</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>03-31-20</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>12-31-19</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>09-30-19</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>06-30-19</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>03-31-19</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>12-31-18</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>12-31-17</b></span><span style="font-size: 8pt">  </span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-right: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span style="text-decoration: underline">This includes balances for:</span></b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (h)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (g)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (f)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (e)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (d)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (c)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (b)</b></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Note (a)</b></span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 11pt Calibri, Helvetica, Sans-Serif"> </span><span style="font-size: 8pt">  </span></td></tr> <tr id="xdx_409_eus-gaap--DebtCurrent_iI_pp0p0_z08HC63TdaBa" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-right: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">      - Debt obligation of JV</span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">478,494 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">394,848 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1457">-</span></span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,633,872 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,778,872 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">128,522 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">289,742 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,500,000 </span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_z1famLAelwV" style="vertical-align: bottom; background-color: white"> <td style="border-right: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">      - Convertible NP, net of discount</span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">2,784,044 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,040,324 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">3,193,548 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">2,688,555 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">2,149,170 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,536,271 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">1,132,668 </span></td> <td style="border-right: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">394,555 </span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr id="xdx_40D_ecustom--LongTermDebts_iI_pp0p0_zXf6PzdCmiHg" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-right: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">      - Long term debt</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1475">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1476">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">172,856 </span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebt_iI_pp0p0_zatHF5pPL9mj" style="vertical-align: bottom; background-color: white"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Total Debt balance</b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>3,262,538</b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>3,435,172 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>3,193,548 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>4,322,427 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>3,928,042 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>1,664,793 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>1,422,410 </b></span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>2,067,411 </b></span></td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> </table> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 1000000 800000 1188500 792500 37673 11043 285986 <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--InvestmentTableTextBlock_zafwAW189did" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENTS (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_zpQ2MJcJsG9f" style="display: none">Schedule of Investment Roll Forward</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="43" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>INVESTMENTS</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SHORT-TERM INVESTMENTS</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">TOTAL</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p> <p style="margin-top: 0; margin-bottom: 0">Hemp</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Cannabis</p> <p style="margin-top: 0; margin-bottom: 0">Global</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"><b>Lynwood</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Bougainville Ventues,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Gate C Research</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Natural Plant</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">TOTAL</p> <p style="margin-top: 0; margin-bottom: 0">Short-Term</p></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Global Hemp</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">INVESTMENTS</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ECOX</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Benihemp</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> JV</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Inc.</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Extract</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vivabuds</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investments</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Group</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MoneyTrac</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Beginning balance @12-31-16</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zyXiweYCx9qf" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zwI9FizLy3Vc" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z8ZHF8zuxtk7" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zbmhY8r1QZVd" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_z0NHDQzXOad6" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zpZfJvKb9ra1" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zOmZw0L9oDN3" style="width: 1%; text-align: right" title="Investment, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1041">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Investments_iS_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zDSY1dSaVlM5" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Investments made during 2017</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Investments made">3,049,275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_pp0p0" style="text-align: right" title="Investments made">10,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_pp0p0" style="text-align: right" title="Investments made">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="text-align: right" title="Investments made">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="text-align: right" title="Investments made">1,188,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_pp0p0" style="text-align: right" title="Investments made">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="text-align: right" title="Investments made"><span style="-sec-ix-hidden: xdx2ixbrl1056">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--InvestmentsMade_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="text-align: right" title="Investments made"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 03-31-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1060">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--GainLossOnInvestments1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z4ErmVvzrFni" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1062">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 06-30-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--GainLossOnInvestments1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zVKf2kzC5gOc" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--GainLossOnInvestments2_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z9KAcZQ7U38k" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 09-30-17 equity method Loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--EquityMethodAccounting_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="text-align: right" title="Equity method accounting">(375,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EquityMethodAccounting_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="text-align: right" title="Equity method accounting">(375,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--EquityMethodAccounting_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zIyhPiLDGhLc" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1072">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Quarter 12-31-17 equity method accounting</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zLoYQXG1Ibhh" style="text-align: right" title="Equity method accounting">313,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zcQVgW8f3Nal" style="text-align: right" title="Equity method accounting">313,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--EquityMethodAccounting1_pp0p0_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_z2uLfIjargSe" style="text-align: right" title="Equity method Loss"><span style="-sec-ix-hidden: xdx2ixbrl1078">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Impairment of Investment in 2017</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(2,292,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1082">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(792,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment">(1,500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1088">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ImpairmentOfInvestments_c20170101__20171231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment of Investment"><span style="-sec-ix-hidden: xdx2ixbrl1090">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balances as of 12/31/17</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember_zWkfgEsdqst7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance">695,477.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempGroupMember_zwLgsT8ocJcd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,775.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--CannabisMember_znioWtTn1qQc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--ECOXMember_zUVglKag2ub3" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BenihempMember_z1oRTlk6jbK4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance">100,000.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--LynwoodMember_z5x7UKug8LHc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zDkNlBAmAUZc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">250,000.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--BougainvilleVentuesMember_zUqPYfxODEEk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">334,702.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GateCResearchMember_zd0fpZyB2RN5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--NaturalPlantMember_z2Th0UAeYX7d" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__custom--InvestmentMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--VivabudsMember_zAMqcwRb8964" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember_zfcv9wjARs3i" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--GlobalHempMember_zJukKLIgrN2l" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iS_pp0p0_c20180101__20181231__us-gaap--InvestmentTypeAxis__us-gaap--ShortTermInvestmentsMember__us-gaap--InvestmentSecondaryCategorizationAxis__custom--MoneyTracMember_zaSPipjZiQI2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Investment, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 3049275 10775 100000 250000 1188500 1500000 -375000 -375000 313702 313702 -2292500 -792500 -1500000 695477.00 10775.00 100000.00 250000.00 334702.00 986654 986654 -37673 -37673 -111043 -11043 -10422 -10422 -31721 -31721 -250000 -250000 250000 250000 560000 560000 -933195 -557631 -89578 -285986 408077 408077 810000 129040 129040 -59541 -59541 -135000 -135000 477576 477576 675000 -135000 3157234 83646 3000000 73588 -171284 141870 -6291 -23123 -150000 -150000 3463526 419352 2993709 50465 525000 -285000 186263 186263 122863 262789 -94987 -44939 -41667 -41667 -362625 -362625 3772652 682141 2898722 191789 120708 -689292 392226 262414 129812 -178164 -75220 -23865 -79079 272285 125143 147142 -3175420 -869335 -2306085 -389664 -389664 -17760 -17760 -75545 -75545 693915 693915 27403 -782597 126845 126845 394848 394848 -521692 -521692 -13945 13945 693915 693915 13458 796542 -7048 -7048 7048 7048 -13458 13458 693915 693915 0 810000 650000 650000 185000 185000 1343915 650000 693915 185000 185000 810000 54064 54064 208086 208086 1552001 858086 693915 239064 239064 810000 650000 650000 620133 620133 2202001 858086 650000 693915 0 859197 859197 810000 30898 30898 115997 115997 2232899 858086 650000 30898 693915 743200 743200 810000 478494 394848 1633872 1778872 128522 289742 1500000 2784044 3040324 3193548 2688555 2149170 1536271 1132668 394555 172856 3262538 3435172 3193548 4322427 3928042 1664793 1422410 2067411 <p id="xdx_809_ecustom--NotesPayableRelatedPartyTextBlock_z2zE1gA8WYal" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 7 – <span id="xdx_829_zwkLBCxlu5Ne">NOTES PAYABLE, RELATED PARTY</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, the Company’s officers and directors have provided advances and incurred expenses on behalf of the Company as such have been evidenced by the issuance of notes to such officers and directors. The notes are unsecured, due on demand and accrue interest at a rate of 5% per annum. The balance due to Notes Payable Related Party as of June 30, 2021 and December 31, 2020 was $<span id="xdx_90A_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20210630_pp0p0" title="Notes payable, related parties">20,000</span> and $<span id="xdx_909_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20201231_pp0p0" title="Notes payable, related parties">40,000</span> respectively. These notes are payable to the estate of Charles Larsen.</p> 20000 40000 <p id="xdx_806_eus-gaap--ShortTermDebtTextBlock_zNKvcIlaudhc" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 8 – <span id="xdx_82F_zVox0r3QzSdf">CONVERTIBLE NOTES PAYABLE</span></b></p> <p style="font: 12pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">During the six months ended June 30, 2021, the Company issued an aggregate of 810,689,880 shares of its common stock in settlement of issued convertible notes payable and accrued interest.</span><span style="font-size: 8pt">  </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">For the six months ended June 30, 2021 and June 30, 2020, the Company recorded amortization of debt discounts of $744,783 and $1,028,931, respectively, as a charge to interest expense.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Convertible notes payable are comprised of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShortTermDebtTextBlock_z7bE92sCpU61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"><span id="xdx_8BD_z14jLfARXAab" style="display: none">Schedule of Convertible Notes Payable</span></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Lender</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Audited)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify; padding-left: 5.4pt">Convertible note payable - Power Up Lending Group</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableElevenMember_z14C9togjzvg" style="width: 14%; text-align: right" title="Total">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableElevenMember_pp0p0" style="width: 14%; text-align: right" title="Total">35,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - Crown Bridge Partners</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableTwelveMember_pp0p0" style="text-align: right" title="Total">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableTwelveMember_pp0p0" style="text-align: right" title="Total">172,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Labrys</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblenotepayableLabrysMember_pp0p0" style="text-align: right" title="Total">537,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblenotepayableLabrysMember_z77SAdQDvEd3" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - GS Capital Partners LLC</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableFifteenMember_z2aiPKC8VKW2" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableFifteenMember_pp0p0" style="text-align: right" title="Total">143,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Geneva Roth</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGenevaRothMember_zO0cObPofqc2" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGenevaRothMember_pp0p0" style="text-align: right" title="Total">33,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - Robert L. Hymers III</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableSeventeenMember_pp0p0" style="text-align: right" title="Total">185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableSeventeenMember_pp0p0" style="text-align: right" title="Total">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Dutchess Capital</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableDutchessCapitalPartnersMember_pp0p0" style="text-align: right" title="Total">135,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableDutchessCapitalPartnersMember_pp0p0" style="text-align: right" title="Total">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Redstart Holdings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableRedstartHLDGSMember_zyGe8SSxJhv4" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableRedstartHLDGSMember_pp0p0" style="text-align: right" title="Total">109,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - GW Holdings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGWHoldingsMember_zFYp2qBMIHcb" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGWHoldingsMember_pp0p0" style="text-align: right" title="Total">98,175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Convertible note payable - St. George/Bucktown</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableStGeorgeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">727,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableStGeorgeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,160,726</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Total</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20210630_pp0p0" style="text-align: right" title="Total">1,620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentCarryingAmount_c20201231_pp0p0" style="text-align: right" title="Total">1,832,401</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less debt discounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less debt discounts">(1,122,225</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_c20201231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less debt discounts">(405,507</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_c20210630_pp0p0" style="text-align: right" title="Net">497,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20201231_pp0p0" style="text-align: right" title="Net">1,426,894</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ConvertibleDebtCurrent_iNI_pp0p0_di_c20210630_zaKSi19ERzKj" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(497,775</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ConvertibleDebtCurrent_iNI_pp0p0_di_c20201231_z98rxva9qPL5" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(1,426,894</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Long term portion</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_d0_c20210630_zi5DrD1SeLp8" style="text-align: right" title="Long term portion">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_d0_c20201231_zgVAK31dZQL6" style="text-align: right" title="Long term portion">—  </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Note Payable-Labrys</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In June 2021, the Company issued a convertible promissory note in the aggregate principal amount of $537,500 to Labrys Funds, LP (“Labrys”). The promissory note accrues interest at 12% per annum, is due one year from the issuance date and includes an original issuance discount in the aggregate amount of $53,750. The Company also paid $33,750 in deferred financing fees and received $450,000 of net proceeds. The note is convertible at any time at a conversion price of $0.005 per share. The Company also issued a five-year warrants to purchase up to 76,349,431 shares of its common stock to Labrys, at an exercise price of $0.00704 per share. In addition, the Company issued five-year warrants to purchase up to 76,349,431 shares of its common stock to an investment banker for services, which warrants have an exercise price of $0.008448 per share. The aggregate debt discount of $533,526 is being amortized to interest expense over the respective terms of the note.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. The Company is prohibited from effecting an exercise of the warrant to the extent that, as a result of such exercise, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the note. Accrued interest on the note was $<span id="xdx_90B_ecustom--AccruedInterest_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--LabrysMember_zRay6bHtXqP5">5,375</span> as of June 30, 2021.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable-Power Up Lending</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">From July 1 through September 12, 2019, the Company issued four convertible promissory notes in the aggregate principal amount of $294,000 to Power Up Lending Group Ltd. (“Power Up”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date and include an original issuance discount in the aggregate amount of $12,000. The notes are convertible at any time at a conversion price equal to 61% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the date of conversion. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the notes should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $169,202 is being amortized to interest expense over the respective terms of the notes.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $<span id="xdx_908_ecustom--DebtPrincipalAmount_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpLendingMember_zFVs1GFrGTL1">0 </span>and $<span id="xdx_905_ecustom--DebtPrincipalAmount_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpLendingMember_zNG26QwEF3Ld">35,000 </span>of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $<span id="xdx_902_ecustom--AccruedInterest_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpLendingMember_zSawyeVZ73ei">0 </span>and $<span id="xdx_90B_ecustom--AccruedInterest_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpLendingMember_z1sTpGsVOweg">1,167</span>, respectively, of accrued interest on the notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable-Crown Bridge Partners</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">From October 1 through December 31, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember_pp0p0">225,000 </span>to Crown Bridge Partners LLC (“Crown Bridge”). The promissory notes accrue interest at a rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember_zEYckCaa3iz3">10</span>% per annum, were due one year from the respective <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20190324__20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember">issuance date and include an original issuance discount in aggregate amount of $22,500. Interest accrues from the issuance date, but interest shall not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 60% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the conversion date. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $88,674 was being amortized to interest expense over the respective terms of the notes. The Company also issued a warrants to purchase up to 519,230 shares of the Company’s common stock with an initial exercise price of $0.26, with reset provisions based on issuances of common stock subsequent to the issuance date. Due to the reset provision, the exercise option of these warrants is also accounted for as a derivative liability. See Note 10.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_909_eus-gaap--DebtInstrumentPaymentTerms_c20191001__20191231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember" title="Convertible promissory note payment terms">The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.</span></p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $35,000 and $172,500 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed accrued interest of $0 and $6,500 on the notes, respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable-Odyssey Funding LLC</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On October 30, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $250,000 to Odyssey Funding LLC (“Odyssey”). The promissory notes accrue interest at a rate of 12% per annum, were due one year from the respective issuance date and include an original issuance discount in an aggregate amount of $12,500. Interest accrues from the issuance date, but interest does not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 55% the average of the two lowest trading prices of the Company’s common stock as quoted on the OTC Markets or such other exchange where the Company's shares are then traded, for the 20 trading days prior to the conversion date.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $207,650 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company an aggregate of $<span id="xdx_901_ecustom--DebtPrincipalAmount_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--OdysseyFundingLLCMember_zNyd4OPR8lSe" title="Debt principal amount">0 </span>and $<span id="xdx_901_ecustom--DebtPrincipalAmount_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--OdysseyFundingLLCMember_zBynbp6jr0c">0</span> of principal, respectively. As of June 30, 2021 and December 31, 2020, the Company owed $<span id="xdx_901_ecustom--AccruedInterest_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--OdysseyFundingLLCMember_z7wyFOU4qwr3" title="Accrued interest">0</span> and $<span id="xdx_905_ecustom--AccruedInterest_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--OdysseyFundingLLCMember_zvwE01k8oaYa">0</span> in accrued interest on the notes, respectively  .</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable - Paladin Advisors LLC</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On October 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $75,000 to Paladin Advisors, LLC (“Paladin”). The promissory notes accrue interest at a rate of 8% per annum and were due six months from the respective issuance date of each note. Pursuant to the notes, Paladin has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 45% discount to the lowest closing bid of the 10 day trading period prior to the date of conversion.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The aggregate debt discount of $46,721 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $<span id="xdx_908_ecustom--DebtPrincipalAmount_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--PaladinAdvisorsLLCMember_zYSfl4B1KEf1">0 </span>and $<span id="xdx_90E_ecustom--DebtPrincipalAmount_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--PaladinAdvisorsLLCMember_zA2czdbFmXY5">0</span> of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $<span id="xdx_90E_ecustom--AccruedInterest_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--PaladinAdvisorsLLCMember_zL85vID2rJ1k">0</span> and $<span id="xdx_90B_ecustom--AccruedInterest_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--PaladinAdvisorsLLCMember_z8MrWDkAlKv4">0</span> in accrued interest on the notes  , respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable-GS Capital Partners LLC</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On December 19, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20191219__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Convertible promissory note face value">173,000</span> to GS Capital Partners LLC (“GS Capital”). The promissory notes accrue interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20191219__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_zZqTcl7vWpM5" title="Convertible promissory note interest rate">10</span>% per annum, were due one year from the respective issuance date, and include an original issuance discount in an aggregate amount of $<span id="xdx_906_ecustom--ConvertiblePromissoryNoteOriginalIssueDiscount_c20191219__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Convertible promissory note original issue discount">15,000</span>. Pursuant to the notes, GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the notes into shares of the Company's common stock at a conversion price equal to 62% of the lowest trading price of the Company's common stock as reported on the OTC Markets or such other exchange on which the Company’s shares are then traded, for the 20 trading days prior to the date of conversion.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20191219__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Debt discount">166,193</span> was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed $<span id="xdx_90C_ecustom--ConvertibleNotesPayables_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Convertible notes payable">0 </span>and $<span id="xdx_90F_ecustom--ConvertibleNotesPayables_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Convertible notes payable">143,500</span> of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $<span id="xdx_906_eus-gaap--InterestPayableCurrent_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Accrued interest">0</span> and $$<span id="xdx_90B_eus-gaap--InterestPayableCurrent_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember_pp0p0" title="Accrued interest">2,789 </span>in accrued interest on the notes  , respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable-St. George Investments</span></p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On November 1, 2017, the Company issued a secured convertible promissory note in the principal amount of $601,420 to St. George Investments LLC (“St. George”). The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on September 10, 2018 and includes an original issue discount of $59,220. The promissory note was funded on November 11, 2017 for $542,200, net of the original issue discount and transaction costs. As of September 30, 2019, the Company owed $417,890 of principal and $38,378 of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate. On December 20, 2017, the Company issued a secured convertible promissory note in the principal amount of up to $1,655,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on October 27, 2018 and includes an original issue discount of $155,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. The promissory note was funded in nine tranches of  $300,000; $200,000; $200,000; $400,000; $75,000; $150,000; $85,000; $120,000 and $70,000, resulting in aggregate net proceeds of $1,500,000. The Company received aggregate net proceeds of $1,200,000 and $300,000 during the years ended December 31, 2018 and 2017, respectively. As an investment incentive, the Company issued five-year warrants to purchase up to 1,100,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 5,274,146 total warrants.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The promissory note is convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 20% prepayment premium. The note is secured by a trust deed of certain assets of the Company. “Market Capitalization” means the total outstanding shares of common stock multiplied by the stock price published on OTC Markets.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On November 5, 2018, $250,000 of principal and accrued interest was assigned to John Fife as an individual with all the terms and conditions of the original note issued to St. George. On March 21, 2019, $150,959 of principal and $4,963 of accrued interest along with $160,454 of derivative liabilities valued as of the respective conversion date were converted into an aggregate of 394,460 shares of the Company’s common stock.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the nine months ended September 30, 2019, $550,000 of principal, $122,694 of accrued interest and $441,394 of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of 1,710,897 shares of the Company’s common stock, resulting in a gain on debt settlement of $21,586. As of September 30, 2019, the Company owed $0 of principal and $0 of accrued interest on these convertible promissory notes. Although these notes were in default until they were repaid, the lender did not enforce the default interest rate.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On August 28, 2018, the Company issued a secured convertible promissory note in the amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Convertible promissory note face value">1,128,518</span> (including overfunding of $23,518) to St. George. The promissory note accrues interest at a rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_zm9Egrm5uN6d" title="Convertible promissory note interest rate">10</span>% per annum compounded daily, was due upon maturity on June 30, 2019, and includes an original issue discount of $<span id="xdx_90B_ecustom--ConvertiblePromissoryNoteOriginalIssueDiscount_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Convertible promissory note original issue discount">100,000</span>. In addition, the Company agreed to pay $<span id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Legal, accounting and other transaction costs with respect to convertible promissory note">5,000</span> for legal, accounting and other transaction costs of the lender. During the year ended December 31, 2018, the Company received aggregate net proceeds of $<span id="xdx_906_ecustom--DebtInstrumentOverFundingAmount_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Convertible promissory note overfunding">825,000</span>. During the nine months ended September 30, 2019, an additional $218,518 was funded under this note resulting in net proceeds of $198,518.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As an investment incentive to St. George, the Company issued St. George five-year warrants to purchase up to<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20180827__20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants issued for debt as an investment incentive"> 750,000</span> shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. The aggregate fair value of the issued warrants was $<span id="xdx_90E_ecustom--FairValueOfIssuedWarrants_c20180827__20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Fair value of issued warrants">1,588,493</span>. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Debt discount">1,114,698</span> is being amortized to interest expense over the respective term of each tranche.   As of June 30, 2020, the warrants had an exercise price of $0.0085 for 3,750,000 total warrants.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20180827__20180828__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember" title="Convertible promissory note conversion terms">The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion rate will be 60% of the three lowest closing trade prices during the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory notes include certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the nine months ended September 30, 2019, $<span id="xdx_905_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Shares issued for settlement of debt, value">1,000,859</span> of principal and $<span id="xdx_90F_ecustom--DerivativeLiabilitiesPortionOfDebtConvertedIntoCommonStock_c20210101__20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Derivative liabilities portion of debt converted into common stock">840,299</span> of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued for settlement of debt, shares">4,475,543</span> shares of the Company’s common stock, resulting in a loss on debt settlement of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210101__20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Gain (loss) on debt settlement">612,034</span>. As of September 30, 2019, the Company owed $<span id="xdx_90D_ecustom--ConvertibleNotesPayables_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Convertible notes payable">828,518 </span>of principal and $<span id="xdx_900_eus-gaap--InterestPayableCurrent_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember_pp0p0" title="Accrued interest">28,138</span> of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On January 29, 2019, the Company issued a secured convertible promissory note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_pp0p0" title="Convertible promissory note face value">2,205,000</span> to St. George. The promissory note accrues interest at a rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_zFLfdRhoj3o6" title="Convertible promissory note interest rate">10</span>% per annum compounded daily, was due upon maturity on December 5, 2019, and includes an original issue discount of $<span id="xdx_90D_ecustom--ConvertiblePromissoryNoteOriginalIssueDiscount_c20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_pp0p0" title="Convertible promissory note original issue discount">200,000</span>. In addition, the Company agreed to pay $<span id="xdx_90C_eus-gaap--DebtInstrumentFeeAmount_c20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_pp0p0" title="Legal, accounting and other transaction costs with respect to convertible promissory note">5,000</span> for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in eight tranches totaling $<span id="xdx_908_ecustom--GrossProceedsFromConvertiblePromissoryNote_c20190101__20190930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_pp0p0" title="Gross proceeds from convertible promissory note">1,406,482</span>, resulting in aggregate net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_c20190101__20190930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember_pp0p0" title="Net proceeds from convertible promissory notes">1,276,482</span>. As an investment incentive to St. George, the Company issued to St. George five-year warrants to purchase up to 1,500,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Exercisable price">2.40</span> per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 7,500,000 total warrants. The aggregate fair value of the issued warrants was $<span id="xdx_903_ecustom--FairValueOfIssuedWarrants_c20190128__20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Fair value of issued warrants">999,838</span>. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20190128__20190129__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember" title="Convertible promissory note conversion terms">The promissory notes  are convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On March 25, 2019, the Company issued a secured convertible promissory note in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember_pp0p0" title="Convertible promissory note face value">580,000</span> to St. George. The promissory note accrues interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember_zPNGppFBEKzk" title="Convertible promissory note interest rate">10</span>% per annum compounded daily, was due upon maturity on January 24, 2020 and includes an original issue discount of $<span id="xdx_90A_ecustom--ConvertiblePromissoryNoteOriginalIssueDiscount_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember_pp0p0" title="Convertible promissory note original issue discount">75,000</span>. In addition, the Company agreed to pay $<span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember_pp0p0" title="Legal, accounting and other transaction costs with respect to convertible promissory note">5,000</span> for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in the amount of $580,000 resulting in net proceeds of $500,000. As an investment incentive, the Company issued five-year warrants to purchase up to 375,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 1,875,000 total warrants. The aggregate fair value of the issued warrants was $258,701. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20190325__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember_pp0p0" title="Debt discount">483,966</span> is being amortized to interest expense over the term of the note.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company entered into five convertible note agreements with Bucktown Capital, LLC, an affiliated entity of St. George in fiscal year 2020 and during the six months ended June 30, 2021. The notes have total principal due of $727,500, bear interest at 8% per annum. The notes mature between December 2021 and March 2022. The notes are convertible at fixed prices, with $225,000 of principal convertible at $0.002 per share, $80,000 convertible at $0.003 per share, and $422,500 convertible at $0.005 per share.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, the Company owed $727,500 and $1,160,726 of principal, respectively, on these notes. As of June 30, 2021 and December 31, 2020, the Company owed $24,042 and $350,525 of accrued interest on the above notes, respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable - Robert L. Hymers III </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On December 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $<span id="xdx_902_ecustom--ConvertibleNotesPayables_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember_pp0p0" title="Convertible notes payable">96,552</span>.70 to Robert L. Hymers III (“Hymers”) in satisfaction of funds owed to Mr. Hymers from his consulting contract with the Company for past services rendered and completed. The promissory notes accrue interest at a rate of 10% per annum, and are were six months from the respective issuance date of the note along with accrued and unpaid interest. Hymers has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 50% discount to the lowest closing bid price of the Company’s common stock during the 15 day trading period prior to the date of conversion. The aggregate debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20201223__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember_pp0p0" title="Debt discount">92,332</span> is being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $185,000 and $70,000 of principal, respectively, to Hymers.  As of June 30, 2021 and December 31, 2020, the Company owed $3,125 and $1,005 in accrued interest on the notes  , respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable – Natural Plant Extract</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. (“NPE”) to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the Company terminated the joint venture.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><i>Definitive Agreement</i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Pursuant to the agreement with NPE, the Company agreed to acquire 20% (equal to 200,000 shares of NPE) of NPE’s authorized shares in exchange for the payment of $2,000,000 and $1,000,000 worth of the Company’s restricted common stock. The Company agreed to form a joint venture with NPE incorporated in California under the name “Viva Buds, Inc.” for the purpose of operating a California licensed cannabis distribution business pursuant to California law legalizing THC psychoactive cannabis for recreational and medicinal use.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s payment obligations were governed by a stock purchase agreement which required the Company to make the following payments: </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: justify">a. Deposit of $350,000 within 5 days of the execution of the agreement;</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: justify">b. Deposit of $250,000 payable within 30 days of the execution of the agreement;</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: justify">c. Deposit of $400,000 within 60 days of the execution of the agreement;</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: justify">d. Deposit of $500,000 within 75 days of the execution of the agreement; and</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: justify">e. Deposit of $500,000 within 90 days of the execution of the agreement.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company made its initial payment pursuant to this schedule, but otherwise failed to comply with the payment schedule and was in breach of contract.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><i>Settlement and Release of All Claims Agreement</i></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On February 3, 2020, the Company and NPE entered into a Settlement and Release of All Claims Agreement. In exchange for a universal release of all claims, the Company and NPE (i) agreed to reduce the Company’s interest in NPE from 20% to 5%; (ii) agreed that the Company would to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement and Release of All Claims Agreement, and $25,000 no later than the 5th calendar day for each of the two months following execution of Settlement and Release of All Claims Agreement; and, (iii) agreed to retire the balance of the Company’s original valuation obligation from the agreement, representing a shortfall of $56,085.15, in a convertible promissory note, with terms allowing NPE to convert the note into the Company’s common stock at a 50% discount to the closing price of the Company’s common stock as of the maturity date.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Of the total amount due and payable by the Company as of the date of this filing, the Company owes $50,000, and is in breach of the Settlement and Release of All Claims Agreement. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Note Payable – GW Holdings Group</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_905_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20200101__20200106__us-gaap--ShortTermDebtTypeAxis__custom--GWHoldingsGroupMember_z0A7I4cHi84c" title="Convertible promissory note conversion terms">On January 6, 2020, the Company entered into a convertible promissory note in the amount of $57,750 with GW Holdings Group, LLC (“GW”). GW has the option, beginning on the six month anniversary of the date of issuance, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a conversion price equal to 40% discount of the lowest trading price for the 15 trading days prior to the date of the conversion. The note accrues interest at a rate of 10% per annum and include a $5,250 original issue discount such that the price of the note was $57,750. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $98,175 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $818 in accrued interest on the note  , respectively.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Note Payable – Jefferson Capital</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On January 20, 2020, the Company issued a convertible promissory note to Jefferson Capital, LLC (“Jefferson”) with note matured on January 20, 2021. Jefferson has the right to convert any or all of the note into common stock of the Company at a conversion price equal to (i) 60% of the lowest trading price of the Company’s common stock during the 20 trading day period prior to the issue date of the note or (ii) 60% multiplied by the market price, meaning the lowest trade price for the Company’s common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Note Payable – BHP Capital</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On January 21, 2021, the Company issued a convertible promissory note in the principal amount of $37,625to BHP Capital NY, Inc. (“BHP”). The Company agreed to pay simple interest on the outstanding principal amount of the note at a rate of 10% per annum. All amounts owed pursuant to the note are convertible, in whole or in part, into shares of the Company’s common stock at BHP’s option at the lower of (i) the lowest price at which the Company has issued stock; or (ii) the market price, defined as 60% of the lowest trading price for the Company’s common stock during the 20 trading day period ending on the last trading day prior to the conversion date. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest   on the note.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Convertible Notes Payable – LG Capital </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On March 2, 2020, the Company entered issued a convertible promissory note in the principal amount of $50,000 to LG Capital Funding, LLC (“LG Capital”) which note matured on March 2, 2021. The note accrues interest at a rate of 8% per annum. LG Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a price per share of equal to 55% of the lowest trading price of the Company’s common stock as quoted on the OTC Markets for the 20 trading days prior to the date of conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note  .</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Convertible Debt Summary:  </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has identified the embedded derivatives related to the above described notes and warrants. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the note and to fair value as of each subsequent reporting date.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">At June 30, 2021, the Company determined the aggregate fair value of embedded derivatives to be $1,904,016. The fair values were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 128.2% to 169.0%, (3) weighted average risk-free interest rate of 0.16% to 0.18%, (4) expected life of 0.05 to 2.7 years, (5) conversion prices of $0.00185 to $0.00333 and (6) the Company's common stock price of $0.0044 per share as of June 30, 2020.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20210101__20210630_zpjHJ8Cqtxo1" title="Convertible promissory note due date description">For the six months ended June 30, 2021, the Company recorded a gain on the change in fair value of derivative liabilities of $1,347,646 and a loss of $1,035,115 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense. For the six months ended June 30, 2020, the Company recorded a gain on change in fair value of derivative liabilities of $1,142,272, a loss of $395,607 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense, and amortization of debt discounts of $1,028,931 as a charge to interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Paycheck Protection Program Loan</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the quarter ended June 30, 2020, the Company's wholly owned subsidiary, H Smart Inc., received a $35,500 loan as part of the Paycheck Protection Program (“PPP”) offered by the Small Business Administration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to account for the PPP loan pursuant to FASB ASC 470, <i>Debt</i>, or as a government grant by analogy to International Accounting Standard 20, <i>Accounting for Government Grants and Disclosure of Government Assistance</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Following the guidance in ASC 470, the Company has recognized the entire loan amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company will not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">For purposes of derecognizing the liability, ASC 470 refers to the extinguishment guidance in ASC 405, <i>Liabilities</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Based on that guidance, the loan would remain recorded as a liability until either of the following criteria are met:</p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"/> <td style="width: 48px; padding-bottom: 11.25pt"><span style="font: 10pt Symbol">·</span></td> <td style="padding-bottom: 11.25pt"><span style="font-size: 10pt">The Company has been legally released from being the primary obligor under the liability.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 48px; padding-bottom: 11.25pt"><span style="font: 10pt Symbol">·</span></td> <td style="padding-bottom: 11.25pt"><span style="font-size: 10pt">The Company pays the lender and is relieved of its obligation for the liability.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Because the Company will not be legally released from being the primary obligor of the PPP loan until forgiveness is actually granted, income from the extinguishment of the loan would only be recognized once the Company's application for forgiveness is approved. If the forgiveness application is approved, any resulting amount forgiven would be recognized and separately disclosed in the income statement as a gain on extinguishment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; background-color: white"><span style="text-decoration: underline">Subscriptions Payable</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On September 30, 2020, the Company entered into a share exchange agreement (“Share Exchange Agreement”) with Cannabis Global, Inc. (“CBGL”) dated September 30, 2020, to acquire the number of shares of CBGL’s common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement.  For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_90F_eus-gaap--DebtInstrumentPaymentTerms_c20210224__20210226_zCxtisODZlgg" title="Convertible promissory note payment terms">On February 26, 2021, the Company entered into a share exchange agreement (“ECOX Share Exchange Agreement”) with Eco Innovation Group, Inc. (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the ECOX Share Exchange Agreement.  For both parties, the ECOX Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the ECOX Share Exchange Agreement to fall below $650,000. Based on the value of ECOX shares in the market as of June 30, 2021, the Company recorded a value for additional shares owed to ECOX pursuant to the ECOX Share Exchange Agreement of $329,572 as a subscription agreement along with a loss from equity investment of $391,194. As of June 30, 2021 41,935,484 shares of the Company’s common stock have been issued. As a result, the balance of subscriptions payable as of June 30, 2021 and December 31, 2020 was $999,355 and $670,000, respectively.</span></p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShortTermDebtTextBlock_z7bE92sCpU61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"><span id="xdx_8BD_z14jLfARXAab" style="display: none">Schedule of Convertible Notes Payable</span></td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Lender</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Audited)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify; padding-left: 5.4pt">Convertible note payable - Power Up Lending Group</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableElevenMember_z14C9togjzvg" style="width: 14%; text-align: right" title="Total">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableElevenMember_pp0p0" style="width: 14%; text-align: right" title="Total">35,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - Crown Bridge Partners</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableTwelveMember_pp0p0" style="text-align: right" title="Total">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableTwelveMember_pp0p0" style="text-align: right" title="Total">172,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Labrys</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblenotepayableLabrysMember_pp0p0" style="text-align: right" title="Total">537,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblenotepayableLabrysMember_z77SAdQDvEd3" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - GS Capital Partners LLC</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableFifteenMember_z2aiPKC8VKW2" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableFifteenMember_pp0p0" style="text-align: right" title="Total">143,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Geneva Roth</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGenevaRothMember_zO0cObPofqc2" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGenevaRothMember_pp0p0" style="text-align: right" title="Total">33,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - Robert L. Hymers III</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableSeventeenMember_pp0p0" style="text-align: right" title="Total">185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableSeventeenMember_pp0p0" style="text-align: right" title="Total">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Dutchess Capital</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableDutchessCapitalPartnersMember_pp0p0" style="text-align: right" title="Total">135,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableDutchessCapitalPartnersMember_pp0p0" style="text-align: right" title="Total">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable – Redstart Holdings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableRedstartHLDGSMember_zyGe8SSxJhv4" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableRedstartHLDGSMember_pp0p0" style="text-align: right" title="Total">109,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Convertible note payable - GW Holdings</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_d0_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGWHoldingsMember_zFYp2qBMIHcb" style="text-align: right" title="Total">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableGWHoldingsMember_pp0p0" style="text-align: right" title="Total">98,175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Convertible note payable - St. George/Bucktown</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_c20210630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableStGeorgeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">727,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotePayableStGeorgeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,160,726</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Total</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_c20210630_pp0p0" style="text-align: right" title="Total">1,620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentCarryingAmount_c20201231_pp0p0" style="text-align: right" title="Total">1,832,401</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less debt discounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less debt discounts">(1,122,225</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_c20201231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less debt discounts">(405,507</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_c20210630_pp0p0" style="text-align: right" title="Net">497,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_c20201231_pp0p0" style="text-align: right" title="Net">1,426,894</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ConvertibleDebtCurrent_iNI_pp0p0_di_c20210630_zaKSi19ERzKj" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(497,775</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ConvertibleDebtCurrent_iNI_pp0p0_di_c20201231_z98rxva9qPL5" style="border-bottom: Black 1pt solid; text-align: right" title="Less current portion">(1,426,894</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Long term portion</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_d0_c20210630_zi5DrD1SeLp8" style="text-align: right" title="Long term portion">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_d0_c20201231_zgVAK31dZQL6" style="text-align: right" title="Long term portion">—  </td><td style="text-align: left"> </td></tr> </table> 0 35000 35000 172500 537500 0 0 143500 0 33500 185000 70000 135000 10000 0 109000 0 98175 727500 1160726 1620000 1832401 -1122225 -405507 497775 1426894 497775 1426894 0 0 5375 0 35000 0 1167 225000 0.10 issuance date and include an original issuance discount in aggregate amount of $22,500. Interest accrues from the issuance date, but interest shall not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 60% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the conversion date. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $88,674 was being amortized to interest expense over the respective terms of the notes. The Company also issued a warrants to purchase up to 519,230 shares of the Company’s common stock with an initial exercise price of $0.26, with reset provisions based on issuances of common stock subsequent to the issuance date. Due to the reset provision, the exercise option of these warrants is also accounted for as a derivative liability. See Note 10. The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. 0 0 0 0 0 0 0 0 173000 0.10 15000 166193 0 143500 0 2789 1128518 0.10 100000 5000 825000 750000 1588493 1114698 The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion rate will be 60% of the three lowest closing trade prices during the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory notes include certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company. 1000859 840299 4475543 612034 828518 28138 2205000 0.10 200000 5000 1406482 1276482 2.40 999838 The promissory notes  are convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company. 580000 0.10 75000 5000 483966 96552 92332 On January 6, 2020, the Company entered into a convertible promissory note in the amount of $57,750 with GW Holdings Group, LLC (“GW”). GW has the option, beginning on the six month anniversary of the date of issuance, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a conversion price equal to 40% discount of the lowest trading price for the 15 trading days prior to the date of the conversion. The note accrues interest at a rate of 10% per annum and include a $5,250 original issue discount such that the price of the note was $57,750. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $98,175 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $818 in accrued interest on the note  , respectively. For the six months ended June 30, 2021, the Company recorded a gain on the change in fair value of derivative liabilities of $1,347,646 and a loss of $1,035,115 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense. For the six months ended June 30, 2020, the Company recorded a gain on change in fair value of derivative liabilities of $1,142,272, a loss of $395,607 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense, and amortization of debt discounts of $1,028,931 as a charge to interest expense. On February 26, 2021, the Company entered into a share exchange agreement (“ECOX Share Exchange Agreement”) with Eco Innovation Group, Inc. (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the ECOX Share Exchange Agreement.  For both parties, the ECOX Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the ECOX Share Exchange Agreement to fall below $650,000. Based on the value of ECOX shares in the market as of June 30, 2021, the Company recorded a value for additional shares owed to ECOX pursuant to the ECOX Share Exchange Agreement of $329,572 as a subscription agreement along with a loss from equity investment of $391,194. As of June 30, 2021 41,935,484 shares of the Company’s common stock have been issued. As a result, the balance of subscriptions payable as of June 30, 2021 and December 31, 2020 was $999,355 and $670,000, respectively. <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zEZLlyFCpGZf" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 9 – <span id="xdx_82D_zBewvs0QBVTf">STOCKHOLDERS’ DEFICIT</span></b></p><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Preferred Stock</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630_zx2tWuNKkfqi" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zTok2ksO2i73" title="Preferred stock, shares authorized">50,000,000</span></span> shares of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210630_z5mBwqjWnBM8" title="Preferred stock, par value per share"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zjBlcn3roLqa" title="Preferred stock, par value per share">0.001</span></span> par value preferred stock (“Series A Preferred Stock”) as of June 30, 2021 and December 31, 2020 of which <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassAMember_z4hww2f9q9fd" title="Preferred stock, shares authorized">10,000,000</span> shares are outstanding as of June 30, 2021. As of June 30, 2021 and December 31, 2020, the Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember_zurvJpFHhD09" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember_zR2qhMJg7SGd" title="Preferred stock, shares authorized">5,000,000</span></span> shares of Class B Preferred Stock of which <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember_z95ggEOa0yxk" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember_zTKs3HZezVk3" title="Preferred stock, shares outstanding">2,000,000</span></span> shares are issued and outstanding as of June 30, 2021.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassAMember" title="Preferred stock voting rights">Each share of Class A Preferred Stock is entitled to 100 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember" title="Preferred stock voting rights">Each share of Class B Preferred Stock is entitled to 1,000 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Common stock</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is authorized to issue 15,000,000,000 shares of $0.001 par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zDMJ2p7Awxt1">0.001 </span>par value common stock. As of June 30, 2021, and December 31, 2020, the Company had <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_zqgjsp7huym2">5,068,524,855 </span>and <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_z64e1lQ2pjqf">3,136,774,861</span> shares of common stock issued and outstanding, respectively. As of August 19, 2021, there were 5,405,130,704 shares of the Company’s common stock issued and outstanding.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company issued an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockOneMember_zrnjMPa7e3h8" title="Common stock issued in exchange for exercise of warrants on a cashless basis, shares">21,000,020 </span>shares of its common stock for services with an estimated fair value of $<span id="xdx_90B_ecustom--SaleOfCommonStockValue_pp0p0_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockOneMember_zTsf4Zul1qtf" title="Sale of common stock, value">140,900</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company issued an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockTwoMember_zmGe5LvLUOSi">810,689,880</span> shares of its common stock, including 153,227,150 related to warrants accounted for as liabilities, in settlement of convertible notes payable, accrued interest of $<span id="xdx_905_ecustom--SaleOfCommonStockValue_pp0p0_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockTwoMember_zlcRtYqgV4z">1,677,373</span>, and reclassified derivative liabilities of $5,975,670 to additional paid in capital in connection with the conversions.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company issued a net amount of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockThreeMember_z1UjSQyD2EY">3,027,031 </span>shares of its common stock in settlement of liabilities with an estimated fair value of $<span id="xdx_903_ecustom--SaleOfCommonStockValue_pp0p0_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockThreeMember_zkTDOICEbBd6">8,623</span>, which included 10,892,411 related to shares to be issued as of December 31, 2020, and the cancellation of 8,755,714 shares for previous settlements, and 890,334 new shares issued for settlement of accounts payable.  </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFourMember_z0x64juY0dEb">22,500,000</span> of its common stock upon the settlement of related party notes payable and accounts payable with an estimated fair value of $<span id="xdx_902_ecustom--SaleOfCommonStockValue_pp0p0_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFourMember_zF5YN0qsDDb4">141,750</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFiveMember_ziXe9Z49WF4g">400,000,000</span> of its common stock upon the exercise of warrants on a cash basis, including warrant liabilities with an estimated value of $63,500.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockSixMember_zcj7EjjSzhbg">632,597,599</span> of its common stock for an aggregate value of $<span id="xdx_904_ecustom--SaleOfCommonStockValue_pp0p0_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--CommonStockSixMember_zIHIL6Mo9Lh1">1,358,767</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2021, <span id="xdx_909_ecustom--CommonStockDescription_c20210101__20210630_zVVHnTNBrXOf" title="Common stock, description">the Company issued 41,935,484 of its common stock with a value of $650,000 and will issue an additional 64,621,893 shares for investments with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to these additional shares during the three months ended June 30, 2021.</span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_zlbHRS3ZgCL7">15,000,000,000</span> shares of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_ztur7pPlsllj">0.001</span> par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $0.001 par value common stock. As of June 30, 2020 and December 31, 2019, the Company had 469,288,934 and 77,958,081 shares of common stock issued and outstanding, respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockOneMember_zxdwg6S3SOR2">8,333</span> shares of its common stock to settle amounts previously accrued with an estimated fair value of $<span id="xdx_90C_ecustom--SaleOfCommonStockValue_pp0p0_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockOneMember_zwmoJabn6Cxi">6,700</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockTwoMember_zXxULpzoannc">44,658,333</span> shares of its common stock for services with an estimated fair value of $<span id="xdx_904_ecustom--SaleOfCommonStockValue_pp0p0_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockTwoMember_zIIvMP4yzL52">542,766</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockThreeMember_ztqAyhhKOjl">270,547,861</span> shares of its common stock in settlement of convertible notes payable, accrued interest and embedded derivative liabilities of an aggregate of $<span id="xdx_90E_ecustom--SaleOfCommonStockValue_pp0p0_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockThreeMember_z7wpLkVY1ZBj">1,531,471</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFourMember_zB4kJsYWH9P6">21,384,103 </span>of its common stock upon the conversion of related party notes payable with an estimated fair value of $<span id="xdx_90D_ecustom--SaleOfCommonStockValue_pp0p0_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFourMember_zrih3j3WsvNh">50,613</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockFiveMember_zc7VRiXkh4o3">51,054,214 </span>shares of its common stock upon the exercise of warrants on a cashless basis.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the six months ended June 30, 2020, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockSixMember_zS6jUSZZQxH7">3,677,889 </span>shares of its common stock in settlement of a legal case with an estimated fair value of $<span id="xdx_904_ecustom--SaleOfCommonStockValue_pp0p0_c20200101__20200630__us-gaap--StatementClassOfStockAxis__custom--CommonStockSixMember_zwdiB4QIN0D3">956,251</span>.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On January 17, 2020, the Company entered into an amendment of an existing convertible promissory note issued to Paladin. The Company authorized the issuance of a warrant to purchase up to 5,750,000 shares of the Company’s common stock, which warrant could be exercised on a cashless basis. This warrant was exercised during the three months ended June 30, 2020.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Options </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021, the Company has no outstanding stock options.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline">Warrants </span></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The following table summarizes the stock warrant activity for the three months ended June 30, 2021:</p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zKMwV99dSUkh" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' DEFICIT (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span id="xdx_8B3_zvScDf0FYA4f" style="display: none">Summarizes the Stock Warrant Activity</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term</b></p></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify"><span style="font-size: 10pt">Outstanding at December 31, 2020</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zUg2O02cuhy8" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">293,054,702</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zFi8sxrYY27l" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">0.0011</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_zT1UZiWrPKw3" title="Outstanding at Beginning of Period">2.22</span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_pp0p0_c20210101__20210630_zqvoRKsxmdia" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">1,023,306</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630_pdd" style="text-align: right" title="Granted"><span style="font-size: 10pt">79,785,156</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"/></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Granted"><span style="font-size: 10pt">0.0071</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermGranted_dtY_c20210101__20210630_zPql7LMq6Gs6" title="Granted, years">5.00</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted_iI_pp0p0_d0_c20210630_zs419Rm4wk0e" style="text-align: right" title="Granted"><span style="font-size: 10pt">—  </span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-size: 10pt">Increase due to reset provision</span></td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIncreased_c20210101__20210630_zIKCRlttFWL9" style="text-align: right" title="Increase due to reset provision"><span style="font-size: 10pt">(9,722,222</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td/> <td style="text-align: right"><span style="font-size: 10pt">0.004</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermIncreased_dtY_c20210101__20210630_zUlviTwvCld8" title="Increase due to reset provision, years">2.41</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised_iI_pp0p0_d0_c20210630_ztYQxa55QEKh" style="text-align: right" title="Increase due to reset provision"><span style="font-size: 10pt">—  </span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Exercised</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630_zCJA24bxQdBf" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">(194,788,035</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">0.004</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised_dtY_c20210101__20210630_zxXtDOCNFKSg" title="Exercised">1.66</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedAggregateIntrinsicValue_c20210630_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">1,427,826  </span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Outstanding at June 30, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zHZaa7N2frY5" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">168,329,601</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_z5Tae01zgip4" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">0.0039</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zJ0z62fJIosd" title="Exercisable at End of Period">3.49</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20210101__20210630_ztBjqGzjjLCi" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">503,850</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Exercisable at June 30, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">168,329,601</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">0.0039</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3_dtY_c20210101__20210630_zeqiGIoo2xY7">3.49</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c20210630_pp0p0" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">503,850</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Certain warrants issued to debt holders have reset provisions whereby upon subsequent issuances of common stock at a price below the current exercise price, the number of warrants increase and the exercise price is reduced to the new price. The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $0.0061 as of June 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.</p> 50000000 50000000 0.001 0.001 10000000 5000000 5000000 2000000 2000000 Each share of Class A Preferred Stock is entitled to 100 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights. Each share of Class B Preferred Stock is entitled to 1,000 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights. 0.001 5068524855 3136774861 21000020 140900 810689880 1677373 3027031 8623 22500000 141750 400000000 632597599 1358767 the Company issued 41,935,484 of its common stock with a value of $650,000 and will issue an additional 64,621,893 shares for investments with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to these additional shares during the three months ended June 30, 2021. 15000000000 0.001 8333 6700 44658333 542766 270547861 1531471 21384103 50613 51054214 3677889 956251 <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zKMwV99dSUkh" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' DEFICIT (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span id="xdx_8B3_zvScDf0FYA4f" style="display: none">Summarizes the Stock Warrant Activity</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term</b></p></td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 41%; text-align: justify"><span style="font-size: 10pt">Outstanding at December 31, 2020</span></td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zUg2O02cuhy8" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">293,054,702</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zFi8sxrYY27l" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">0.0011</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_zT1UZiWrPKw3" title="Outstanding at Beginning of Period">2.22</span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_pp0p0_c20210101__20210630_zqvoRKsxmdia" style="width: 10%; text-align: right" title="Outstanding at Beginning of Period"><span style="font-size: 10pt">1,023,306</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630_pdd" style="text-align: right" title="Granted"><span style="font-size: 10pt">79,785,156</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"/></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Granted"><span style="font-size: 10pt">0.0071</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermGranted_dtY_c20210101__20210630_zPql7LMq6Gs6" title="Granted, years">5.00</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted_iI_pp0p0_d0_c20210630_zs419Rm4wk0e" style="text-align: right" title="Granted"><span style="font-size: 10pt">—  </span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-size: 10pt">Increase due to reset provision</span></td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIncreased_c20210101__20210630_zIKCRlttFWL9" style="text-align: right" title="Increase due to reset provision"><span style="font-size: 10pt">(9,722,222</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td/> <td style="text-align: right"><span style="font-size: 10pt">0.004</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermIncreased_dtY_c20210101__20210630_zUlviTwvCld8" title="Increase due to reset provision, years">2.41</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised_iI_pp0p0_d0_c20210630_ztYQxa55QEKh" style="text-align: right" title="Increase due to reset provision"><span style="font-size: 10pt">—  </span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">Exercised</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630_zCJA24bxQdBf" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">(194,788,035</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">0.004</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised_dtY_c20210101__20210630_zxXtDOCNFKSg" title="Exercised">1.66</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedAggregateIntrinsicValue_c20210630_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Exercised"><span style="font-size: 10pt">1,427,826  </span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Outstanding at June 30, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zHZaa7N2frY5" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">168,329,601</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_z5Tae01zgip4" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">0.0039</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zJ0z62fJIosd" title="Exercisable at End of Period">3.49</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20210101__20210630_ztBjqGzjjLCi" style="border-bottom: black 2.25pt double; text-align: right" title="Outstanding at End of Period"><span style="font-size: 10pt">503,850</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-size: 10pt">Exercisable at June 30, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">168,329,601</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">0.0039</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3_dtY_c20210101__20210630_zeqiGIoo2xY7">3.49</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c20210630_pp0p0" style="border-bottom: black 2.25pt double; text-align: right" title="Exercisable at End of Period"><span style="font-size: 10pt">503,850</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 293054702 0.0011 P2Y2M19D 1023306 79785156 0.0071 P5Y 0 -9722222 P2Y4M28D 0 194788035 0.004 P1Y7M28D 1427826 168329601 0.0039 P3Y5M26D 503850 168329601 0.0039 P3Y5M26D 503850 <p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zs8eWsOfb5R5" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 10 — <span id="xdx_82D_zVDvpVjkUtd1">FAIR VALUE MEASUREMENT</span> </b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"/> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, the Company did not have any items that would be classified as level 1 or 2 disclosures.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in Note 3. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 3 are that of volatility and market price of the underlying common stock of the Company.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, the Company did not have any derivative instruments that were designated as hedges.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The derivative liability as of June 30, 2021 and December 31, 2020, in the amount of $1,904,016 and $4,426,057, respectively, have a level 3 classification.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended June 30, 2021:</p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zC3mtmBjYtl9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BA_zZ0EvrGJkrxd" style="display: none">Summary of Changes in Fair Value of Derivative Liabilities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Debt</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Derivative</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: justify">Balance, January 1, 2021</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9vUWbwIXuJc" style="width: 18%; font-size: 10pt; text-align: right" title="Balance at beginning">4,426,057</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Increase resulting from initial issuance of additional convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Increase resulting from initial issuances of additional convertible notes payable">1,824,340</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Decreases resulting from conversion of convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--InducedConversionOfConvertibleDebtExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6FRypEMUgKf" style="font-size: 10pt; text-align: right" title="Decreases resulting from conversion or payoff of convertible notes payable">(5,975,670</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Decreases resulting from payoff of convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--DecreasesResultingFromPayoffOfConvertibleNotesPayable_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Decreases resulting from payoff of convertible notes payable">(649,961</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Loss from change in fair value included in earnings</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiRealizedLoss_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss due to change in fair value included in earnings">2,279,250</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zah96GZz4ML2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance at end">1,904,016</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. During the period ended June 30, 2021, the Company’s stock price decreased significantly from initial valuations. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.</p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zC3mtmBjYtl9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BA_zZ0EvrGJkrxd" style="display: none">Summary of Changes in Fair Value of Derivative Liabilities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Debt</b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Derivative</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: justify">Balance, January 1, 2021</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9vUWbwIXuJc" style="width: 18%; font-size: 10pt; text-align: right" title="Balance at beginning">4,426,057</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Increase resulting from initial issuance of additional convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Increase resulting from initial issuances of additional convertible notes payable">1,824,340</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Decreases resulting from conversion of convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--InducedConversionOfConvertibleDebtExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6FRypEMUgKf" style="font-size: 10pt; text-align: right" title="Decreases resulting from conversion or payoff of convertible notes payable">(5,975,670</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Decreases resulting from payoff of convertible notes payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--DecreasesResultingFromPayoffOfConvertibleNotesPayable_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="font-size: 10pt; text-align: right" title="Decreases resulting from payoff of convertible notes payable">(649,961</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Loss from change in fair value included in earnings</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiRealizedLoss_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss due to change in fair value included in earnings">2,279,250</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20210101__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zah96GZz4ML2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance at end">1,904,016</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 4426057 1824340 5975670 -649961 2279250 1904016 <p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zBuXaGfp7j58" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 11 — <span id="xdx_824_zmApmJRv3snf">RELATED PARTY TRANSACTIONS</span></b></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s current officers and stockholders advanced funds to the Company for travel related   to business meetings and due diligence with respect to acquisition targets and working capital purposes. As of June 30, 2021 and December 31, 2020, the balance due to officers for travel and working capital purposes was $<span id="xdx_90B_eus-gaap--NotesPayable_c20210630_pp0p0" title="Note payable">0</span> and $<span id="xdx_90E_eus-gaap--NotesPayable_c20201231_pp0p0" title="Note payable">0</span>, respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of June 30, 2021 and December 31, 2020, accrued compensation due to officers and executives included as accrued compensation was $<span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAndExecutivesMember_pp0p0" title="Accrued compensation">9,000 </span>and $<span id="xdx_906_eus-gaap--EmployeeRelatedLiabilitiesCurrent_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAndExecutivesMember_pp0p0" title="Accrued compensation">79,214</span>, respectively.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Related party sales contributed $<span id="xdx_90F_ecustom--RelatedPartySalesContributed_c20210401__20210630_ztzMouT0FSI3" title="Related party sales contributed">0 </span>and $<span id="xdx_906_ecustom--RelatedPartySalesContributed_c20200401__20200630_zv7NbY77odAa">5,131</span> to revenues for the three months ended June 30, 2021 and 2020, respectively, while related party sales contributed $<span id="xdx_907_ecustom--RelatedPartySalesContributed_c20210101__20210630_zBdVemieoTfl">0</span> and $<span id="xdx_904_ecustom--RelatedPartySalesContributed_c20200101__20200630_zMpXywLnOPTb">8,303</span> to revenues for the six months ended June 30, 2021 and 2020, respectively. Related party sales are comprised of sales of the Company’s hempSMART products to the Company’s directors, officers, employees, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0 0 9000 79214 0 5131 0 8303 <p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_z6r75JmCyli8" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 12 – <span id="xdx_826_zpDNFguMa3yb">ACQUISITION</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2021, the Company, cDistro Merger Sub, Inc., a Nevada corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and cDistro, Inc., a privately-held Nevada corporation engaged in the hemp and CBD product distribution business (“cDistro”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger Sub merged with and into cDistro on June 30, 2021, with cDistro becoming a wholly-owned subsidiary of the Company and the surviving corporation in the merger (the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Contingent Consideration - Earnout Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection to the Merger, the Company and the securityholder of cDistro (the “cDistro Stockholder”) entered into an earnout agreement dated June 29, 2021 (the “Earnout Agreement”), whereby the Company agreed to issue additional shares of its common stock to the cDistro Stockholder as compensation for the Merger conditioned upon the achievement of certain gross revenue milestones. If cDistro meets revenue targets of $600,000 per quarter, up to a total of $2,400,000 of revenue, the Company will issue shares worth $250,000 upon the achievement each quarterly revenue target, with the number of shares to be issued at each payout date calculated based on the lessor of 220,970,059 shares of common stock or a 30% discount to the average close price of the Company’s common stock for the 20-day period immediately preceding the payout date of the earnout. In accordance with ASC 805, the Company accounts for this earnout agreement as contingent consideration based on the number of shares calculated as owed as of each quarter end, with changes in value to be recorded in earnings each reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Leak-Out Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2021, in connection with the Merger and the Earnout Agreement, the cDistro Stockholder entered into a Lock-Up and Leak-Out Agreement with the Company pursuant to which, among other thing, such stockholder agreed to certain restrictions regarding the resale of the common stock issued pursuant to the Merger for a period of six months from the date of the Merger.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Employment Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2021, in connection with the Merger, the Company and the Chief Executive Officer of cDistro entered into an employment agreement, pursuant to which that employee will serve as cDistro’s Chief Executive Officer for a three-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The acquisition of cDistro is being accounted for as a business combination under ASC 805. The Company is continuing to gather evidence to evaluate what identifiable intangible assets were acquired, such as a customer list, and the fair value of each, and expects to finalize the fair value of the acquired assets within one year of the acquisition date. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate preliminary fair value of consideration for the cDistro acquisition was as follows</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--AssetAcquisitionTableTextBlock_z7d3qJDCFkL6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_z3JcMSe1VsI7" style="display: none">Schedule of aggregate preliminary fair value</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210630_zGEtwNUPtGfg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zbn4JfVriyZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash, net of cash acquired of $99,393</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">250,607</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentsconsideration_iI_zCm4xlgKfjKg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent Consideration - Earnout Agreement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonstock_iI_zY1kWFqn8MJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">265,164,070 shares of common stock (not issued as of June 30, 2021)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,617,501</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConsiderationtransferred_iI_zrPZzIwuRrN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total preliminary consideration transferred</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,868,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zS3nUFp2aNr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended June 30, 2021, the Company has paid $<span id="xdx_902_ecustom--CashPaid_c20210401__20210630_zmRzWQcOHx11" title="Cash Paid">250,000</span> of the cash consideration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following information summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed at the acquisition date:</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b/></p> <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--SchedulePreliminaryAllocationoffairvaluesTableTextBlock_zSzlbcjErqkk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8BF_zloVYGpXniWh" style="display: none">Schedule summarizes the preliminary allocation of the fair values</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20210630_zFFQhMhtLVh5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessAcquisitionAccountsReceivable_iI_z6095qmciVz7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Accounts Receivable</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">40,291</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessAcquisitionInventorynet_iI_zCG8LPfnPJA5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,746</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_zDTHLKuiSjBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"> Other Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,310</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessAcquisitionGoodwill_iI_zmB2x5FKoyH2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,989,803</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessAcquisitionAccountspayables_iI_zpbvuirdxBSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"> Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(181,042</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--BusinessAcquisitionOtherAccruedLiabilities_iI_zglxhJAC8j02" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"> other accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessAcquisitionNetAssetsAcquired_iI_zTheHefYKfci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Net assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,868,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zk19JprK8Ng9" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b/></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt"><b><i>Unaudited Pro Forma Financial Information</i></b></p> <p style="font: 12pt/107% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth the pro-forma consolidated results of operations for the three and six months ended June 30, 2021 and 2020 as if the cDistro acquisition occurred on January 1, 2020. The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the acquisitions had taken place on the dates noted above, or of results that may occur in the future.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b/></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleProformaConsolidatedResultsofOperationsTableTextBlock_zFx2vmlKdl94" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zutcWy0z98y3" style="display: none">Schedule of pro-forma consolidated results of operations</span></td><td> </td> <td colspan="3" id="xdx_49F_20210401__20210630_zL0QLdkjbP5l"> </td><td> </td> <td colspan="3" id="xdx_49B_20200401__20200630_zBHg6lWuYxwj"> </td><td> </td> <td colspan="3" id="xdx_49C_20210101__20210630_zOemm5VmoaKc"> </td><td> </td> <td colspan="3" id="xdx_497_20200101__20200630_zFctO1wP3WJi"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six months ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td></tr> <tr id="xdx_407_eus-gaap--BusinessAcquisitionsProFormaRevenue_zMjf691OVd3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; padding-left: 5.4pt">Revenue</td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">290,196</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">152,402</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">444,239</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">234,221</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_zB7dUXWePXO9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Operating loss</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,067,780</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(965,158</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,855,860</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,357,315</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_z44qxHmomymc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Net loss</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,869,775</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(276,742</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(5,532,928</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(2,395,044</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_zweqjBLqxC3g" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"> Net loss per common share</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.01</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--BusinessAcquisitionProFormaBasicWeightedAverageCommonSharesOutstanding_z4vQqJfJe4Cc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt">Weighted Average common shares outstanding</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,102,510,297</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">510,164,598</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">4,730,796,549</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">451,015,744</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zpROyphEwl2a" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b/></p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--AssetAcquisitionTableTextBlock_z7d3qJDCFkL6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_z3JcMSe1VsI7" style="display: none">Schedule of aggregate preliminary fair value</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210630_zGEtwNUPtGfg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zbn4JfVriyZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash, net of cash acquired of $99,393</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">250,607</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentsconsideration_iI_zCm4xlgKfjKg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent Consideration - Earnout Agreement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonstock_iI_zY1kWFqn8MJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">265,164,070 shares of common stock (not issued as of June 30, 2021)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,617,501</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConsiderationtransferred_iI_zrPZzIwuRrN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total preliminary consideration transferred</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,868,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 250607 1000000 1617501 2868108 250000 <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--SchedulePreliminaryAllocationoffairvaluesTableTextBlock_zSzlbcjErqkk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8BF_zloVYGpXniWh" style="display: none">Schedule summarizes the preliminary allocation of the fair values</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20210630_zFFQhMhtLVh5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessAcquisitionAccountsReceivable_iI_z6095qmciVz7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Accounts Receivable</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">40,291</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessAcquisitionInventorynet_iI_zCG8LPfnPJA5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,746</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_zDTHLKuiSjBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"> Other Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,310</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessAcquisitionGoodwill_iI_zmB2x5FKoyH2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,989,803</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessAcquisitionAccountspayables_iI_zpbvuirdxBSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"> Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(181,042</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--BusinessAcquisitionOtherAccruedLiabilities_iI_zglxhJAC8j02" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"> other accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessAcquisitionNetAssetsAcquired_iI_zTheHefYKfci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Net assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,868,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 40291 6746 19310 2989803 -181042 -7000 2868108 <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleProformaConsolidatedResultsofOperationsTableTextBlock_zFx2vmlKdl94" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zutcWy0z98y3" style="display: none">Schedule of pro-forma consolidated results of operations</span></td><td> </td> <td colspan="3" id="xdx_49F_20210401__20210630_zL0QLdkjbP5l"> </td><td> </td> <td colspan="3" id="xdx_49B_20200401__20200630_zBHg6lWuYxwj"> </td><td> </td> <td colspan="3" id="xdx_49C_20210101__20210630_zOemm5VmoaKc"> </td><td> </td> <td colspan="3" id="xdx_497_20200101__20200630_zFctO1wP3WJi"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six months ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td></tr> <tr id="xdx_407_eus-gaap--BusinessAcquisitionsProFormaRevenue_zMjf691OVd3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; padding-left: 5.4pt">Revenue</td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">290,196</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">152,402</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">444,239</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">234,221</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_zB7dUXWePXO9" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Operating loss</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,067,780</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(965,158</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,855,860</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,357,315</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_z44qxHmomymc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Net loss</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(1,869,775</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(276,742</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(5,532,928</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(2,395,044</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_zweqjBLqxC3g" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"> Net loss per common share</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.00</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.01</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--BusinessAcquisitionProFormaBasicWeightedAverageCommonSharesOutstanding_z4vQqJfJe4Cc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt">Weighted Average common shares outstanding</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,102,510,297</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">510,164,598</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">4,730,796,549</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">451,015,744</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 290196 152402 444239 234221 -1067780 -965158 -1855860 -1357315 -1869775 -276742 -5532928 -2395044 -0.00 -0.00 -0.00 -0.01 5102510297 510164598 4730796549 451015744 <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zCvBhxdbpFBf" style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 13 – <span id="xdx_829_zS4psmaXexwj">SUBSEQUENT EVENTS</span></b> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"/> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
6 Months Ended
Jun. 30, 2021
Aug. 19, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-27039  
Entity Registrant Name MARIJUANA COMPANY OF AMERICA, INC.  
Entity Central Index Key 0001078799  
Entity Tax Identification Number 98-1246221  
Entity Incorporation, State or Country Code UT  
Entity Address, Address Line One 633 West Fifth Street  
Entity Address, Address Line Two Suite 2826  
Entity Address, City or Town Los Angeles  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90071  
City Area Code (888)  
Local Phone Number 777-4362  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,405,130,704
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash $ 179,811 $ 74,503
Short-term investments 743,200 239,063
Accounts receivable, net 47,570 8,640
Inventory 203,898 103,483
Prepaid insurance 55,783
Other current assets 93,830 56,121
  Total current assets 1,268,309 537,593
Property and equipment, net 111,898 6,542
Other assets:    
Long-term investments 2,232,899 1,552,001
Right-of-use-assets 7,858
Goodwill 2,989,803
Security deposit 2,500 2,500
Total assets 6,605,409 2,106,494
Current liabilities:    
Accounts payable 706,396 480,877
Accrued compensation 9,000 79,214
Accrued liabilities 136,108 401,461
Notes payable, related parties 20,000 40,000
Loans payable PPP Stimulus 35,500 35,500
Convertible notes payable, net of debt discount of $1,122,225 and $808,980, respectively 497,775 1,426,894
Loans payable - acquisition 100,000
Contingent liability - acquisition 1,000,000
Right-of-use liabilities - current portion 7,858
Subscriptions payable 1,063,977 670,000
Derivative liability 1,904,016 4,426,057
  Total current liabilities 5,472,772 7,567,861
Total liabilities 5,472,772 7,567,861
Stockholders' deficit:    
Common stock, $0.001 par value; 15,000,000,000 shares authorized; 5,068,524,855 and 3,136,774,861 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 5,068,525 3,136,775
Common stock to be issued, 266,164,070 and 11,892,411 shares, respectively 266,164 11,892
Additional paid in capital 87,581,650 77,687,561
Accumulated deficit (91,795,702) (86,309,595)
  Total stockholders' deficit 1,132,637 (5,461,367)
Total liabilities and stockholders' deficit $ 6,605,409 $ 2,106,494
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Convertible note payable, net of debt discount $ 1,122,225 $ 808,980
Preferred stock, par value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 50,000,000 50,000,000
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 15,000,000,000 15,000,000,000
Common stock, shares issued 5,068,524,855 3,136,774,861
Common stock, shares outstanding 5,068,524,855 3,136,774,861
Common stock to be issued 266,164,070 11,892,411
Preferred Class A [Member]    
Preferred stock, par value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 10,000,000 10,000,000
Preferred stock, shares outstanding 10,000,000 10,000,000
Preferred Class B [Member]    
Preferred stock, par value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 2,000,000 2,000,000
Preferred stock, shares outstanding 2,000,000 2,000,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
REVENUES:        
Sales $ 16,880 $ 77,827 $ 51,810 $ 156,474
Related party sales 5,131 8,303
Total Revenues 16,880 82,958 51,810 164,777
Cost of sales 3,301 39,187 28,481 73,392
Gross profit 13,579 43,771 23,329 91,385
OPERATING EXPENSES:        
Depreciation 1,262 1,582 2,653 3,328
Selling and marketing 155,212 74,212 262,761 200,667
Payroll and related 132,257 95,644 270,402 196,843
Stock-based compensation 139,000 536,452 158,900 542,767
General and administrative 611,970 211,116 1,137,652 415,172
  Total operating expenses 1,039,701 919,006 1,832,368 1,358,777
Net loss from operations (1,026,122) (875,235) (1,809,039) (1,267,392)
OTHER INCOME (EXPENSES):        
Interest expense, net (891,783) (881,945) (1,992,745) (1,772,096)
Impairment gain (loss) on joint ventures 7,048 (260,954)
Loss on equity investment (394,194) (7,048) (394,194) (133,893)
Gain (loss) on change in fair value of derivative liabilities 696,729 1,572,964 (1,629,289) 1,142,272
Unrealized gain (loss) on trading securities (115,997) 504,137 (13,945)
Loss on sale of trading securities (2,603) (2,603)
(Loss) gain on settlement of debt (96,750) (164,977) 3,490
Total other income (expense) (801,995) 688,416 (3,677,068) (1,037,729)
Net loss before income taxes (1,828,117) (186,819) (5,486,107) (2,305,121)
Income taxes (benefit)
NET INCOME (LOSS) $ (1,828,117) $ (186,819) $ (5,486,107) $ (2,305,121)
Loss per common share, basic and diluted $ (0.00) $ (0.00) $ (0.00) $ (0.01)
Weighted average number of common shares outstanding, basic and diluted (after stock-split) 4,837,346,227 245,000,528 4,465,632,479 185,851,674
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Preferred Stock Class A [Member]
Preferred Stock Class B [Member]
Common Stock [Member]
Common Stock To Be Issued [Member]
Stock Subcriptions [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 10,000 $ 77,958 $ 63,467,054 $ (74,164,213) $ (10,609,201)
Beginning Balance, shares at Dec. 31, 2019 10,000,000 77,958,081        
Common stock issued to settle amounts previously accrued     $ 8     6,692   6,700
Common stock issued to settle amounts previously accrued, shares     8,333          
Common stock issued for services rendered   $ 44,658     498,108   542,766
Common stock issued for services rendered, shares     44,658,333          
Common stock issued in settlement of convertible notes payable and accrued interest   $ 270,549 $ 43,995   1,216,928   1,531,472
Common stock issued in settlement of convertible notes payable and accrued interest, shares     270,547,861 43,994,720        
Issuance of common stock for settlement of liabilities – related parties     $ 21,384     29,229   50,613
Converson of related party notes payable, Shares     21,384,103          
Common stock issued in exchange for exercise of warrants on a cashless basis   $ 51,054 $ 1,000   375,446   427,500
Common stock issued in exchange for exercise of warrants on a cashless basis, shares     51,054,214 1,000,000        
Common shares issued in settlement of legal case     $ 3,678     952,573   956,251
Common stock issued in settlement of legal case, shares     3,677,889          
Reclassification of derivative liabilities to additional paid in capital           2,231,014   2,231,014
Net Loss (2,305,121) (2,305,121)
Ending balance, value at Jun. 30, 2020 $ 10,000 $ 469,289 $ 44,995 68,777,044 (76,469,334) (7,168,006)
Ending Balance, shares at Jun. 30, 2020 10,000,000 469,288,814 44,994,720        
Beginning balance, value at Dec. 31, 2020 $ 10,000 $ 2,000 $ 3,136,775 $ 11,892 77,687,561 (86,309,595) (5,461,367)
Beginning Balance, shares at Dec. 31, 2020 10,000,000 2,000,000 3,136,774,841 11,892,411        
Common stock issued to settle amounts previously accrued          
Issuance of preferred stock to officer
Common stock issued for services rendered   $ 21,000   119,900   140,900
Common stock issued for services rendered, shares     21,000,020          
Common stock issued in settlement of convertible notes payable and accrued interest   $ 810,690   930,184 1,740,874
Common stock issued in settlement of convertible notes payable and accrued interest, shares     810,689,880          
Issuance of common stock for settlement of liabilities   $ 3,027 $ (10,892)   16,488   8,623
Issuance of common stock for setlement of liabilities, shares     3,027,031 (10,892,411)        
Issuance of common stock for settlement of liabilities – related parties     $ 22,500   119,250   141,750
Converson of related party notes payable, Shares     22,500,000          
Common stock issued in exchange for exercise of warrants on a cashless basis   $ 400,000 (400,000)
Common stock issued in exchange for exercise of warrants on a cashless basis, shares     400,000,000          
Sale of common stock   $ 632,598   726,169 1,358,767
Sale of common stock, shares     632,597,599          
Issuance of common stock for investments     $ 41,935     608,065   650,000
Issuance of common stock for investments, shares     41,935,484          
Reclassification of derivative liabilities to additional paid in capital           5,975,670   5,975,670
Debt discount from warrants issued with convertible notes payable           446,026   446,026
Common stock issued for acquisition of business       $ 265,164   1,352,337   1,617,501
Common stock issued for acquisition of business, Shares       265,164,070        
Net Loss (5,486,107) (5,486,107)
Ending balance, value at Jun. 30, 2021 $ 10,000 $ 2,000 $ 5,068,525 $ 266,164 $ 87,581,650 $ (91,795,702) $ 1,132,637
Ending Balance, shares at Jun. 30, 2021 10,000,000 2,000,000 5,068,524,855 266,164,070        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (5,486,107) $ (2,305,121)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of debt discount 744,783 1,028,931
Depreciation and amortization 2,653 3,328
Impairment loss on equity investment 260,954
Loss on equity investment 394,194 133,895
Loss (gain) on change in fair value of derivative liability 1,629,289 (1,142,272)
Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance 1,035,115 395,607
Loss on share inducement and settlement of warrant liability 0 138,885
Stock-based compensation 140,900 542,767
Unrealized (gain) loss on trading securities (504,137) 27,403
Loss on settlement of liabilities 168,272 0
Changes in operating assets and liabilities:    
Accounts receivable 1,361 9,752
Inventories (93,669) (9,290)
Prepaid expenses and other current assets 37,309 (95,384)
Accounts payable 155,661 145,784
Accrued expenses and other current liabilities (67,264) 195,874
Right-of-use assets 7,858 6,767
Right-of-use liabilities (7,858) (6,885)
Net cash provided by (used in) operating activities (1,841,640) (669,005)
Cash flows from investing activities:    
Purchases of property and equipment (107,934) (1,271)
Payment to establish joint venture (30,898) 0
Acquisition of business (150,607) 0
Net cash provided by (used in) investing activities (289,439) (1,271)
Cash flows from financing activities:    
Proceeds from issuance of notes payable 1,508,250 442,000
Proceeds from PPP loan payable 0 35,500
Repayments of notes payable (610,630) 0
Repayments to related parties (20,000) 0
Proceeds from sale of common stock 1,358,767 0
Net cash provided by (used in) financing activities 2,236,387 477,500
Net increase (decrease) in cash 105,308 (192,776)
Cash at beginning of period 74,503 211,765
Cash at end of period 179,811 18,989
Supplemental disclosure of cash flow information:    
Cash paid for interest
Cash paid for taxes
Non cash financing activities:    
Common stock issued in settlement of convertible notes payable 1,740,874 1,531,471
Reclassification of derivative liabilities to additional paid-in capital 5,975,670 2,231,014
Common stock issued for investment 650,000
Common stock issued to settle liabilities 8,623
Common stock to be issued for acquisition of business 1,617,501
Common shares issued in settlement of legal case $ 956,251
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Marijuana Company of America, Inc. (the “Company”) was incorporated under the laws of the State of Utah in October 1985 under the name Mormon Mint, Inc. The corporation was originally a startup company organized to manufacture and market commemorative medallions related to the Church of Jesus Christ of Latter Day Saints. On January 5, 1999, Bekam Investments, Ltd. acquired one hundred percent of the common shares of the Company and spun the Company off changing its name Converge Global, Inc. From August 13, 1999 until November 20, 2002, the Company focused on the development and implementation of Internet web content and e-commerce applications. In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties. From 2009 to 2014, we operated primarily in the mining exploration business.

In 2015, the Company changed its business model to a marketing and distribution company for medical marijuana. In conjunction with the change, the Company changed its name to Marijuana Company of America, Inc. At the time of the transition in 2015, there were no remaining assets, liabilities or operating activities of the mining business.

On September 21, 2015, the Company formed H Smart, Inc., a Delaware corporation as a wholly owned subsidiary for the purpose of operating the hempSMART™ brand.

On February 1, 2016, the Company formed MCOA CA, Inc., a California corporation as a wholly owned subsidiary to facilitate mergers, acquisitions and the offering of investments or loans to the Company.

On May 3, 2017, the Company formed Hempsmart Limited, a United Kingdom corporation as a wholly owned subsidiary for the purpose of future expansion into the European market.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries H Smart, Inc., Hempsmart Limited and MCOA CA, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements set forth in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2021 (the “Annual Report”).

Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, during the six months ended June 30, 2021, the Company incurred net losses from operations of $5,486,107 and used cash in operations of $1,841,640. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company's primary source of operating funds for the six months ended June 30, 2021 was from revenue generated from the issuance of convertible and non-convertible debt. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2021 and beyond as it continues to develop its direct sales and marketing programs; however, no assurance can be provided that the Company will not continue to experience losses in the future. The Company has stockholders' deficiencies as of June 30, 2021 and requires additional financing to fund future operations.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding; however, there can be no assurance that the Company will be successful in developing profitable operations or that it will be able to obtain financing on favorable terms, if at all. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Interim Financial Statements

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.

Identification of Our Contracts with Customers 

Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.

In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.

 

Determination of the Price in Our Sales Contracts

The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.

Allocation of the Transaction Price of Our Sales Contracts

The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.

With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. 

Identifying the Performance Obligations in Our Sales Contracts

 

In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.

 

Product Sales

Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.

Consulting Services

The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.

For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.  

The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605   to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Cash

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash   in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Accounts Receivable 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $0 and $0, respectively.

Inventories

Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.

Cost of Sales 

Cost of sales is comprised of cost of product sold, packaging, and shipping costs.

Stock-Based Compensation - Employees

The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  

The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  

If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. 

 

  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. 

Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.

The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.

Stock-Based Compensation – Non Employees

Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.

 

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.   
  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. 
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.

 

Earnings per Share

Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years.

 

Investments 

The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).

Derivative Financial Instruments

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   

The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $168,780 and $44,659 for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.

Segment Information

ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.

hempSMART

STATEMENT OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

 

                   
   For the three months ended 

6 Months

Ended

  For the three months ended 

6 Months

Ended

   March 31, 2021  June 30, 2021  June 30, 2021  March 31, 2020  June 30, 2020  June 30, 2020
                   
                   
Revenues  $34,872   $16,537   $51,409   $81,819   $82,958   $164,777 
                               
Cost of Goods Sold   25,032    3,301    28,333    34,205    39,187    73,392 
                               
Gross Profit   9,840    13,236    23,076    47,614    43,771    91,385 
                               
Expense                              
Stock Based Compensation                        17,850    17,850 
Selling and Marketing   97,812    150,881    248,693    101,897    74,356    176,253 
Payroll and Related expenses   53,947    54,864    108,811    18,749    32,113    50,862 
Depreciation Expense   1,391    1,391    2,782    1,746    1,582    3,328 
General and Admin Expenses   55,801    95,864    151,665    67,949    53,911    121,860 
Total Expense   208,951    303,000    511,951    190,341    179,812    370,153 
                               
Net Loss from Operations  $(199,111)  $(289,764)  $(488,875)  $(142,727)  $(136,041)  $(278,768)

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has not recorded any unrecognized tax benefits.

 

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.

 

Recently Issued Accounting Pronouncements Adopted 

 

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
OPERATING LEASE
6 Months Ended
Jun. 30, 2021
Leases [Abstract]  
OPERATING LEASE

NOTE 4 – OPERATING LEASE

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. ASU 2018-11, Topic 842   can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach on January 1, 2019. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced before the adoption date; initial direct costs for leases that commenced before the adoption date; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASU 2018-11, Leases, allowing it to account for its existing operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or, (iii) the accounting for indirect costs as defined in ASC 842.  

 

On May 31, 2021, the Company’s operating lease for its office space located at 1340 West Valley Parkway, Suite 205, Escondido, CA 92029 expired and, at that time, the Company fully amortized its right-of-use asset for such lease. On June 1, 2021, the Company entered into an office accommodation agreement whereby it may access a shared office space located at 633 West Fifth Street, Suite 2826, Los Angeles, CA 90071 on a month-to-month basis over a one-year term for a fee of $2,349 per month. In considering its qualitative disclosure obligations under ASC 842-20-50-3, the Company examined its office accommodation agreement for office space that has a fixed monthly fee with no variable payments and no options to extend. The office accommodation agreement creates no tenancy, leasehold, or other real property interest, other than a shared right-of-use. The office accommodation agreement does not provide for terms and conditions granting residual value guarantees by the Company, or any restrictions or covenants imposed for dividends or incurring additional financial obligations by the Company.

 

The Company determined under ASC 2018-11, Leases (Topic 842), due to the short-term nature of the office accommodation agreement, that such agreement met the criteria of ASC 842-20-25-2 and as such it is not necessary to capitalize the office accommodation agreement and fees will be recognized on a monthly straight-line basis. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY, MACHINERY AND EQUIPMENT
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY, MACHINERY AND EQUIPMENT

NOTE 5 – PROPERTY, MACHINERY AND EQUIPMENT

Property and equipment as of June 30, 2021 and December 31, 2020 is summarized as follows:

          
  

June 30,

2021

 

December 31,

2020

Computer equipment  $23,784   $20,143 
Furniture and fixtures   5,407    5,140 
Machinery   104,102    —   
Subtotal   133,293    25,283 
Less accumulated depreciation   (21,395)   (18,741)
Property, machinery and equipment, net  $111,898   $6,542 

 

Property, machinery and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. On May 20, 2021, the Company purchased a new cannabis extraction machine which is to be leased to a cannabis distributor and manufacturer called Lynwood-MCOA joint venture. This joint venture is between Cannabis Global Inc. and the Company and pertains to the licensed cannabis operations of Natural Plant Extract of California Inc. in the city of Lynwood, CA. The lease payments are scheduled to commence during the third quarter of 2021.

 

Depreciation expense was $2,653 and $3,328 for the six months ended June 30, 2021 and 2020, respectively. 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENTS
6 Months Ended
Jun. 30, 2021
Investments, All Other Investments [Abstract]  
INVESTMENTS

NOTE 6 – INVESTMENTS 

Bougainville Ventures, Inc. Joint Venture

 

On March 16, 2017, the Company entered into a joint venture agreement with Bougainville Ventures, Inc. (“Bougainville”), a Canadian corporation, to (i) jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville's high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I-502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to, sales and marketing, agricultural procedures, operations, security and monitoring, processing and delivery, branding, capital resources and financial management; and (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through BV-MCOA Management, LLC, a limited liability company organized in the State of Washington on May 17, 2017.

 

Pursuant to the joint venture agreement, the Company committed to raise not less than $1,000,000 to fund joint venture operations, based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry.

 

The joint venture agreement provided that funding provided by the Company would contribute towards the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.

 

As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment from $1,000,000 to $800,000, and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.

 

Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach of contract for non-payment. Bougainville also did not possess an agreement with a Tier 3 I-502 license holder to grow marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land, but did not deed the real property to the joint venture. Bougainville failed to pay delinquent property taxes to Okanogan County, and as a result, as further discussed below, to date, the property has not been deeded to the joint venture.

 

To clarify the respective contributions and roles of the parties, the Company offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville to enter into an amended and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.

 

On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of $800,000 contributed by the Company to the joint venture. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 I-502 cannabis license holder to grow cannabis on the real property; and (iii) that clear title to the real property associated with the Tier 3 I-502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed a lawsuit against Bougainville, BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2-0045324. The Company seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, the appointment of a receiver, the return to treasury of 15 million shares of restricted common stock issued by the Company to Bougainville and treble damages pursuant to the Consumer Protection Act. The Company has filed a lis pendens on the real property. The case is currently in litigation.

 

In connection with the joint venture agreement, the Company recorded a cash investment of $1,188,500 to the joint venture during 2017. This was comprised of a 49.5% ownership of BV-MCOA Management, LLC, and was accounted for using the equity method of accounting. The Company recorded an annual impairment in 2017 of $792,500, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $37,673 and $11,043 for the quarters ended March 31, 2018 and June 30, 2018, respectively, and recorded an annual impairment of $285,986 for the year ended December 31, 2018, at which time the Company determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation, as discussed above.

 

Natural Plant Extract

 

On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. and its   subsidiaries (collectively, “NPE”), to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the parties terminated the joint venture and entered into a settlement and release agreement (the “Settlement Agreement”). In exchange for a complete release of all claims, the Company and NPE (1) agreed that the Company would reduce its interest in NPE from 20% to 5%; (2) the Company agreed to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement Agreement, and $25,000 no later than the fifth calendar day for each of the two months following execution of Settlement Agreement; and, (3) to retire the balance of the Company’s original valuation obligation from the material definitive agreement, representing a shortfall of $56,085, in a convertible promissory note, with terms allowing NPE to convert the note into shares of the Company’s common stock of at a 50% discount to the closing price of the Company’s common stock as of the maturity date. The note was satisfied in full during the year ended December 31, 2020.

 

As of the date of this filing, the Company owes $0 and is in compliance with the terms of the Settlement Agreement . On February 3, 2020, the Company issued NPE a convertible promissory note in the principal amount of $56,085. Additionally, as a result of the Settlement Agreement, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE.

 

Of the total amount due and payable by the Company with regards to the NPE joint venture agreement as of the date of this filing, the Company owes $75,000 and is in breach of the Settlement and Release of All Claims Agreement with NPE. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.

Brazilian Joint Ventures

 

On September 30, 2020, the Company entered into two joint venture agreements (the “Joint Venture Agreements”) with Marco Guerrero, a director of the Company (“Guerrero”) and related party, to form joint ventures in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America and to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of the joint venture entities in Uruguay and Brazil. The Brazilian joint venture, HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”), will be headquartered in São Paulo, Brazil. The Uruguayan joint venture, Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”), will be headquartered in Montevideo, Uruguay.

Pursuant to the Joint Venture Agreements, the Company acquired a 70% equity interest in both HempSmart Brazil and HempSmart Uruguay, with a minority 30% equity interest in both HempSmart Brazil and HempSmart Uruguay being held by newly formed entities controlled by Guerrero. Pursuant to the Joint Venture Agreements, the Company agreed to provide capital in the amount of $50,000 to both HempSmart Brazil and HempSmart Uruguay, for a total capital outlay obligation of $100,000. It is expected that the proceeds of the initial capital contribution will be used for contracting with third-party manufacturing facilities in Brazil and Uruguay and related infrastructure and employment of key personnel. As of June 30, 2021, the Company has not initiated the capital contribution but is pending to be done in the third quarter.

 

The boards of directors of HempSmart Brazil and HempSmart Uruguay will consist of three directors, elected by the joint venture partners. Pursuant to the Joint Venture Agreements, the Company agreed to license, on a royalty-free basis, certain of its intellectual property regarding its existing products to HempSmart Brazil and HempSmart Uruguay to enable the joint ventures to manufacture and sell its products in Brazil, Uruguay, and for export to other Latin American countries, the United States, and globally in accordance with the terms of the Joint Venture Agreements.

 

In addition, as majority partner, in the event a joint venture is frustrated in its intent or purpose, the Company may trigger a compulsory buy-sell procedure pursuant to which the Company could pursue a sale of all or substantially all of the joint venture. Subject to certain exceptions, the joint venture partners may not transfer their interests in HempSmart Brazil and HempSmart Uruguay.  

 

Cannabis Global, Inc. 

 

Joint Venture

 

On May 12, 2021, the Company entered into a joint venture agreement with Cannabis Global, Inc. (“Cannabis Global”) pursuant to which the Company will invest up to $250,000 into a newly formed entity (“MCOA Lynwood”) and Cannabis Global, through Natural Plant Extracts of California, Inc. (“Natural Plant”), an entity in which Cannabis Global owns a majority interest, will operate a regulated and licensed laboratory to manufacture various cannabis products in the State of California. As of June 30, 2021, the Company has invested $115,000.

Share Exchange

 

On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis Global pursuant to which the Company issued 650,000,000 shares of its common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global common stock. In addition, the Company and Cannabis Global entered into a lock-up leak-out agreement which contains certain restrictions with respect to the sales of such securities.

Eco Innovation Group Inc. – Share Exchange

 

On February 26, 2021, the Company entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, par value $0.001, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”). For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. As of June 30, 2021, the Company owed ECOX and additional 64,621,893 with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to the shares to be issued.

Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month.

For a period of two years following the Effective Date, at the closing of each fiscal quarter, should the per-share closing price of the common shares of the same class as the Shares or the Exchange Shares, as quoted by the OTC Markets for the last day of the relevant fiscal quarter, decrease below original issuance value with the effect that the aggregate value of the Shares or the Exchange Shares at the fiscal quarter close would be lower than $650,000, then either MCOA, in the case of the Shares, or ECOX, in the case of the Exchange Shares, shall issue the other party the number of shares of common stock necessary to cause the aggregate value of the Shares or the Exchange Shares, as applicable, be $650,000 as of the end of the relevant fiscal quarter. The parties shall irrevocably instruct their respective transfer agents to reserve and maintain authorized and unissued common stock in a reserve account designated for the purpose of issuing such shares pursuant to this share exchange adjustment provision. Such share reserve accounts shall be maintained with a number of authorized and unissued common stock not less than three (3) times the number of Shares or Exchange Shares, as the case may be, that are issued pursuant to the Share Exchange Closing.

 

On February 24, 2021, the closing price of the Company’s common stock was $0.0155, so that the number of shares of Company common stock issuable to ECOX under the Share Exchange Agreement is 41,935,484. As a result of the transactions pursuant to the Share Exchange Agreement, the Company will have 4,179,073,945 shares of common stock outstanding, with the shares issued to ECOX pursuant to the Share Exchange Agreement representing 1.00% of the Company’s outstanding shares.

 

For the quarter ended June 30, 2021, the Company recorded a Loss on Equity Investment and corresponding increase in Subscriptions Payable of $394,194 to address the decline in the Company's stock price from the original issuance price of $.0155.

 

 

MARIJUANA COMPANY OF AMERICA, INC.

INVESTMENT ROLL-FORWARD

AS OF JUNE 30, 2021

 

 

                                          
   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Beginning balance @12-31-16  $   $             $        $   $   $             $        $ 
                                                                       
Investments made during 2017   3,049,275    10,775              100,000         250,000    1,188,500    1,500,000                        
                                                                       
Quarter 03-31-17 equity method Loss                                                                    
                                                                       
Quarter 06-30-17 equity method Loss                                                                    
                                                                       
Quarter 09-30-17 equity method Loss   (375,000)                                 (375,000)                             
                                                                       
Quarter 12-31-17 equity method accounting   313,702                                  313,702                              
                                                                       
Impairment of Investment in 2017   (2,292,500)                                (792,500)   (1,500,000)                       
Balances as of 12/31/17  $695,477.00   $10,775.00   $   $   $100,000.00   $   $250,000.00   $334,702.00   $   $   $   $   $   $ 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during 2018   986,654    986,654                                                            
                                                                       
Quarter 03-31-18 equity method Loss   (37,673)                                 (37,673)                             
                                                                       
Quarter 06-30-18 equity method Loss   (111,043)                                 (11,043)                             
                                                                       
Quarter 09-30-18 equity method Loss   (10,422)                  (10,422)                                            
                                                                       
Quarter 12-31-18 equity method Loss   (31,721)   (31,721)                                                          
                                                                       
Moneytrac investment reclassified to Short-Term investments   (250,000)                            (250,000)                       250,000         250,000 
                                                                       
Unrealized gains on trading securities - 2018                                                         560,000         560,000 
                                                                       
Impairment of investment in 2018   (933,195)   (557,631)             (89,578)             (285,986)                             
Balance @12-31-18  $408,077   $408,077   $   $   $   $   $   $   $   $   $   $810,000   $   $ 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during quarter ended 03-31-19   129,040    129,040                                                             
                                                                       
Quarter 03-31-19 equity method Loss   (59,541)   (59,541)                                                            
                                                                       
Unrealized gains on trading securities - quarter ended 03-31-19                                                          (135,000)       $(135,000)
                                                                       
Balance @03-31-19  $477,576   $477,576   $   $   $   $   $   $   $   $   $   $675,000   $   $(135,000)
                                                                       
Investments made during quarter ended 06-30-19  $3,157,234   $83,646                                      $3,000,000   $73,588                
                                                                       
Quarter 06-30-19 equity method Income (Loss)  $(171,284)  ($141,870)                                     $(6,291)  $(23,123)               
                                                                       
Unrealized gains on trading securities - quarter ended 06-30-19  $                                                      (150,000)       $(150,000)
                                                                       
Balance @06-30-19  $3,463,526   $419,352   $   $   $   $   $   $   $   $2,993,709   $50,465   $525,000   $   $(285,000)

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
                                                                       
Investments made during quarter ended 09-30-19  $186,263                                                $186,263                
                                                                       
Quarter 09-30-19 equity method Income (Loss)  $122,863   $262,789                                      $(94,987)  $(44,939)               
                                                                       
Sale of trading securities during quarter ended 09-30-19                                                         $(41,667)       $(41,667)
                                                                       
Unrealized gains on trading securities - quarter ended 09-30-19  $                                                      (362,625)       $(362,625)
                                                                       
Balance @09-30-19  $3,772,652   $682,141   $   $   $   $   $   $   $   $2,898,722   $191,789   $120,708   $   $(689,292)

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during quarter ended 12-31-19  $392,226   $262,414                                           $129,812                
                                                                       
Quarter 12-31-19 equity method Income (Loss)  $(178,164)  $(75,220)                                     $(23,865)  $(79,079)               
Reversal of Equity method Loss for 2019  $272,285                                           $125,143   $147,142                
Impairment of investment in 2019  $(3,175,420)  $(869,335)                                     $(2,306,085)  $                
Loss on disposition of investment  $(389,664)                                               $(389,664)               
Sale of trading securities during quarter ended 12-31-19  $                                                     $(17,760)       $(17,760)
                                                                       
Unrealized gains on trading securities - quarter ended 12-31-19  $                                                      (75,545)       $(75,545)
Balance @12-31-19  $693,915   $  $   $   $   $   $   $   $   $693,915   $   $27,403   $   $(782,597)

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
                                                                       
Equity Loss for Quarter ended 03-31-20   126,845    126,845                                                             
                                                                       
Recognize Joint venture liabilities per JV agreement @03-31-20   394,848    394,848                                                             
                                                                       
Impairment of Equity Loss for Quarter ended 03-31-20   (521,692)   (521,692)                                                            
                                                                       
Unrealized gains on trading securities - quarter ended 03-31-19                                                          (13,945)       ($13,945)
Balance @03-31-20  $693,915   $   $   $   $   $   $   $   $   $693,915   $   $13,458   $   ($796,542)

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Equity Loss for Quarter ended 06-30-20   (7,048)   (7,048)                                                            
                                                                       
Impairment of Equity Loss for Quarter ended 06-30-20   7,048    7,048                                                             
                                                                       
Sales of of trading securities - quarter ended 06-30-20                                                          (13,458)       ($13,458)
Balance @06-30-20  $693,915   $   $   $   $   $   $   $   $   $693,915   $   $   $0   ($810,000)
                                                                       
Global Hemp Group trading securities issued   650,000        $650,000                                           $185,000   $185,000      
                                                                       
Investment in Cannabis Global                                                                     
                                                                       
Balance @09-30-20  $1,343,915   $   $650,000   $   $   $   $   $   $   $693,915   $   $185,000   $185,000   ($810,000)
                                                                       
Unrealized gain on Global Hemp Group securities - 4th Quarter 2020                                                         $54,064   $54,064      
                                                                       
Unrealized gains on Cannabis Global Inc securities - 4th Quarter 2020   208,086        $208,086                                                        
Balance @12-31-20  $1,552,001   $   $858,086   $   $   $   $   $   $   $693,915   $   $239,064   $239,064   ($810,000)
                                                                       
Investment in ECOX   650,000             $650,000                                      $620,133   $620,133      
                                                                       
Balance @03-31-21  $2,202,001   $   $858,086   $650,000   $   $   $   $   $   $693,915   $0   $859,197   $859,197   ($810,000)
                                                                       
Investments made during quarter ended 06-30-21   30,898                       $30,898                                         
                                                                       
Unrealized gain on Global Hemp Group securities - 2nd quarter 2021                                                         ($115,997)  ($115,997)     
                                                                       
Balance @06-30-21  $2,232,899   $   $858,086   $650,000   $   $30,898   $   $   $   $693,915   $   $743,200   $743,200   ($810,000)

 

 

 

                   
  06-30-20 03-31-20 12-31-19 09-30-19 06-30-19 03-31-19 12-31-18 12-31-17    
This includes balances for: Note (h) Note (g) Note (f) Note (e) Note (d) Note (c) Note (b) Note (a)    
      - Debt obligation of JV 478,494 394,848 - 1,633,872 1,778,872 128,522 289,742 1,500,000  
      - Convertible NP, net of discount 2,784,044 3,040,324 3,193,548 2,688,555 2,149,170 1,536,271 1,132,668 394,555  
      - Long term debt - - - - - - - 172,856  
Total Debt balance 3,262,538 3,435,172 3,193,548 4,322,427 3,928,042 1,664,793 1,422,410 2,067,411  

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE, RELATED PARTY
6 Months Ended
Jun. 30, 2021
Notes Payable Related Party  
NOTES PAYABLE, RELATED PARTY

NOTE 7 – NOTES PAYABLE, RELATED PARTY

As of June 30, 2021 and December 31, 2020, the Company’s officers and directors have provided advances and incurred expenses on behalf of the Company as such have been evidenced by the issuance of notes to such officers and directors. The notes are unsecured, due on demand and accrue interest at a rate of 5% per annum. The balance due to Notes Payable Related Party as of June 30, 2021 and December 31, 2020 was $20,000 and $40,000 respectively. These notes are payable to the estate of Charles Larsen.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
CONVERTIBLE NOTES PAYABLE
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

NOTE 8 – CONVERTIBLE NOTES PAYABLE

During the six months ended June 30, 2021, the Company issued an aggregate of 810,689,880 shares of its common stock in settlement of issued convertible notes payable and accrued interest.  

For the six months ended June 30, 2021 and June 30, 2020, the Company recorded amortization of debt discounts of $744,783 and $1,028,931, respectively, as a charge to interest expense.

Convertible notes payable are comprised of the following:

      
   June 30,  December 31,
   2021  2020
Lender  (Unaudited)  (Audited)
Convertible note payable - Power Up Lending Group  $—     $35,000 
Convertible note payable - Crown Bridge Partners  $35,000   $172,500 
Convertible note payable – Labrys  $537,500   $—   
Convertible note payable - GS Capital Partners LLC  $—     $143,500 
Convertible note payable – Geneva Roth  $—     $33,500 
Convertible note payable - Robert L. Hymers III  $185,000   $70,000 
Convertible note payable – Dutchess Capital  $135,000   $10,000 
Convertible note payable – Redstart Holdings  $—     $109,000 
Convertible note payable - GW Holdings  $—     $98,175 
Convertible note payable - St. George/Bucktown  $727,500   $1,160,726 
Total  $1,620,000   $1,832,401 
Less debt discounts  $(1,122,225)  $(405,507)
Net  $497,775   $1,426,894 
Less current portion  $(497,775)  $(1,426,894)
Long term portion  $—     $—   

 

 

 

Convertible Note Payable-Labrys

In June 2021, the Company issued a convertible promissory note in the aggregate principal amount of $537,500 to Labrys Funds, LP (“Labrys”). The promissory note accrues interest at 12% per annum, is due one year from the issuance date and includes an original issuance discount in the aggregate amount of $53,750. The Company also paid $33,750 in deferred financing fees and received $450,000 of net proceeds. The note is convertible at any time at a conversion price of $0.005 per share. The Company also issued a five-year warrants to purchase up to 76,349,431 shares of its common stock to Labrys, at an exercise price of $0.00704 per share. In addition, the Company issued five-year warrants to purchase up to 76,349,431 shares of its common stock to an investment banker for services, which warrants have an exercise price of $0.008448 per share. The aggregate debt discount of $533,526 is being amortized to interest expense over the respective terms of the note.

The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. The Company is prohibited from effecting an exercise of the warrant to the extent that, as a result of such exercise, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the note. Accrued interest on the note was $5,375 as of June 30, 2021.

Convertible Notes Payable-Power Up Lending

From July 1 through September 12, 2019, the Company issued four convertible promissory notes in the aggregate principal amount of $294,000 to Power Up Lending Group Ltd. (“Power Up”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date and include an original issuance discount in the aggregate amount of $12,000. The notes are convertible at any time at a conversion price equal to 61% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the date of conversion. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the notes should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $169,202 is being amortized to interest expense over the respective terms of the notes.

The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.

As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $0 and $35,000 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $1,167, respectively, of accrued interest on the notes.

 

Convertible Notes Payable-Crown Bridge Partners

From October 1 through December 31, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $225,000 to Crown Bridge Partners LLC (“Crown Bridge”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date and include an original issuance discount in aggregate amount of $22,500. Interest accrues from the issuance date, but interest shall not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 60% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the conversion date. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $88,674 was being amortized to interest expense over the respective terms of the notes. The Company also issued a warrants to purchase up to 519,230 shares of the Company’s common stock with an initial exercise price of $0.26, with reset provisions based on issuances of common stock subsequent to the issuance date. Due to the reset provision, the exercise option of these warrants is also accounted for as a derivative liability. See Note 10.

The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.

As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $35,000 and $172,500 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed accrued interest of $0 and $6,500 on the notes, respectively.

Convertible Notes Payable-Odyssey Funding LLC

On October 30, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $250,000 to Odyssey Funding LLC (“Odyssey”). The promissory notes accrue interest at a rate of 12% per annum, were due one year from the respective issuance date and include an original issuance discount in an aggregate amount of $12,500. Interest accrues from the issuance date, but interest does not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 55% the average of the two lowest trading prices of the Company’s common stock as quoted on the OTC Markets or such other exchange where the Company's shares are then traded, for the 20 trading days prior to the conversion date.

As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $207,650 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company an aggregate of $0 and $0 of principal, respectively. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the notes, respectively  .

Convertible Notes Payable - Paladin Advisors LLC

On October 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $75,000 to Paladin Advisors, LLC (“Paladin”). The promissory notes accrue interest at a rate of 8% per annum and were due six months from the respective issuance date of each note. Pursuant to the notes, Paladin has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 45% discount to the lowest closing bid of the 10 day trading period prior to the date of conversion.

 

The aggregate debt discount of $46,721 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $0 and $0 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the notes  , respectively.

Convertible Notes Payable-GS Capital Partners LLC

On December 19, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $173,000 to GS Capital Partners LLC (“GS Capital”). The promissory notes accrue interest at a rate of 10% per annum, were due one year from the respective issuance date, and include an original issuance discount in an aggregate amount of $15,000. Pursuant to the notes, GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the notes into shares of the Company's common stock at a conversion price equal to 62% of the lowest trading price of the Company's common stock as reported on the OTC Markets or such other exchange on which the Company’s shares are then traded, for the 20 trading days prior to the date of conversion.

As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $166,193 was being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $143,500 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $$2,789 in accrued interest on the notes  , respectively.

Convertible Notes Payable-St. George Investments

On November 1, 2017, the Company issued a secured convertible promissory note in the principal amount of $601,420 to St. George Investments LLC (“St. George”). The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on September 10, 2018 and includes an original issue discount of $59,220. The promissory note was funded on November 11, 2017 for $542,200, net of the original issue discount and transaction costs. As of September 30, 2019, the Company owed $417,890 of principal and $38,378 of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate. On December 20, 2017, the Company issued a secured convertible promissory note in the principal amount of up to $1,655,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on October 27, 2018 and includes an original issue discount of $155,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. The promissory note was funded in nine tranches of  $300,000; $200,000; $200,000; $400,000; $75,000; $150,000; $85,000; $120,000 and $70,000, resulting in aggregate net proceeds of $1,500,000. The Company received aggregate net proceeds of $1,200,000 and $300,000 during the years ended December 31, 2018 and 2017, respectively. As an investment incentive, the Company issued five-year warrants to purchase up to 1,100,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 5,274,146 total warrants.

The promissory note is convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 20% prepayment premium. The note is secured by a trust deed of certain assets of the Company. “Market Capitalization” means the total outstanding shares of common stock multiplied by the stock price published on OTC Markets.

On November 5, 2018, $250,000 of principal and accrued interest was assigned to John Fife as an individual with all the terms and conditions of the original note issued to St. George. On March 21, 2019, $150,959 of principal and $4,963 of accrued interest along with $160,454 of derivative liabilities valued as of the respective conversion date were converted into an aggregate of 394,460 shares of the Company’s common stock.

During the nine months ended September 30, 2019, $550,000 of principal, $122,694 of accrued interest and $441,394 of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of 1,710,897 shares of the Company’s common stock, resulting in a gain on debt settlement of $21,586. As of September 30, 2019, the Company owed $0 of principal and $0 of accrued interest on these convertible promissory notes. Although these notes were in default until they were repaid, the lender did not enforce the default interest rate.

 

On August 28, 2018, the Company issued a secured convertible promissory note in the amount of $1,128,518 (including overfunding of $23,518) to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on June 30, 2019, and includes an original issue discount of $100,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the year ended December 31, 2018, the Company received aggregate net proceeds of $825,000. During the nine months ended September 30, 2019, an additional $218,518 was funded under this note resulting in net proceeds of $198,518.

As an investment incentive to St. George, the Company issued St. George five-year warrants to purchase up to 750,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. The aggregate fair value of the issued warrants was $1,588,493. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $1,114,698 is being amortized to interest expense over the respective term of each tranche.   As of June 30, 2020, the warrants had an exercise price of $0.0085 for 3,750,000 total warrants.

The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion rate will be 60% of the three lowest closing trade prices during the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory notes include certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

During the nine months ended September 30, 2019, $1,000,859 of principal and $840,299 of derivative liabilities valued as of the respective conversion dates were converted into an aggregate of 4,475,543 shares of the Company’s common stock, resulting in a loss on debt settlement of $612,034. As of September 30, 2019, the Company owed $828,518 of principal and $28,138 of accrued interest on this convertible promissory note. As of September 30, 2019, this note was in default, but the lender has not enforced the default interest rate.

On January 29, 2019, the Company issued a secured convertible promissory note in the principal amount of $2,205,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on December 5, 2019, and includes an original issue discount of $200,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in eight tranches totaling $1,406,482, resulting in aggregate net proceeds of $1,276,482. As an investment incentive to St. George, the Company issued to St. George five-year warrants to purchase up to 1,500,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 7,500,000 total warrants. The aggregate fair value of the issued warrants was $999,838. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of each tranche of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense.

 

The promissory notes  are convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

On March 25, 2019, the Company issued a secured convertible promissory note in the principal amount of $580,000 to St. George. The promissory note accrues interest at a rate of 10% per annum compounded daily, was due upon maturity on January 24, 2020 and includes an original issue discount of $75,000. In addition, the Company agreed to pay $5,000 for legal, accounting and other transaction costs of the lender. During the nine months ended September 30, 2019, the promissory note was funded in the amount of $580,000 resulting in net proceeds of $500,000. As an investment incentive, the Company issued five-year warrants to purchase up to 375,000 shares of the Company’s common stock at an exercise price of $2.40 per share, with certain reset provisions. As of June 30, 2020, the warrants had an exercise price of $0.0085 for 1,875,000 total warrants. The aggregate fair value of the issued warrants was $258,701. The face value of the debt was then allocated, on a relative fair value basis, between the debt and the warrants. The portion allocated to warrants has been added to the debt discount with a resulting increase in additional paid-in capital. As of the funding date of this note, the Company determined the fair value of the embedded derivative associated with the convertibility of this note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $483,966 is being amortized to interest expense over the term of the note.

The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices from the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.

The Company entered into five convertible note agreements with Bucktown Capital, LLC, an affiliated entity of St. George in fiscal year 2020 and during the six months ended June 30, 2021. The notes have total principal due of $727,500, bear interest at 8% per annum. The notes mature between December 2021 and March 2022. The notes are convertible at fixed prices, with $225,000 of principal convertible at $0.002 per share, $80,000 convertible at $0.003 per share, and $422,500 convertible at $0.005 per share.

As of June 30, 2021 and December 31, 2020, the Company owed $727,500 and $1,160,726 of principal, respectively, on these notes. As of June 30, 2021 and December 31, 2020, the Company owed $24,042 and $350,525 of accrued interest on the above notes, respectively.

Convertible Notes Payable - Robert L. Hymers III

On December 23, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $96,552.70 to Robert L. Hymers III (“Hymers”) in satisfaction of funds owed to Mr. Hymers from his consulting contract with the Company for past services rendered and completed. The promissory notes accrue interest at a rate of 10% per annum, and are were six months from the respective issuance date of the note along with accrued and unpaid interest. Hymers has the option to convert all or any portion of the unpaid principal amount of the notes, plus accrued interest, into shares of the Company’s common stock at a conversion price equal to a 50% discount to the lowest closing bid price of the Company’s common stock during the 15 day trading period prior to the date of conversion. The aggregate debt discount of $92,332 is being amortized to interest expense over the respective terms of the notes. As of June 30, 2021 and December 31, 2020, the Company owed an aggregate of $185,000 and $70,000 of principal, respectively, to Hymers.  As of June 30, 2021 and December 31, 2020, the Company owed $3,125 and $1,005 in accrued interest on the notes  , respectively.

Convertible Notes Payable – Natural Plant Extract

On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. (“NPE”) to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the Company terminated the joint venture.

Definitive Agreement

Pursuant to the agreement with NPE, the Company agreed to acquire 20% (equal to 200,000 shares of NPE) of NPE’s authorized shares in exchange for the payment of $2,000,000 and $1,000,000 worth of the Company’s restricted common stock. The Company agreed to form a joint venture with NPE incorporated in California under the name “Viva Buds, Inc.” for the purpose of operating a California licensed cannabis distribution business pursuant to California law legalizing THC psychoactive cannabis for recreational and medicinal use.

The Company’s payment obligations were governed by a stock purchase agreement which required the Company to make the following payments: 

a. Deposit of $350,000 within 5 days of the execution of the agreement;

b. Deposit of $250,000 payable within 30 days of the execution of the agreement;

c. Deposit of $400,000 within 60 days of the execution of the agreement;

d. Deposit of $500,000 within 75 days of the execution of the agreement; and

e. Deposit of $500,000 within 90 days of the execution of the agreement.

The Company made its initial payment pursuant to this schedule, but otherwise failed to comply with the payment schedule and was in breach of contract.

Settlement and Release of All Claims Agreement

On February 3, 2020, the Company and NPE entered into a Settlement and Release of All Claims Agreement. In exchange for a universal release of all claims, the Company and NPE (i) agreed to reduce the Company’s interest in NPE from 20% to 5%; (ii) agreed that the Company would to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement and Release of All Claims Agreement, and $25,000 no later than the 5th calendar day for each of the two months following execution of Settlement and Release of All Claims Agreement; and, (iii) agreed to retire the balance of the Company’s original valuation obligation from the agreement, representing a shortfall of $56,085.15, in a convertible promissory note, with terms allowing NPE to convert the note into the Company’s common stock at a 50% discount to the closing price of the Company’s common stock as of the maturity date.

Of the total amount due and payable by the Company as of the date of this filing, the Company owes $50,000, and is in breach of the Settlement and Release of All Claims Agreement. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.

Convertible Note Payable – GW Holdings Group

On January 6, 2020, the Company entered into a convertible promissory note in the amount of $57,750 with GW Holdings Group, LLC (“GW”). GW has the option, beginning on the six month anniversary of the date of issuance, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a conversion price equal to 40% discount of the lowest trading price for the 15 trading days prior to the date of the conversion. The note accrues interest at a rate of 10% per annum and include a $5,250 original issue discount such that the price of the note was $57,750. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $98,175 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $818 in accrued interest on the note  , respectively.

Convertible Note Payable – Jefferson Capital

On January 20, 2020, the Company issued a convertible promissory note to Jefferson Capital, LLC (“Jefferson”) with note matured on January 20, 2021. Jefferson has the right to convert any or all of the note into common stock of the Company at a conversion price equal to (i) 60% of the lowest trading price of the Company’s common stock during the 20 trading day period prior to the issue date of the note or (ii) 60% multiplied by the market price, meaning the lowest trade price for the Company’s common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note.

 

Convertible Note Payable – BHP Capital

On January 21, 2021, the Company issued a convertible promissory note in the principal amount of $37,625to BHP Capital NY, Inc. (“BHP”). The Company agreed to pay simple interest on the outstanding principal amount of the note at a rate of 10% per annum. All amounts owed pursuant to the note are convertible, in whole or in part, into shares of the Company’s common stock at BHP’s option at the lower of (i) the lowest price at which the Company has issued stock; or (ii) the market price, defined as 60% of the lowest trading price for the Company’s common stock during the 20 trading day period ending on the last trading day prior to the conversion date. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the notes. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest   on the note.

Convertible Notes Payable – LG Capital

On March 2, 2020, the Company entered issued a convertible promissory note in the principal amount of $50,000 to LG Capital Funding, LLC (“LG Capital”) which note matured on March 2, 2021. The note accrues interest at a rate of 8% per annum. LG Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a price per share of equal to 55% of the lowest trading price of the Company’s common stock as quoted on the OTC Markets for the 20 trading days prior to the date of conversion. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $0 in accrued interest on the note  .

Convertible Debt Summary:  

The Company has identified the embedded derivatives related to the above described notes and warrants. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the note and to fair value as of each subsequent reporting date.

At June 30, 2021, the Company determined the aggregate fair value of embedded derivatives to be $1,904,016. The fair values were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 128.2% to 169.0%, (3) weighted average risk-free interest rate of 0.16% to 0.18%, (4) expected life of 0.05 to 2.7 years, (5) conversion prices of $0.00185 to $0.00333 and (6) the Company's common stock price of $0.0044 per share as of June 30, 2020.

For the six months ended June 30, 2021, the Company recorded a gain on the change in fair value of derivative liabilities of $1,347,646 and a loss of $1,035,115 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense. For the six months ended June 30, 2020, the Company recorded a gain on change in fair value of derivative liabilities of $1,142,272, a loss of $395,607 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense, and amortization of debt discounts of $1,028,931 as a charge to interest expense.

Paycheck Protection Program Loan

 

During the quarter ended June 30, 2020, the Company's wholly owned subsidiary, H Smart Inc., received a $35,500 loan as part of the Paycheck Protection Program (“PPP”) offered by the Small Business Administration.

 

The Company has elected to account for the PPP loan pursuant to FASB ASC 470, Debt, or as a government grant by analogy to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance.

 

Following the guidance in ASC 470, the Company has recognized the entire loan amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company will not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.

For purposes of derecognizing the liability, ASC 470 refers to the extinguishment guidance in ASC 405, Liabilities.

Based on that guidance, the loan would remain recorded as a liability until either of the following criteria are met:

· The Company has been legally released from being the primary obligor under the liability.

  · The Company pays the lender and is relieved of its obligation for the liability.

Because the Company will not be legally released from being the primary obligor of the PPP loan until forgiveness is actually granted, income from the extinguishment of the loan would only be recognized once the Company's application for forgiveness is approved. If the forgiveness application is approved, any resulting amount forgiven would be recognized and separately disclosed in the income statement as a gain on extinguishment.

Subscriptions Payable

On September 30, 2020, the Company entered into a share exchange agreement (“Share Exchange Agreement”) with Cannabis Global, Inc. (“CBGL”) dated September 30, 2020, to acquire the number of shares of CBGL’s common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the Share Exchange Agreement.  For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000.

On February 26, 2021, the Company entered into a share exchange agreement (“ECOX Share Exchange Agreement”) with Eco Innovation Group, Inc. (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the ECOX Share Exchange Agreement.  For both parties, the ECOX Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the ECOX Share Exchange Agreement to fall below $650,000. Based on the value of ECOX shares in the market as of June 30, 2021, the Company recorded a value for additional shares owed to ECOX pursuant to the ECOX Share Exchange Agreement of $329,572 as a subscription agreement along with a loss from equity investment of $391,194. As of June 30, 2021 41,935,484 shares of the Company’s common stock have been issued. As a result, the balance of subscriptions payable as of June 30, 2021 and December 31, 2020 was $999,355 and $670,000, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 9 – STOCKHOLDERS’ DEFICIT

Preferred Stock

The Company is authorized to issue 50,000,000 shares of $0.001 par value preferred stock (“Series A Preferred Stock”) as of June 30, 2021 and December 31, 2020 of which 10,000,000 shares are outstanding as of June 30, 2021. As of June 30, 2021 and December 31, 2020, the Company is authorized to issue 5,000,000 shares of Class B Preferred Stock of which 2,000,000 shares are issued and outstanding as of June 30, 2021.

 

 

Each share of Class A Preferred Stock is entitled to 100 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.

 

Each share of Class B Preferred Stock is entitled to 1,000 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.

Common stock

The Company is authorized to issue 15,000,000,000 shares of $0.001 par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $0.001 par value common stock. As of June 30, 2021, and December 31, 2020, the Company had 5,068,524,855 and 3,136,774,861 shares of common stock issued and outstanding, respectively. As of August 19, 2021, there were 5,405,130,704 shares of the Company’s common stock issued and outstanding.

During the six months ended June 30, 2021, the Company issued an aggregate of 21,000,020 shares of its common stock for services with an estimated fair value of $140,900.

During the six months ended June 30, 2021, the Company issued an aggregate of 810,689,880 shares of its common stock, including 153,227,150 related to warrants accounted for as liabilities, in settlement of convertible notes payable, accrued interest of $1,677,373, and reclassified derivative liabilities of $5,975,670 to additional paid in capital in connection with the conversions.

During the six months ended June 30, 2021, the Company issued a net amount of 3,027,031 shares of its common stock in settlement of liabilities with an estimated fair value of $8,623, which included 10,892,411 related to shares to be issued as of December 31, 2020, and the cancellation of 8,755,714 shares for previous settlements, and 890,334 new shares issued for settlement of accounts payable.  

During the six months ended June 30, 2021, the Company issued 22,500,000 of its common stock upon the settlement of related party notes payable and accounts payable with an estimated fair value of $141,750.

During the six months ended June 30, 2021, the Company issued 400,000,000 of its common stock upon the exercise of warrants on a cash basis, including warrant liabilities with an estimated value of $63,500.

During the six months ended June 30, 2021, the Company sold 632,597,599 of its common stock for an aggregate value of $1,358,767.

During the six months ended June 30, 2021, the Company issued 41,935,484 of its common stock with a value of $650,000 and will issue an additional 64,621,893 shares for investments with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to these additional shares during the three months ended June 30, 2021.

The Company is authorized to issue 15,000,000,000 shares of $0.001 par value common stock as of June 30, 2021. As of December 31, 2020, the Company was authorized to issue 5,000,000,000 shares of $0.001 par value common stock. As of June 30, 2020 and December 31, 2019, the Company had 469,288,934 and 77,958,081 shares of common stock issued and outstanding, respectively.

During the six months ended June 30, 2020, the Company issued an aggregate of 8,333 shares of its common stock to settle amounts previously accrued with an estimated fair value of $6,700.

During the six months ended June 30, 2020, the Company issued an aggregate of 44,658,333 shares of its common stock for services with an estimated fair value of $542,766.

During the six months ended June 30, 2020, the Company issued an aggregate of 270,547,861 shares of its common stock in settlement of convertible notes payable, accrued interest and embedded derivative liabilities of an aggregate of $1,531,471.

During the six months ended June 30, 2020, the Company issued 21,384,103 of its common stock upon the conversion of related party notes payable with an estimated fair value of $50,613.

During the six months ended June 30, 2020, the Company issued 51,054,214 shares of its common stock upon the exercise of warrants on a cashless basis.

During the six months ended June 30, 2020, the Company issued 3,677,889 shares of its common stock in settlement of a legal case with an estimated fair value of $956,251.

On January 17, 2020, the Company entered into an amendment of an existing convertible promissory note issued to Paladin. The Company authorized the issuance of a warrant to purchase up to 5,750,000 shares of the Company’s common stock, which warrant could be exercised on a cashless basis. This warrant was exercised during the three months ended June 30, 2020.

Options

As of June 30, 2021, the Company has no outstanding stock options.

 

Warrants

The following table summarizes the stock warrant activity for the three months ended June 30, 2021:

                               
    Shares  

Weighted-Average

Exercise Price

 

Weighted Average

Remaining

Contractual Term

 

Aggregate

Intrinsic Value

Outstanding at December 31, 2020     293,054,702     $ 0.0011       2.22     $ 1,023,306  
Granted     79,785,156     0.0071       5.00       —    
Increase due to reset provision     (9,722,222 )   0.004       2.41       —    
Exercised     (194,788,035 )     0.004       1.66       1,427,826    
Outstanding at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  
Exercisable at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  

 

Certain warrants issued to debt holders have reset provisions whereby upon subsequent issuances of common stock at a price below the current exercise price, the number of warrants increase and the exercise price is reduced to the new price. The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $0.0061 as of June 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENT
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENT

NOTE 10 — FAIR VALUE MEASUREMENT

ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of June 30, 2021 and December 31, 2020, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in Note 3. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 3 are that of volatility and market price of the underlying common stock of the Company.

As of June 30, 2021 and December 31, 2020, the Company did not have any derivative instruments that were designated as hedges.

The derivative liability as of June 30, 2021 and December 31, 2020, in the amount of $1,904,016 and $4,426,057, respectively, have a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended June 30, 2021:

     
  

Debt

Derivative

Balance, January 1, 2021  $4,426,057 
Increase resulting from initial issuance of additional convertible notes payable   1,824,340 
Decreases resulting from conversion of convertible notes payable   (5,975,670)
Decreases resulting from payoff of convertible notes payable   (649,961)
Loss from change in fair value included in earnings   2,279,250 
Balance, June 30, 2021  $1,904,016 

 

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. During the period ended June 30, 2021, the Company’s stock price decreased significantly from initial valuations. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 11 — RELATED PARTY TRANSACTIONS

The Company’s current officers and stockholders advanced funds to the Company for travel related   to business meetings and due diligence with respect to acquisition targets and working capital purposes. As of June 30, 2021 and December 31, 2020, the balance due to officers for travel and working capital purposes was $0 and $0, respectively.

As of June 30, 2021 and December 31, 2020, accrued compensation due to officers and executives included as accrued compensation was $9,000 and $79,214, respectively.

 

Related party sales contributed $0 and $5,131 to revenues for the three months ended June 30, 2021 and 2020, respectively, while related party sales contributed $0 and $8,303 to revenues for the six months ended June 30, 2021 and 2020, respectively. Related party sales are comprised of sales of the Company’s hempSMART products to the Company’s directors, officers, employees, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITION
6 Months Ended
Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
ACQUISITION

NOTE 12 – ACQUISITION 

On June 29, 2021, the Company, cDistro Merger Sub, Inc., a Nevada corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and cDistro, Inc., a privately-held Nevada corporation engaged in the hemp and CBD product distribution business (“cDistro”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger Sub merged with and into cDistro on June 30, 2021, with cDistro becoming a wholly-owned subsidiary of the Company and the surviving corporation in the merger (the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

 

Contingent Consideration - Earnout Agreement

 

In connection to the Merger, the Company and the securityholder of cDistro (the “cDistro Stockholder”) entered into an earnout agreement dated June 29, 2021 (the “Earnout Agreement”), whereby the Company agreed to issue additional shares of its common stock to the cDistro Stockholder as compensation for the Merger conditioned upon the achievement of certain gross revenue milestones. If cDistro meets revenue targets of $600,000 per quarter, up to a total of $2,400,000 of revenue, the Company will issue shares worth $250,000 upon the achievement each quarterly revenue target, with the number of shares to be issued at each payout date calculated based on the lessor of 220,970,059 shares of common stock or a 30% discount to the average close price of the Company’s common stock for the 20-day period immediately preceding the payout date of the earnout. In accordance with ASC 805, the Company accounts for this earnout agreement as contingent consideration based on the number of shares calculated as owed as of each quarter end, with changes in value to be recorded in earnings each reporting period.

 

Leak-Out Agreement

 

On June 29, 2021, in connection with the Merger and the Earnout Agreement, the cDistro Stockholder entered into a Lock-Up and Leak-Out Agreement with the Company pursuant to which, among other thing, such stockholder agreed to certain restrictions regarding the resale of the common stock issued pursuant to the Merger for a period of six months from the date of the Merger.

 

Employment Agreement

 

On June 29, 2021, in connection with the Merger, the Company and the Chief Executive Officer of cDistro entered into an employment agreement, pursuant to which that employee will serve as cDistro’s Chief Executive Officer for a three-year term.

 

The acquisition of cDistro is being accounted for as a business combination under ASC 805. The Company is continuing to gather evidence to evaluate what identifiable intangible assets were acquired, such as a customer list, and the fair value of each, and expects to finalize the fair value of the acquired assets within one year of the acquisition date. 

 

The aggregate preliminary fair value of consideration for the cDistro acquisition was as follows

 

     
   Amount
Cash, net of cash acquired of $99,393  $250,607 
Contingent Consideration - Earnout Agreement   1,000,000 
265,164,070 shares of common stock (not issued as of June 30, 2021)   1,617,501 
Total preliminary consideration transferred  $2,868,108 

 

During the three months ended June 30, 2021, the Company has paid $250,000 of the cash consideration.

 

The following information summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed at the acquisition date:

     
Accounts Receivable  $40,291 
 Inventory   6,746 
 Other Assets   19,310 
 Goodwill   2,989,803 
 Accounts payable   (181,042)
 other accrued liabilities   (7,000)
 Net assets acquired  $2,868,108 

Unaudited Pro Forma Financial Information

 

The following table sets forth the pro-forma consolidated results of operations for the three and six months ended June 30, 2021 and 2020 as if the cDistro acquisition occurred on January 1, 2020. The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the acquisitions had taken place on the dates noted above, or of results that may occur in the future.

            
   Three months ended June 30,  Six months ended June 30,
   2021  2020  2021  2020
Revenue  $290,196   $152,402   $444,239   $234,221 
Operating loss   (1,067,780)   (965,158)   (1,855,860)   (1,357,315)
Net loss   (1,869,775)   (276,742)   (5,532,928)   (2,395,044)
 Net loss per common share  $(0.00)  $(0.00)  $(0.00)  $(0.01)
Weighted Average common shares outstanding   5,102,510,297    510,164,598    4,730,796,549    451,015,744 
                     

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 13 – SUBSEQUENT EVENTS 

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Interim Financial Statements

Interim Financial Statements

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Revenue Recognition

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.

Identification of Our Contracts with Customers

Identification of Our Contracts with Customers 

Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.

In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.

 

Determination of the Price in Our Sales Contracts

The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.

Allocation of the Transaction Price of Our Sales Contracts

The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.

With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. 

Identifying the Performance Obligations in Our Sales Contracts

 

In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.

 

Product Sales

Product Sales

Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.

Consulting Services

Consulting Services

The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.

For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.  

The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605   to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Cash

Cash

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Concentrations of Credit Risk

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash   in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Accounts Receivable

Accounts Receivable 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $0 and $0, respectively.

Inventories

Inventories

Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.

Cost of Sales

Cost of Sales 

Cost of sales is comprised of cost of product sold, packaging, and shipping costs.

Stock-Based Compensation - Employees

Stock-Based Compensation - Employees

The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  

The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  

If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. 

 

  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. 

Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.

The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.

Stock-Based Compensation – Non Employees

Stock-Based Compensation – Non Employees

Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.

 

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.   
  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. 
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.

 

Earnings per Share

Earnings per Share

Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years.

 

Investments

Investments 

The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).

Derivative Financial Instruments

Derivative Financial Instruments

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   

The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.

Advertising

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $168,780 and $44,659 for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.

Segment Information

Segment Information

ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.

hempSMART

STATEMENT OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

 

                   
   For the three months ended 

6 Months

Ended

  For the three months ended 

6 Months

Ended

   March 31, 2021  June 30, 2021  June 30, 2021  March 31, 2020  June 30, 2020  June 30, 2020
                   
                   
Revenues  $34,872   $16,537   $51,409   $81,819   $82,958   $164,777 
                               
Cost of Goods Sold   25,032    3,301    28,333    34,205    39,187    73,392 
                               
Gross Profit   9,840    13,236    23,076    47,614    43,771    91,385 
                               
Expense                              
Stock Based Compensation                        17,850    17,850 
Selling and Marketing   97,812    150,881    248,693    101,897    74,356    176,253 
Payroll and Related expenses   53,947    54,864    108,811    18,749    32,113    50,862 
Depreciation Expense   1,391    1,391    2,782    1,746    1,582    3,328 
General and Admin Expenses   55,801    95,864    151,665    67,949    53,911    121,860 
Total Expense   208,951    303,000    511,951    190,341    179,812    370,153 
                               
Net Loss from Operations  $(199,111)  $(289,764)  $(488,875)  $(142,727)  $(136,041)  $(278,768)

Income Taxes

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has not recorded any unrecognized tax benefits.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.

 

Recently Issued Accounting Pronouncements Adopted 

 

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Segment Information
                   
   For the three months ended 

6 Months

Ended

  For the three months ended 

6 Months

Ended

   March 31, 2021  June 30, 2021  June 30, 2021  March 31, 2020  June 30, 2020  June 30, 2020
                   
                   
Revenues  $34,872   $16,537   $51,409   $81,819   $82,958   $164,777 
                               
Cost of Goods Sold   25,032    3,301    28,333    34,205    39,187    73,392 
                               
Gross Profit   9,840    13,236    23,076    47,614    43,771    91,385 
                               
Expense                              
Stock Based Compensation                        17,850    17,850 
Selling and Marketing   97,812    150,881    248,693    101,897    74,356    176,253 
Payroll and Related expenses   53,947    54,864    108,811    18,749    32,113    50,862 
Depreciation Expense   1,391    1,391    2,782    1,746    1,582    3,328 
General and Admin Expenses   55,801    95,864    151,665    67,949    53,911    121,860 
Total Expense   208,951    303,000    511,951    190,341    179,812    370,153 
                               
Net Loss from Operations  $(199,111)  $(289,764)  $(488,875)  $(142,727)  $(136,041)  $(278,768)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY, MACHINERY AND EQUIPMENT (Tables)
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
          
  

June 30,

2021

 

December 31,

2020

Computer equipment  $23,784   $20,143 
Furniture and fixtures   5,407    5,140 
Machinery   104,102    —   
Subtotal   133,293    25,283 
Less accumulated depreciation   (21,395)   (18,741)
Property, machinery and equipment, net  $111,898   $6,542 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENTS (Tables)
6 Months Ended
Jun. 30, 2021
Investments, All Other Investments [Abstract]  
Schedule of Investment Roll Forward
                                          
   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Beginning balance @12-31-16  $   $             $        $   $   $             $        $ 
                                                                       
Investments made during 2017   3,049,275    10,775              100,000         250,000    1,188,500    1,500,000                        
                                                                       
Quarter 03-31-17 equity method Loss                                                                    
                                                                       
Quarter 06-30-17 equity method Loss                                                                    
                                                                       
Quarter 09-30-17 equity method Loss   (375,000)                                 (375,000)                             
                                                                       
Quarter 12-31-17 equity method accounting   313,702                                  313,702                              
                                                                       
Impairment of Investment in 2017   (2,292,500)                                (792,500)   (1,500,000)                       
Balances as of 12/31/17  $695,477.00   $10,775.00   $   $   $100,000.00   $   $250,000.00   $334,702.00   $   $   $   $   $   $ 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
CONVERTIBLE NOTES PAYABLE (Tables)
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Convertible Notes Payable
      
   June 30,  December 31,
   2021  2020
Lender  (Unaudited)  (Audited)
Convertible note payable - Power Up Lending Group  $—     $35,000 
Convertible note payable - Crown Bridge Partners  $35,000   $172,500 
Convertible note payable – Labrys  $537,500   $—   
Convertible note payable - GS Capital Partners LLC  $—     $143,500 
Convertible note payable – Geneva Roth  $—     $33,500 
Convertible note payable - Robert L. Hymers III  $185,000   $70,000 
Convertible note payable – Dutchess Capital  $135,000   $10,000 
Convertible note payable – Redstart Holdings  $—     $109,000 
Convertible note payable - GW Holdings  $—     $98,175 
Convertible note payable - St. George/Bucktown  $727,500   $1,160,726 
Total  $1,620,000   $1,832,401 
Less debt discounts  $(1,122,225)  $(405,507)
Net  $497,775   $1,426,894 
Less current portion  $(497,775)  $(1,426,894)
Long term portion  $—     $—   
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT (Tables)
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Summarizes the Stock Warrant Activity
                               
    Shares  

Weighted-Average

Exercise Price

 

Weighted Average

Remaining

Contractual Term

 

Aggregate

Intrinsic Value

Outstanding at December 31, 2020     293,054,702     $ 0.0011       2.22     $ 1,023,306  
Granted     79,785,156     0.0071       5.00       —    
Increase due to reset provision     (9,722,222 )   0.004       2.41       —    
Exercised     (194,788,035 )     0.004       1.66       1,427,826    
Outstanding at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  
Exercisable at June 30, 2021     168,329,601     $ 0.0039       3.49     $ 503,850  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENT (Tables)
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Summary of Changes in Fair Value of Derivative Liabilities
     
  

Debt

Derivative

Balance, January 1, 2021  $4,426,057 
Increase resulting from initial issuance of additional convertible notes payable   1,824,340 
Decreases resulting from conversion of convertible notes payable   (5,975,670)
Decreases resulting from payoff of convertible notes payable   (649,961)
Loss from change in fair value included in earnings   2,279,250 
Balance, June 30, 2021  $1,904,016 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITION (Tables)
6 Months Ended
Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Schedule of aggregate preliminary fair value
     
   Amount
Cash, net of cash acquired of $99,393  $250,607 
Contingent Consideration - Earnout Agreement   1,000,000 
265,164,070 shares of common stock (not issued as of June 30, 2021)   1,617,501 
Total preliminary consideration transferred  $2,868,108 
Schedule summarizes the preliminary allocation of the fair values
     
Accounts Receivable  $40,291 
 Inventory   6,746 
 Other Assets   19,310 
 Goodwill   2,989,803 
 Accounts payable   (181,042)
 other accrued liabilities   (7,000)
 Net assets acquired  $2,868,108 
Schedule of pro-forma consolidated results of operations
            
   Three months ended June 30,  Six months ended June 30,
   2021  2020  2021  2020
Revenue  $290,196   $152,402   $444,239   $234,221 
Operating loss   (1,067,780)   (965,158)   (1,855,860)   (1,357,315)
Net loss   (1,869,775)   (276,742)   (5,532,928)   (2,395,044)
 Net loss per common share  $(0.00)  $(0.00)  $(0.00)  $(0.01)
Weighted Average common shares outstanding   5,102,510,297    510,164,598    4,730,796,549    451,015,744 
                     
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative)
1 Months Ended
Oct. 31, 2009
Sparrowtech, Inc. [Member]  
Noncash or Part Noncash Acquisitions [Line Items]  
Merger description of Sparrowtech, Inc In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net losses from operations $ 5,486,107  
Net cash used cash in operations $ 1,841,640 $ 669,005
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]            
Revenues $ 16,880   $ 82,958   $ 51,810 $ 164,777
Cost of Goods Sold 3,301   39,187   28,481 73,392
Gross Profit 13,579   43,771   23,329 91,385
Expense            
Stock Based Compensation 139,000   536,452   158,900 542,767
Selling and Marketing 155,212   74,212   262,761 200,667
Depreciation Expense 1,262   1,582   2,653 3,328
General and Admin Expenses 611,970   211,116   1,137,652 415,172
Total Expense 1,039,701   919,006   1,832,368 1,358,777
Operating Segment [Member]            
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]            
Revenues 16,537 $ 34,872 82,958 $ 81,819 51,409 164,777
Cost of Goods Sold 3,301 25,032 39,187 34,205 28,333 73,392
Gross Profit 13,236 9,840 43,771 47,614 23,076 91,385
Expense            
Stock Based Compensation 17,850 17,850
Selling and Marketing 150,881 97,812 74,356 101,897 248,693 176,253
Payroll and Related expenses 54,864 53,947 32,113 18,749 108,811 50,862
Depreciation Expense 1,391 1,391 1,582 1,746 2,782 3,328
General and Admin Expenses 95,864 55,801 53,911 67,949 151,665 121,860
Total Expense 303,000 208,951 179,812 190,341 511,951 370,153
Net Loss from Operations $ (289,764) $ (199,111) $ (136,041) $ (142,727) $ (488,875) $ (278,768)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Property, Plant and Equipment [Line Items]      
Allowance for doubtful accounts $ 0   $ 0
Advertising cost 168,780 $ 44,659  
Unrecognized tax benefits $ 0   $ 0
Property, Plant and Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Depreciation calculation method straight-line method    
Property, Plant and Equipment [Member] | Minimum [Member]      
Property, Plant and Equipment [Line Items]      
Estimatied useful lives 3 years    
Property, Plant and Equipment [Member] | Maximum [Member]      
Property, Plant and Equipment [Line Items]      
Estimatied useful lives 5 years    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
OPERATING LEASE (Details Narrative)
Jul. 02, 2019
USD ($)
Lease Agreements [Member]  
Other Commitments [Line Items]  
Monthly rent $ 2,349
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY, MACHINERY AND EQUIPMENT (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 133,293 $ 25,283
Less accumulated depreciation (21,395) (18,741)
Property and equipment, net 111,898 6,542
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 23,784 20,143
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 5,407 5,140
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 104,102 $ 0
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 1,262 $ 1,582 $ 2,653 $ 3,328
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENTS (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2018
Dec. 31, 2017
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Equity method Loss $ (394,194)       $ (7,048)           $ (394,194) $ (133,893)    
      - Debt obligation of JV         478,494 $ 394,848 $ 1,633,872 $ 1,778,872 $ 128,522   478,494 $ 289,742 $ 1,500,000
      - Convertible NP, net of discount 497,775   $ 1,426,894   2,784,044 3,040,324 3,193,548 2,688,555 2,149,170 1,536,271 497,775 2,784,044 1,132,668 394,555
      - Long term debt           172,856
Total Debt balance         3,262,538 3,435,172 3,193,548 4,322,427 3,928,042 1,664,793   3,262,538 1,422,410 2,067,411
Investments [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 2,202,001 $ 1,552,001 1,343,915 $ 693,915 693,915 693,915 3,772,652 3,463,526 477,576 408,077 1,552,001 693,915 695,477.00
Investments made             392,226 186,263 3,157,234 129,040     986,654 3,049,275
Equity method Loss       650,000 (7,048) 126,845 (178,164) 122,863 (171,284) (59,541)     (111,043)
Equity method Loss                         (10,422)
Equity method Loss                         (31,721)  
Equity method Loss                         (250,000) (375,000)
Equity method Loss                       313,702
Impairment of Investment   650,000 30,898 7,048 (521,692) (3,175,420)           (933,195) (2,292,500)
Investments made                         (37,673)  
Investment, Ending balance 2,232,899 2,202,001 1,552,001 1,343,915 693,915 693,915 693,915 3,772,652 3,463,526 477,576 2,232,899 693,915 408,077 695,477.00
Unrealized gains on trading securities     208,086                
Reversal of Equity method Loss             272,285              
Loss on disposition of investment             (389,664)              
Recognize Joint venture liabilities per JV agreement           394,848                
Investments [Member] | Global Hemp Group [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 682,141 419,352 477,576 408,077 10,775.00
Investments made                 83,646 129,040     986,654 10,775
Equity method Loss               262,789 141,870 (59,541)        
Equity method Loss                         (31,721)  
Impairment of Investment                         (557,631)
Investment, Ending balance 682,141 419,352 477,576 408,077 10,775.00
Sale of trading securities               (41,667)            
Investments [Member] | Benihemp [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance   100,000.00
Investments made                           100,000
Equity method Loss                         (10,422)  
Equity method Loss                          
Impairment of Investment                         (89,578)  
Investment, Ending balance   100,000.00
Investments [Member] | Money Trac [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 250,000.00
Investments made                           250,000
Equity method Loss                         (250,000)  
Investment, Ending balance 250,000.00
Investments [Member] | Bougainville Ventues [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 334,702.00
Investments made                           1,188,500
Equity method Loss                         (11,043)  
Equity method Loss                           (375,000)
Equity method Loss                           313,702
Impairment of Investment                         (285,986) (792,500)
Investments made                         (37,673)  
Investment, Ending balance 334,702.00
Investments [Member] | Stock Option Plan [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance
Investments made                           1,500,000
Impairment of Investment               (362,625) (150,000)         (1,500,000)
Investment, Ending balance
Investments [Member] | Cannabis [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 858,086 858,086 650,000 858,086  
Investment, Ending balance 858,086 858,086 858,086 650,000 858,086
Investments [Member] | E C O X [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 650,000  
Impairment of Investment   650,000                        
Investment, Ending balance 650,000 650,000 650,000
Investments [Member] | Lynwood [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance    
Impairment of Investment 30,898                          
Investment, Ending balance 30,898 30,898  
Investments [Member] | Natural Plant [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 693,915 693,915 693,915 693,915   693,915 2,898,722 2,993,709 693,915 693,915  
Investments made                 3,000,000          
Equity method Loss               (94,987) (6,291)          
Investment, Ending balance 693,915 693,915 693,915 693,915 693,915   693,915 2,898,722 2,993,709 693,915 693,915
Investments [Member] | Vivabuds [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 0 191,789 50,465  
Investments made               186,263 73,588          
Equity method Loss               (44,939) (23,123)          
Investment, Ending balance 0 191,789 50,465
Investments [Member] | Global Hemp [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 859,197 239,064 185,000 0     239,064    
Equity method Loss       185,000                    
Impairment of Investment   620,133                        
Investment, Ending balance 743,200 859,197 239,064 185,000 0     743,200 0  
Unrealized gains on trading securities 115,997                          
Unrealized gain on Global Hemp Group securities     54,064                      
Short-term Investments [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 859,197 239,064 185,000 13,458 27,403 120,708 525,000 675,000 810,000 239,064 27,403
Investments made                          
Equity method Loss       185,000                  
Equity method Loss                        
Equity method Loss                        
Equity method Loss                         250,000
Equity method Loss         (13,458)   (17,760)           560,000
Impairment of Investment   620,133               (135,000)    
Investment, Beginning balance                          
Investments made                          
Investment, Ending balance 743,200 859,197 239,064 185,000 13,458 27,403 120,708 525,000 675,000 743,200 810,000
Unrealized gains on trading securities 115,997         (13,945) (75,545)              
Unrealized gain on Global Hemp Group securities     54,064                      
Short-term Investments [Member] | Money Trac [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance         796,542            
Investments made                          
Equity method Loss                         250,000  
Equity method Loss         13,458   (17,760)           560,000  
Impairment of Investment               (362,625) (150,000) (135,000)      
Investment, Beginning balance           (782,597) (689,292) (285,000) (135,000)          
Investment, Ending balance           796,542            
Unrealized gains on trading securities           13,945 (75,545)              
Short-term Investments [Member] | Global Hemp [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance                      
Investment, Ending balance                      
Global Hemp Group [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investments made             262,414              
Equity method Loss       650,000 (7,048) 126,845 (75,220)              
Impairment of Investment         7,048 (521,692) (869,335)              
Unrealized gains on trading securities     208,086                      
Recognize Joint venture liabilities per JV agreement           $ 394,848                
Vivabuds [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investments made             129,812              
Equity method Loss             (79,079)              
Impairment of Investment                          
Reversal of Equity method Loss             147,142              
Loss on disposition of investment             (389,664)              
Natural Plant [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Equity method Loss             (23,865)              
Impairment of Investment             (2,306,085)              
Reversal of Equity method Loss             $ 125,143              
Money Trac [Member]                            
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]                            
Investment, Beginning balance 810,000 810,000 810,000 810,000             810,000      
Investment, Ending balance $ 810,000 $ 810,000 $ 810,000 $ 810,000 $ 810,000           $ 810,000 $ 810,000    
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENTS (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Nov. 06, 2017
Mar. 16, 2017
Schedule of Equity Method Investments [Line Items]            
Cash investment       $ 1,188,500    
Annual impairment       $ 792,500    
Equity losse $ 11,043 $ 37,673 $ 285,986      
Joint Venture Agreement With Bougainville Ventures Inc [Member]            
Schedule of Equity Method Investments [Line Items]            
Total committed amount to raise for joint ventures         $ 800,000 $ 1,000,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE, RELATED PARTY (Details Narrative) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Notes Payable Related Party    
Notes payable, related parties $ 20,000 $ 40,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
CONVERTIBLE NOTES PAYABLE (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Total $ 1,620,000 $ 1,832,401
Less debt discounts (1,122,225) (405,507)
Net 497,775 1,426,894
Less current portion (497,775) (1,426,894)
Long term portion 0 0
Convertible Notes Payable - Power Up Lending Group [Member]    
Short-term Debt [Line Items]    
Total 0 35,000
Convertible Notes Payable - Crown Bridge Partners [Member]    
Short-term Debt [Line Items]    
Total 35,000 172,500
Convertiblenotepayable Labrys [Member]    
Short-term Debt [Line Items]    
Total 537,500 0
Convertible Notes Payable - GS Capital Partners LLC [Member]    
Short-term Debt [Line Items]    
Total 0 143,500
Convertible Note Payable Geneva Roth [Member]    
Short-term Debt [Line Items]    
Total 0 33,500
Convertible Notes Payable - Robert Hymers III [Member]    
Short-term Debt [Line Items]    
Total 185,000 70,000
Convertible Promissory Notes - October 30, 2019, Odyssey Funding LLC [Member]    
Short-term Debt [Line Items]    
Total 135,000 10,000
Convertible Note Payable Redstart H L D G S [Member]    
Short-term Debt [Line Items]    
Total 0 109,000
Convertible Note Payable G W Holdings [Member]    
Short-term Debt [Line Items]    
Total 0 98,175
Convertible Promissory Notes - October 23, 2019, Paladin Advisors LLC [Member]    
Short-term Debt [Line Items]    
Total $ 727,500 $ 1,160,726
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended
Feb. 26, 2021
Jan. 06, 2020
Mar. 25, 2019
Jan. 29, 2019
Aug. 28, 2018
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2019
Mar. 30, 2021
Dec. 31, 2020
Dec. 23, 2020
Dec. 19, 2019
Short-term Debt [Line Items]                              
Convertible promissory note payment terms On February 26, 2021, the Company entered into a share exchange agreement (“ECOX Share Exchange Agreement”) with Eco Innovation Group, Inc. (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date of the ECOX Share Exchange Agreement.  For both parties, the ECOX Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the ECOX Share Exchange Agreement to fall below $650,000. Based on the value of ECOX shares in the market as of June 30, 2021, the Company recorded a value for additional shares owed to ECOX pursuant to the ECOX Share Exchange Agreement of $329,572 as a subscription agreement along with a loss from equity investment of $391,194. As of June 30, 2021 41,935,484 shares of the Company’s common stock have been issued. As a result, the balance of subscriptions payable as of June 30, 2021 and December 31, 2020 was $999,355 and $670,000, respectively.                            
Debt discount           $ 1,122,225     $ 1,122,225       $ 808,980    
Gain (loss) on debt settlement           (96,750)   (164,977) $ 3,490          
Net proceeds from convertible promissory notes                 $ 1,508,250 $ 442,000          
Convertible promissory note due date description                 For the six months ended June 30, 2021, the Company recorded a gain on the change in fair value of derivative liabilities of $1,347,646 and a loss of $1,035,115 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense. For the six months ended June 30, 2020, the Company recorded a gain on change in fair value of derivative liabilities of $1,142,272, a loss of $395,607 related to the excess of the fair value of derivatives at issuance above convertible note principle as a charge to interest expense, and amortization of debt discounts of $1,028,931 as a charge to interest expense.            
Convertible Promissory Notes From October 01 Through December 31, 2019 - Crown Bridge Partners [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note face value           $ 225,000     $ 225,000            
Convertible promissory note interest rate           10.00%     10.00%            
Convertible promissory note payment terms               The Company has the right to prepay the notes for an amount ranging from 125% to 140% multiplied by the outstanding balance (all principal and accrued interest) depending on the prepayment period (ranging from 1 to 180 days following the issuance date). The Company is prohibited from effecting a conversion of any note to the extent that, as a result of such conversion, the investor, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.              
Secured Convertible Promissory Notes March 25, 2019 - St George Investments [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note face value     $ 580,000                        
Convertible promissory note interest rate     10.00%                        
Convertible promissory note conversion terms     issuance date and include an original issuance discount in aggregate amount of $22,500. Interest accrues from the issuance date, but interest shall not become payable until the notes becomes payable. The notes are convertible at any time at a conversion price equal to 60% of the market price of the Company’s common stock, defined as the lowest trading price during the 15-trading-day period prior to the conversion date. Upon the issuance of these convertible notes, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares of common stock would be available to settle all potential future conversion transactions. As of the funding date of each note, the Company determined the fair value of the embedded derivative associated with the convertibility of each note. The fair value of the embedded derivative has been added to the debt discount (total debt discount is limited to the face value of the debt) with any excess of the derivative liability recognized as interest expense. The aggregate debt discount of $88,674 was being amortized to interest expense over the respective terms of the notes. The Company also issued a warrants to purchase up to 519,230 shares of the Company’s common stock with an initial exercise price of $0.26, with reset provisions based on issuances of common stock subsequent to the issuance date. Due to the reset provision, the exercise option of these warrants is also accounted for as a derivative liability. See Note 10.                        
Convertible promissory note original issue discount     $ 75,000                        
Debt discount     483,966                        
Legal, accounting and other transaction costs with respect to convertible promissory note     $ 5,000                        
Secured Convertible Promissory Notes March 25, 2019 - St George Investments [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Exercisable price     $ 2.40                        
Convertible Promissory Notes - December 19, 2019, GS Capital Partners LLC [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note face value                             $ 173,000
Convertible promissory note interest rate                             10.00%
Convertible promissory note original issue discount                             $ 15,000
Debt discount                             $ 166,193
Convertible notes payable           $ 0     $ 0       143,500    
Accrued interest           0     0       2,789    
Secured Convertible Promissory Notes August 28, 2018 - St George Investments [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note face value         $ 1,128,518                    
Convertible promissory note interest rate         10.00%                    
Convertible promissory note conversion terms         The promissory notes are convertible, at any time at St. George’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion rate will be 60% of the three lowest closing trade prices during the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory notes include certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.                    
Convertible promissory note original issue discount         $ 100,000                    
Debt discount         1,114,698                    
Convertible notes payable                       $ 828,518      
Accrued interest                       $ 28,138      
Legal, accounting and other transaction costs with respect to convertible promissory note         5,000                    
Convertible promissory note overfunding         $ 825,000                    
Secured Convertible Promissory Notes August 28, 2018 - St George Investments [Member] | Common Stock [Member]                              
Short-term Debt [Line Items]                              
Shares issued for settlement of debt, value                 1,000,859            
Derivative liabilities portion of debt converted into common stock                 $ 840,299            
Shares issued for settlement of debt, shares                 4,475,543            
Gain (loss) on debt settlement                 $ 612,034            
Secured Convertible Promissory Notes August 28, 2018 - St George Investments [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Warrants issued for debt as an investment incentive         750,000                    
Fair value of issued warrants         $ 1,588,493                    
Secured Convertible Promissory Notes January 29, 2019 - St George Investments [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note face value       $ 2,205,000                      
Convertible promissory note interest rate       10.00%                      
Convertible promissory note conversion terms       The promissory notes  are convertible, at any time at the lender’s option, at $2.40 per share. However, in the event the Company’s Market Capitalization falls below $30,000,000, the conversion price will be 60% of the three lowest closing trade prices the 20 trading days immediately prior to the date of conversion, subject to additional adjustments. In addition, the promissory note includes certain anti-dilution provisions should the Company subsequently issue any common stock or common stock equivalents at an effective price per share that is less than the conversion price then in effect. The Company has a right to prepayment of the note, subject to a 15% prepayment premium. The note is secured by a trust deed of certain assets of the Company.                      
Convertible promissory note original issue discount       $ 200,000                      
Legal, accounting and other transaction costs with respect to convertible promissory note       5,000                      
Gross proceeds from convertible promissory note                     $ 1,406,482        
Net proceeds from convertible promissory notes                     $ 1,276,482        
Secured Convertible Promissory Notes January 29, 2019 - St George Investments [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Fair value of issued warrants       $ 999,838                      
Convertible Promissory Notes - December 23, 2019, Robert L. Hymers III [Member]                              
Short-term Debt [Line Items]                              
Debt discount                           $ 92,332  
Convertible notes payable           96,552     96,552            
G W Holdings Group [Member]                              
Short-term Debt [Line Items]                              
Convertible promissory note conversion terms   On January 6, 2020, the Company entered into a convertible promissory note in the amount of $57,750 with GW Holdings Group, LLC (“GW”). GW has the option, beginning on the six month anniversary of the date of issuance, to convert all or any amount of the principal face amount of the note then outstanding into shares of the Company's common stock at a conversion price equal to 40% discount of the lowest trading price for the 15 trading days prior to the date of the conversion. The note accrues interest at a rate of 10% per annum and include a $5,250 original issue discount such that the price of the note was $57,750. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $98,175 of principal, respectively, on the note. As of June 30, 2021 and December 31, 2020, the Company owed $0 and $818 in accrued interest on the note  , respectively.                          
Labrys [Member]                              
Short-term Debt [Line Items]                              
Accrued interest           5,375     5,375            
Power Up Lending [Member]                              
Short-term Debt [Line Items]                              
Accrued interest           0     0       1,167    
Debt principal amount           0     0       35,000    
Odyssey Funding L L C [Member]                              
Short-term Debt [Line Items]                              
Accrued interest           0     0       0    
Debt principal amount           0     0       0    
Paladin Advisors L L C [Member]                              
Short-term Debt [Line Items]                              
Accrued interest           0     0       0    
Debt principal amount           $ 0     $ 0       $ 0    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' DEFICIT (Details)
6 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Equity [Abstract]  
Outstanding at Beginning of Period | shares 293,054,702
Outstanding at Beginning of Period | $ / shares $ 0.0011
Outstanding at Beginning of Period 2 years 2 months 19 days
Outstanding at Beginning of Period | $ $ 1,023,306
Granted | shares 79,785,156
Granted | $ / shares $ 0.0071
Granted, years 5 years
Granted | $ $ 0
Increase due to reset provision | shares (9,722,222)
Increase due to reset provision, years 2 years 4 months 28 days
Increase due to reset provision | $ $ 0
Exercised | shares (194,788,035)
Exercised | $ / shares $ 0.004
Exercised 1 year 7 months 28 days
Exercised | $ $ 1,427,826
Outstanding at End of Period | shares 168,329,601
Outstanding at End of Period | $ / shares $ 0.0039
Exercisable at End of Period 3 years 5 months 26 days
Outstanding at End of Period | $ $ 503,850
Exercisable at End of Period | shares 168,329,601
Exercisable at End of Period | $ / shares $ 0.0039
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3] 3 years 5 months 26 days
Exercisable at End of Period | $ $ 503,850
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Class of Stock [Line Items]      
Preferred stock, shares authorized 50,000,000   50,000,000
Preferred stock, par value per share $ 0.001   $ 0.001
Common Stock, Par or Stated Value Per Share $ 0.001   $ 0.001
Common Stock, Shares, Outstanding 5,068,524,855   3,136,774,861
Common stock, description the Company issued 41,935,484 of its common stock with a value of $650,000 and will issue an additional 64,621,893 shares for investments with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to these additional shares during the three months ended June 30, 2021.    
Common Stock, Shares Authorized 15,000,000,000   15,000,000,000
Preferred Class A [Member]      
Class of Stock [Line Items]      
Preferred stock, shares authorized 10,000,000   10,000,000
Preferred stock, par value per share $ 0.001   $ 0.001
Preferred stock, shares issued 10,000,000   10,000,000
Preferred stock, shares outstanding 10,000,000   10,000,000
Preferred stock voting rights Each share of Class A Preferred Stock is entitled to 100 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.    
Preferred Class B [Member]      
Class of Stock [Line Items]      
Preferred stock, shares authorized 5,000,000   5,000,000
Preferred stock, par value per share $ 0.001   $ 0.001
Preferred stock, shares issued 2,000,000   2,000,000
Preferred stock, shares outstanding 2,000,000   2,000,000
Preferred stock voting rights Each share of Class B Preferred Stock is entitled to 1,000 votes on all matters submitted to a vote to the stockholders of the Company and does not have conversion, dividend or distribution upon liquidation rights.    
Common Stock One [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 21,000,020 8,333  
Sale of common stock, value $ 140,900 $ 6,700  
Common Stock Two [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 810,689,880 44,658,333  
Sale of common stock, value $ 1,677,373 $ 542,766  
Common Stock Three [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 3,027,031 270,547,861  
Sale of common stock, value $ 8,623 $ 1,531,471  
Common Stock Four [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 22,500,000 21,384,103  
Sale of common stock, value $ 141,750 $ 50,613  
Common Stock Five [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 400,000,000 51,054,214  
Common Stock Six [Member]      
Class of Stock [Line Items]      
Common stock issued in exchange for exercise of warrants on a cashless basis, shares 632,597,599 3,677,889  
Sale of common stock, value $ 1,358,767 $ 956,251  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENT (Details)
6 Months Ended
Jun. 30, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Balance at beginning $ 4,426,057
Balance at end 1,904,016
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Balance at beginning 4,426,057
Increase resulting from initial issuances of additional convertible notes payable 1,824,340
Decreases resulting from conversion or payoff of convertible notes payable (5,975,670)
Decreases resulting from payoff of convertible notes payable (649,961)
Loss due to change in fair value included in earnings 2,279,250
Balance at end $ 1,904,016
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Related Party Transaction [Line Items]          
Note payable $ 0   $ 0   $ 0
Accrued compensation 9,000   9,000   79,214
Related party sales contributed 0 $ 5,131 0 $ 8,303  
Officers And Executives [Member]          
Related Party Transaction [Line Items]          
Accrued compensation $ 9,000   $ 9,000   $ 79,214
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITION (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Business Combination and Asset Acquisition [Abstract]        
Cash, net of cash acquired of $99,393 $ 250,607   $ 250,607  
Contingent Consideration - Earnout Agreement 1,000,000   1,000,000  
265,164,070 shares of common stock (not issued as of June 30, 2021) 1,617,501   1,617,501  
Total preliminary consideration transferred 2,868,108   2,868,108  
Revenue 290,196 $ 152,402 444,239 $ 234,221
Operating loss (1,067,780) (965,158) (1,855,860) (1,357,315)
Net loss $ (1,869,775) $ (276,742) $ (5,532,928) $ (2,395,044)
 Net loss per common share $ (0.00) $ (0.00) $ (0.00) $ (0.01)
Weighted Average common shares outstanding 5,102,510,297 510,164,598 4,730,796,549 451,015,744
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITION (Details 1)
Jun. 30, 2021
USD ($)
Business Combination and Asset Acquisition [Abstract]  
Accounts Receivable $ 40,291
 Inventory 6,746
 Other Assets 19,310
 Goodwill 2,989,803
 Accounts payable (181,042)
 other accrued liabilities (7,000)
 Net assets acquired $ 2,868,108
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
ACQUISITION (Details Narrative)
3 Months Ended
Jun. 30, 2021
USD ($)
Business Combination and Asset Acquisition [Abstract]  
Cash Paid $ 250,000
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 380 374 1 false 67 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://marijuanacompanyofamerica.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) Sheet http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS Sheet http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlans GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - OPERATING LEASE Sheet http://marijuanacompanyofamerica.com/role/OperatingLease OPERATING LEASE Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT Sheet http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipment PROPERTY, MACHINERY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - INVESTMENTS Sheet http://marijuanacompanyofamerica.com/role/Investments INVESTMENTS Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE, RELATED PARTY Notes http://marijuanacompanyofamerica.com/role/NotesPayableRelatedParty NOTES PAYABLE, RELATED PARTY Notes 13 false false R14.htm 00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS??? DEFICIT Sheet http://marijuanacompanyofamerica.com/role/StockholdersDeficit STOCKHOLDERS??? DEFICIT Notes 15 false false R16.htm 00000016 - Disclosure - FAIR VALUE MEASUREMENT Sheet http://marijuanacompanyofamerica.com/role/FairValueMeasurement FAIR VALUE MEASUREMENT Notes 16 false false R17.htm 00000017 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://marijuanacompanyofamerica.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 00000018 - Disclosure - ACQUISITION Sheet http://marijuanacompanyofamerica.com/role/Acquisition ACQUISITION Notes 18 false false R19.htm 00000019 - Disclosure - SUBSEQUENT EVENTS Sheet http://marijuanacompanyofamerica.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Tables) Sheet http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentTables PROPERTY, MACHINERY AND EQUIPMENT (Tables) Tables http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipment 22 false false R23.htm 00000023 - Disclosure - INVESTMENTS (Tables) Sheet http://marijuanacompanyofamerica.com/role/InvestmentsTables INVESTMENTS (Tables) Tables http://marijuanacompanyofamerica.com/role/Investments 23 false false R24.htm 00000024 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayable 24 false false R25.htm 00000025 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables) Sheet http://marijuanacompanyofamerica.com/role/StockholdersDeficitTables STOCKHOLDERS??? DEFICIT (Tables) Tables http://marijuanacompanyofamerica.com/role/StockholdersDeficit 25 false false R26.htm 00000026 - Disclosure - FAIR VALUE MEASUREMENT (Tables) Sheet http://marijuanacompanyofamerica.com/role/FairValueMeasurementTables FAIR VALUE MEASUREMENT (Tables) Tables http://marijuanacompanyofamerica.com/role/FairValueMeasurement 26 false false R27.htm 00000027 - Disclosure - ACQUISITION (Tables) Sheet http://marijuanacompanyofamerica.com/role/AcquisitionTables ACQUISITION (Tables) Tables http://marijuanacompanyofamerica.com/role/Acquisition 27 false false R28.htm 00000028 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) Details http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentation 28 false false R29.htm 00000029 - Disclosure - GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS (Details Narrative) Details http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlans 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - OPERATING LEASE (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative OPERATING LEASE (Details Narrative) Details http://marijuanacompanyofamerica.com/role/OperatingLease 32 false false R33.htm 00000033 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details) Sheet http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails PROPERTY, MACHINERY AND EQUIPMENT (Details) Details http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentTables 33 false false R34.htm 00000034 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetailsNarrative PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative) Details http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentTables 34 false false R35.htm 00000035 - Disclosure - INVESTMENTS (Details) Sheet http://marijuanacompanyofamerica.com/role/InvestmentsDetails INVESTMENTS (Details) Details http://marijuanacompanyofamerica.com/role/InvestmentsTables 35 false false R36.htm 00000036 - Disclosure - INVESTMENTS (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative INVESTMENTS (Details Narrative) Details http://marijuanacompanyofamerica.com/role/InvestmentsTables 36 false false R37.htm 00000037 - Disclosure - NOTES PAYABLE, RELATED PARTY (Details Narrative) Notes http://marijuanacompanyofamerica.com/role/NotesPayableRelatedPartyDetailsNarrative NOTES PAYABLE, RELATED PARTY (Details Narrative) Details http://marijuanacompanyofamerica.com/role/NotesPayableRelatedParty 37 false false R38.htm 00000038 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) Notes http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails CONVERTIBLE NOTES PAYABLE (Details) Details http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableTables 38 false false R39.htm 00000039 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableTables 39 false false R40.htm 00000040 - Disclosure - STOCKHOLDERS' DEFICIT (Details) Sheet http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails STOCKHOLDERS' DEFICIT (Details) Details 40 false false R41.htm 00000041 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://marijuanacompanyofamerica.com/role/StockholdersDeficitTables 41 false false R42.htm 00000042 - Disclosure - FAIR VALUE MEASUREMENT (Details) Sheet http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails FAIR VALUE MEASUREMENT (Details) Details http://marijuanacompanyofamerica.com/role/FairValueMeasurementTables 42 false false R43.htm 00000043 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://marijuanacompanyofamerica.com/role/RelatedPartyTransactions 43 false false R44.htm 00000044 - Disclosure - ACQUISITION (Details) Sheet http://marijuanacompanyofamerica.com/role/AcquisitionDetails ACQUISITION (Details) Details http://marijuanacompanyofamerica.com/role/AcquisitionTables 44 false false R45.htm 00000045 - Disclosure - ACQUISITION (Details 1) Sheet http://marijuanacompanyofamerica.com/role/AcquisitionDetails1 ACQUISITION (Details 1) Details http://marijuanacompanyofamerica.com/role/AcquisitionTables 45 false false R46.htm 00000046 - Disclosure - ACQUISITION (Details Narrative) Sheet http://marijuanacompanyofamerica.com/role/AcquisitionDetailsNarrative ACQUISITION (Details Narrative) Details http://marijuanacompanyofamerica.com/role/AcquisitionTables 46 false false All Reports Book All Reports mcoa_10q-063021v2.htm ex31x1.htm ex31x2.htm ex32x1.htm ex32x2.htm mcoa-20210630.xsd mcoa-20210630_cal.xml mcoa-20210630_def.xml mcoa-20210630_lab.xml mcoa-20210630_pre.xml http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mcoa_10q-063021v2.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 380, "dts": { "calculationLink": { "local": [ "mcoa-20210630_cal.xml" ] }, "definitionLink": { "local": [ "mcoa-20210630_def.xml" ] }, "inline": { "local": [ "mcoa_10q-063021v2.htm" ] }, "labelLink": { "local": [ "mcoa-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "mcoa-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "mcoa-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 486, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 181, "http://marijuanacompanyofamerica.com/20210630": 46, "http://xbrl.sec.gov/dei/2021": 5, "total": 232 }, "keyCustom": 94, "keyStandard": 280, "memberCustom": 47, "memberStandard": 16, "nsprefix": "MCOA", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://marijuanacompanyofamerica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - OPERATING LEASE", "role": "http://marijuanacompanyofamerica.com/role/OperatingLease", "shortName": "OPERATING LEASE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT", "role": "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipment", "shortName": "PROPERTY, MACHINERY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVESTMENTS", "role": "http://marijuanacompanyofamerica.com/role/Investments", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "MCOA:NotesPayableRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - NOTES PAYABLE, RELATED PARTY", "role": "http://marijuanacompanyofamerica.com/role/NotesPayableRelatedParty", "shortName": "NOTES PAYABLE, RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "MCOA:NotesPayableRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 DEFICIT", "role": "http://marijuanacompanyofamerica.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - FAIR VALUE MEASUREMENT", "role": "http://marijuanacompanyofamerica.com/role/FairValueMeasurement", "shortName": "FAIR VALUE MEASUREMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - ACQUISITION", "role": "http://marijuanacompanyofamerica.com/role/Acquisition", "shortName": "ACQUISITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUBSEQUENT EVENTS", "role": "http://marijuanacompanyofamerica.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "MCOA:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "MCOA:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Tables)", "role": "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentTables", "shortName": "PROPERTY, MACHINERY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - INVESTMENTS (Tables)", "role": "http://marijuanacompanyofamerica.com/role/InvestmentsTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)", "role": "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableTables", "shortName": "CONVERTIBLE NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)", "role": "http://marijuanacompanyofamerica.com/role/StockholdersDeficitTables", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - FAIR VALUE MEASUREMENT (Tables)", "role": "http://marijuanacompanyofamerica.com/role/FairValueMeasurementTables", "shortName": "FAIR VALUE MEASUREMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - ACQUISITION (Tables)", "role": "http://marijuanacompanyofamerica.com/role/AcquisitionTables", "shortName": "ACQUISITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2009-10-012009-10-31_custom_SparrowtechIncMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NoncashOrPartNoncashAcquisitionDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative", "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2009-10-012009-10-31_custom_SparrowtechIncMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NoncashOrPartNoncashAcquisitionDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:OperatingLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:OperatingLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30_custom_OperatingSegmentMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2019-06-292019-07-02_us-gaap_LeaseAgreementsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseMinimumRentals", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - OPERATING LEASE (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative", "shortName": "OPERATING LEASE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2019-06-292019-07-02_us-gaap_LeaseAgreementsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseMinimumRentals", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details)", "role": "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails", "shortName": "PROPERTY, MACHINERY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetailsNarrative", "shortName": "PROPERTY, MACHINERY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - INVESTMENTS (Details)", "role": "http://marijuanacompanyofamerica.com/role/InvestmentsDetails", "shortName": "INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2017-01-012017-12-31", "decimals": "0", "first": true, "lang": null, "name": "MCOA:CashInvestment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - INVESTMENTS (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative", "shortName": "INVESTMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2017-01-012017-12-31", "decimals": "0", "first": true, "lang": null, "name": "MCOA:CashInvestment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - NOTES PAYABLE, RELATED PARTY (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/NotesPayableRelatedPartyDetailsNarrative", "shortName": "NOTES PAYABLE, RELATED PARTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details)", "role": "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails", "shortName": "CONVERTIBLE NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-02-242021-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-02-242021-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:Sales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:Sales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - STOCKHOLDERS' DEFICIT (Details)", "role": "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails", "shortName": "STOCKHOLDERS' DEFICIT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "lang": "en-US", "name": "MCOA:CommonStockDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - FAIR VALUE MEASUREMENT (Details)", "role": "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails", "shortName": "FAIR VALUE MEASUREMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - ACQUISITION (Details)", "role": "http://marijuanacompanyofamerica.com/role/AcquisitionDetails", "shortName": "ACQUISITION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "MCOA:ScheduleProformaConsolidatedResultsofOperationsTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "MCOA:SchedulePreliminaryAllocationoffairvaluesTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:BusinessAcquisitionAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - ACQUISITION (Details 1)", "role": "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1", "shortName": "ACQUISITION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "MCOA:SchedulePreliminaryAllocationoffairvaluesTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:BusinessAcquisitionAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:CashPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - ACQUISITION (Details Narrative)", "role": "http://marijuanacompanyofamerica.com/role/AcquisitionDetailsNarrative", "shortName": "ACQUISITION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "MCOA:CashPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2019-12-31_custom_PreferredStockClassAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED)", "role": "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "AsOf2019-12-31_custom_PreferredStockClassAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "role": "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentation", "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS", "role": "http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlans", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mcoa_10q-063021v2.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "MCOA_AccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_AcquisitionOfBusiness": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Acquisition of business" } } }, "localname": "AcquisitionOfBusiness", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_AnnualImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual impairment" } } }, "localname": "AnnualImpairment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_BenihempMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benihemp [Member]" } } }, "localname": "BenihempMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_BougainvilleVentuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bougainville Ventues [Member]" } } }, "localname": "BougainvilleVentuesMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_BusinessAcquisitionAccountsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "BusinessAcquisitionAccountsReceivable", "verboseLabel": "Accounts Receivable" } } }, "localname": "BusinessAcquisitionAccountsReceivable", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionAccountspayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable" } } }, "localname": "BusinessAcquisitionAccountspayables", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Goodwill" } } }, "localname": "BusinessAcquisitionGoodwill", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionInventorynet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "BusinessAcquisitionInventorynet", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionNetAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net assets acquired" } } }, "localname": "BusinessAcquisitionNetAssetsAcquired", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionOtherAccruedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "other accrued liabilities" } } }, "localname": "BusinessAcquisitionOtherAccruedLiabilities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessAcquisitionProFormaBasicWeightedAverageCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average common shares outstanding" } } }, "localname": "BusinessAcquisitionProFormaBasicWeightedAverageCommonSharesOutstanding", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "sharesItemType" }, "MCOA_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonstock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "265,164,070 shares of common stock (not issued as of June 30, 2021)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCommonstock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConsiderationtransferred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total preliminary consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConsiderationtransferred", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentsconsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Contingent Consideration - Earnout Agreement" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentsconsideration", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_CannabisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cannabis [Member]" } } }, "localname": "CannabisMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_CashInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash investment" } } }, "localname": "CashInvestment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_CashPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash Paid" } } }, "localname": "CashPaid", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonSharesIssuedInSettlementOfLegalCase": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommonSharesIssuedInSettlementOfLegalCase", "verboseLabel": "Common shares issued in settlement of legal case" } } }, "localname": "CommonSharesIssuedInSettlementOfLegalCase", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, description" } } }, "localname": "CommonStockDescription", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "MCOA_CommonStockFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Five [Member]" } } }, "localname": "CommonStockFiveMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Four [Member]" } } }, "localname": "CommonStockFourMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockIssuedForAcquisitionOfBusiness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for acquisition of business" } } }, "localname": "CommonStockIssuedForAcquisitionOfBusiness", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockIssuedForAcquisitionOfBusinessShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for acquisition of business, Shares" } } }, "localname": "CommonStockIssuedForAcquisitionOfBusinessShares", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_CommonStockIssuedForInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for investment" } } }, "localname": "CommonStockIssuedForInvestment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockIssuedInSettlementOfLegalCaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued in settlement of legal case, shares" } } }, "localname": "CommonStockIssuedInSettlementOfLegalCaseShares", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_CommonStockIssuedInSettlementOfLegalCaseValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common shares issued in settlement of legal case" } } }, "localname": "CommonStockIssuedInSettlementOfLegalCaseValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockIssuedToSettleAmountsPreviouslyAccruedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle amounts previously accrued, shares" } } }, "localname": "CommonStockIssuedToSettleAmountsPreviouslyAccruedShares", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_CommonStockIssuedToSettleAmountsPreviouslyAccruedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle amounts previously accrued" } } }, "localname": "CommonStockIssuedToSettleAmountsPreviouslyAccruedValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockIssuedToSettleLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle liabilities" } } }, "localname": "CommonStockIssuedToSettleLiabilities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock One [Member]" } } }, "localname": "CommonStockOneMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Six [Member]" } } }, "localname": "CommonStockSixMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Three [Member]" } } }, "localname": "CommonStockThreeMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockToBeIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock to be issued" } } }, "localname": "CommonStockToBeIssue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "MCOA_CommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock to be issued, 266,164,070 and 11,892,411 shares, respectively" } } }, "localname": "CommonStockToBeIssued", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockToBeIssuedForAcquisitionOfBusiness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock to be issued for acquisition of business" } } }, "localname": "CommonStockToBeIssuedForAcquisitionOfBusiness", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "MCOA_CommonStockTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Two [Member]" } } }, "localname": "CommonStockTwoMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConsultingServicesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Services" } } }, "localname": "ConsultingServicesPolicyTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MCOA_ContingentLiabilityAcquisition": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Contingent liability - acquisition" } } }, "localname": "ContingentLiabilityAcquisition", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "MCOA_ConversionOfRelatedPartyNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for settlement of liabilities \u2013 related parties" } } }, "localname": "ConversionOfRelatedPartyNotes", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_ConversonOfRelatedPartyNotesPayableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Converson of related party notes payable, Shares" } } }, "localname": "ConversonOfRelatedPartyNotesPayableShares", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_ConvertibleNotePayableDutchessCapitalPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes - October 30, 2019, Odyssey Funding LLC [Member]" } } }, "localname": "ConvertibleNotePayableDutchessCapitalPartnersMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Power Up Lending Group [Member]" } } }, "localname": "ConvertibleNotePayableElevenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - GS Capital Partners LLC [Member]" } } }, "localname": "ConvertibleNotePayableFifteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableGWHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable G W Holdings [Member]" } } }, "localname": "ConvertibleNotePayableGWHoldingsMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableGenevaRothMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Geneva Roth [Member]" } } }, "localname": "ConvertibleNotePayableGenevaRothMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableRedstartHLDGSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Redstart H L D G S [Member]" } } }, "localname": "ConvertibleNotePayableRedstartHLDGSMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Robert Hymers III [Member]" } } }, "localname": "ConvertibleNotePayableSeventeenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableStGeorgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes - October 23, 2019, Paladin Advisors LLC [Member]" } } }, "localname": "ConvertibleNotePayableStGeorgeMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotePayableTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Crown Bridge Partners [Member]" } } }, "localname": "ConvertibleNotePayableTwelveMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Promissory Notes August 28, 2018 - St George Investments [Member]" } } }, "localname": "ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes - December 19, 2019, GS Capital Partners LLC [Member]" } } }, "localname": "ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes - December 23, 2019, Robert L. Hymers III [Member]" } } }, "localname": "ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes From October 01 Through December 31, 2019 - Crown Bridge Partners [Member]" } } }, "localname": "ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Promissory Notes January 29, 2019 - St George Investments [Member]" } } }, "localname": "ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Convertible Promissory Notes March 25, 2019 - St George Investments [Member]" } } }, "localname": "ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_ConvertibleNotesPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayables", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_ConvertiblePromissoryNoteOriginalIssueDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible promissory note original issue discount" } } }, "localname": "ConvertiblePromissoryNoteOriginalIssueDiscount", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_ConvertiblenotepayableLabrysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertiblenotepayable Labrys [Member]" } } }, "localname": "ConvertiblenotepayableLabrysMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "MCOA_DebtDiscountFromWarrantsIssuedWithConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt discount from warrants issued with convertible notes payable" } } }, "localname": "DebtDiscountFromWarrantsIssuedWithConvertibleNotesPayable", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_DebtInstrumentOverFundingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible promissory note overfunding" } } }, "localname": "DebtInstrumentOverFundingAmount", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_DebtPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt principal amount" } } }, "localname": "DebtPrincipalAmount", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_DecreasesResultingFromPayoffOfConvertibleNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Decreases resulting from payoff of convertible notes payable" } } }, "localname": "DecreasesResultingFromPayoffOfConvertibleNotesPayable", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_DerivativeLiabilitiesPortionOfDebtConvertedIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative liabilities portion of debt converted into common stock" } } }, "localname": "DerivativeLiabilitiesPortionOfDebtConvertedIntoCommonStock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_DerivativeLossOnDerivatives": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "DerivativeLossOnDerivatives", "negatedLabel": "Gain (loss) on change in fair value of derivative liabilities" } } }, "localname": "DerivativeLossOnDerivatives", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "MCOA_DisclosureNotesPayableRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable Related Party" } } }, "localname": "DisclosureNotesPayableRelatedPartyAbstract", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "xbrltype": "stringItemType" }, "MCOA_ECOXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "E C O X [Member]" } } }, "localname": "ECOXMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_EquityLosse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equity losse" } } }, "localname": "EquityLosse", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_EquityMethodAccounting": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "EquityMethodAccounting", "verboseLabel": "Equity method Loss" } } }, "localname": "EquityMethodAccounting", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_EquityMethodAccounting1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "EquityMethodAccounting1", "verboseLabel": "Equity method Loss" } } }, "localname": "EquityMethodAccounting1", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_FairValueOfIssuedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of issued warrants" } } }, "localname": "FairValueOfIssuedWarrants", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_GWHoldingsGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "G W Holdings Group [Member]" } } }, "localname": "GWHoldingsGroupMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_GainLossOnInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainLossOnInvestment", "verboseLabel": "Investments made" } } }, "localname": "GainLossOnInvestment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_GainLossOnInvestments1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equity method Loss" } } }, "localname": "GainLossOnInvestments1", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_GainLossOnInvestments2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainLossOnInvestments2", "verboseLabel": "Equity method Loss" } } }, "localname": "GainLossOnInvestments2", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_GainLossOnSettlementOfDebt": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainLossOnSettlementOfDebt", "negatedLabel": "Loss on settlement of liabilities" } } }, "localname": "GainLossOnSettlementOfDebt", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_GateCResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan [Member]" } } }, "localname": "GateCResearchMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_GlobalHempGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Global Hemp Group [Member]" } } }, "localname": "GlobalHempGroupMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_GlobalHempMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Global Hemp [Member]" } } }, "localname": "GlobalHempMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_GrossProceedsFromConvertiblePromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gross proceeds from convertible promissory note" } } }, "localname": "GrossProceedsFromConvertiblePromissoryNote", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_IdentificationOurContractswithCustomersTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Identification of Our Contracts with Customers" } } }, "localname": "IdentificationOurContractswithCustomersTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MCOA_ImpairmentOfJointVenture": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "ImpairmentOfJointVenture", "negatedLabel": "Impairment gain (loss) on joint ventures" } } }, "localname": "ImpairmentOfJointVenture", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "MCOA_IncreaseDecreaseInRightofuseLiabilities": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right-of-use liabilities" } } }, "localname": "IncreaseDecreaseInRightofuseLiabilities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_InterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Financial Statements" } } }, "localname": "InterimFinancialStatementsPolicyTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MCOA_Investment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investment, Beginning balance" } } }, "localname": "Investment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_InvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Member]" } } }, "localname": "InvestmentMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_InvestmentsMade": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Investments made" } } }, "localname": "InvestmentsMade", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_IssuanceOfCommonStockForInvestmentsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for investments, shares" } } }, "localname": "IssuanceOfCommonStockForInvestmentsShares", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_IssuanceOfCommonStockForInvestmentsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for investments" } } }, "localname": "IssuanceOfCommonStockForInvestmentsValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_IssuanceOfCommonStockForSetlementOfLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for setlement of liabilities, shares" } } }, "localname": "IssuanceOfCommonStockForSetlementOfLiabilities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "MCOA_IssuanceOfCommonStockForSetlementOfLiabilitiesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for settlement of liabilities" } } }, "localname": "IssuanceOfCommonStockForSetlementOfLiabilitiesValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_IssuanceOfPreferredStockToOfficerValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of preferred stock to officer" } } }, "localname": "IssuanceOfPreferredStockToOfficerValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "MCOA_JointVentureAgreementWithBougainvilleVenturesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Joint Venture Agreement With Bougainville Ventures Inc [Member]" } } }, "localname": "JointVentureAgreementWithBougainvilleVenturesIncMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_LabrysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Labrys [Member]" } } }, "localname": "LabrysMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_LongTermDebts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "- Long term debt" } } }, "localname": "LongTermDebts", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_LossOnDispositionOfInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss on disposition of investment" } } }, "localname": "LossOnDispositionOfInvestment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_LossOnEquityInvestment": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LossOnEquityInvestment", "negatedLabel": "Loss on equity investment" } } }, "localname": "LossOnEquityInvestment", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_LossOnShareInducementAndSettlementOfWarrantLiability": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on share inducement and settlement of warrant liability" } } }, "localname": "LossOnShareInducementAndSettlementOfWarrantLiability", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_LynwoodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lynwood [Member]" } } }, "localname": "LynwoodMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_MoneyTracMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Money Trac [Member]" } } }, "localname": "MoneyTracMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_NaturalPlantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Natural Plant [Member]" } } }, "localname": "NaturalPlantMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "MCOA_NotesPayableRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE, RELATED PARTY" } } }, "localname": "NotesPayableRelatedPartyTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/NotesPayableRelatedParty" ], "xbrltype": "textBlockItemType" }, "MCOA_OdysseyFundingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Odyssey Funding L L C [Member]" } } }, "localname": "OdysseyFundingLLCMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_OfficerAndExecutivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Executives [Member]" } } }, "localname": "OfficerAndExecutivesMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_OperatingLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net losses from operations" } } }, "localname": "OperatingLoss", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_OperatingSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Segment [Member]" } } }, "localname": "OperatingSegmentMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "MCOA_PaladinAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paladin Advisors L L C [Member]" } } }, "localname": "PaladinAdvisorsLLCMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_PaymentToEstablishJointVenture": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentToEstablishJointVenture", "negatedLabel": "Payment to establish joint venture" } } }, "localname": "PaymentToEstablishJointVenture", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_PayrollAndRelatedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payroll and Related expenses" } } }, "localname": "PayrollAndRelatedExpenses", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_PowerUpLendingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Power Up Lending [Member]" } } }, "localname": "PowerUpLendingMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_PreferredStockClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Class A [Member]" } } }, "localname": "PreferredStockClassAMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "MCOA_PreferredStockClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Class B [Member]" } } }, "localname": "PreferredStockClassBMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "MCOA_ProductSalesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Sales" } } }, "localname": "ProductSalesPolicyTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MCOA_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassification of derivative liabilities to additional paid-in capital" } } }, "localname": "ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_RecognizeJointVentureLiabilitiesPerJvAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Recognize Joint venture liabilities per JV agreement" } } }, "localname": "RecognizeJointVentureLiabilitiesPerJvAgreement", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_RelatedPartySalesContributed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Related party sales contributed" } } }, "localname": "RelatedPartySalesContributed", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_ReversalOfEquityMethodLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reversal of Equity method Loss" } } }, "localname": "ReversalOfEquityMethodLoss", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_SaleOfCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sale of common stock, value" } } }, "localname": "SaleOfCommonStockValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MCOA_SaleOfTradingSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sale of trading securities" } } }, "localname": "SaleOfTradingSecurities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_Sales": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sales" } } }, "localname": "Sales", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "MCOA_SchedulePreliminaryAllocationoffairvaluesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule summarizes the preliminary allocation of the fair values" } } }, "localname": "SchedulePreliminaryAllocationoffairvaluesTableTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "MCOA_ScheduleProformaConsolidatedResultsofOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of pro-forma consolidated results of operations" } } }, "localname": "ScheduleProformaConsolidatedResultsofOperationsTableTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "MCOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIncreased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase due to reset provision" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIncreased", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "MCOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cancellation of JV debt obligation", "verboseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedAggregateIntrinsicValue", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised", "verboseLabel": "Increase due to reset provision" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicExrecised", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicGranted", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable at End of Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding at Beginning of Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm1", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTerm3", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted, years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermGranted", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermIncreased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase due to reset provision, years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingOpeningWeightedAverageRemainingContractualTermIncreased", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised", "verboseLabel": "Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercised", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "MCOA_SparrowtechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sparrowtech, Inc. [Member]" } } }, "localname": "SparrowtechIncMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "MCOA_StockBasedCompensationNonEmployeesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation \u2013 Non Employees" } } }, "localname": "StockBasedCompensationNonEmployeesTextBlock", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MCOA_StockSubcriptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Subcriptions [Member]" } } }, "localname": "StockSubcriptionsMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "MCOA_SubscriptionsPayable": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Subscriptions payable" } } }, "localname": "SubscriptionsPayable", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "MCOA_TradingSecuritiesRealizedLos": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "TradingSecuritiesRealizedLos", "negatedLabel": "Loss on sale of trading securities" } } }, "localname": "TradingSecuritiesRealizedLos", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "MCOA_UnrealizedGainLossOnTradingSecurities": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "UnrealizedGainLossOnTradingSecurities", "negatedLabel": "Unrealized (gain) loss on trading securities" } } }, "localname": "UnrealizedGainLossOnTradingSecurities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MCOA_UnrealizedGainOnGlobalHempGroupSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain on Global Hemp Group securities" } } }, "localname": "UnrealizedGainOnGlobalHempGroupSecurities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_UnrealizedGainsOnTradingSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gains on trading securities" } } }, "localname": "UnrealizedGainsOnTradingSecurities", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "MCOA_VivabudsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vivabuds [Member]" } } }, "localname": "VivabudsMember", "nsuri": "http://marijuanacompanyofamerica.com/20210630", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r474", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://marijuanacompanyofamerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r233", "r252", "r287", "r288", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r463", "r464" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r233", "r252", "r287", "r288", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r463", "r464" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r233", "r252", "r277", "r287", "r288", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r463", "r464" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r233", "r252", "r277", "r287", "r288", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r463", "r464" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesReportableDataLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]" } } }, "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesReportableDataLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_SupplementaryInsuranceInformationBySegmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]" } } }, "localname": "SupplementaryInsuranceInformationBySegmentLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r23", "r177", "r178" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r305", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r107", "r108", "r109", "r302", "r303", "r304", "r336" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a tax deficiency associated with a share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Reclassification of derivative liabilities to additional paid in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising cost" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r29", "r180", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r76", "r88", "r238", "r355" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionTableTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of asset acquisition.", "label": "Schedule of aggregate preliminary fair value" } } }, "localname": "AssetAcquisitionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "ACQUISITION" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/Acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r88", "r207" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Impairment loss on equity investment" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r153", "r165", "r172", "r194", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r331", "r333", "r346", "r376", "r378", "r406", "r420" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r56", "r102", "r194", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r331", "r333", "r346", "r376", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r290", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Net loss per common share" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r322", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Operating loss" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r322", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r322", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "auth_ref": [ "r326", "r327", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset recognized arising from contingent consideration in a business combination.", "label": "Other Assets" } } }, "localname": "BusinessCombinationContingentConsiderationAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, net of cash acquired of $99,393" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r31", "r90" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r14", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r82", "r347" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r100", "r102", "r119", "r120", "r121", "r123", "r125", "r130", "r131", "r132", "r194", "r218", "r223", "r224", "r225", "r229", "r230", "r250", "r251", "r255", "r259", "r346", "r480" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercisable price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r107", "r108", "r336" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value per share", "verboseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 15,000,000,000 shares authorized; 5,068,524,855 and 3,136,774,861 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r136", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "negatedLabel": "Less current portion" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Long term portion" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r19", "r407", "r421", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Net" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, net of debt discount of $1,122,225 and $808,980, respectively", "verboseLabel": "- Convertible NP, net of discount" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r71", "r102", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r346" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales", "verboseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r93", "r95" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued for settlement of debt, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r93", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for settlement of debt, value" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "- Debt obligation of JV" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r239", "r407", "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r46", "r267", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Convertible promissory note conversion terms" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r232", "r242", "r243", "r356", "r359", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Convertible promissory note face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Legal, accounting and other transaction costs with respect to convertible promissory note" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r43", "r241", "r356", "r359" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Convertible promissory note interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Convertible promissory note due date description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r45", "r415" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Convertible promissory note payment terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r355", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Convertible note payable, net of debt discount", "verboseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r234", "r355", "r356", "r357", "r358", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Less debt discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r208" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation Expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetailsNarrative", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r148" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at beginning" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r61", "r62", "r63", "r107", "r108", "r109", "r111", "r116", "r118", "r129", "r197", "r266", "r273", "r302", "r303", "r304", "r317", "r318", "r336", "r348", "r349", "r350", "r351", "r352", "r353", "r434", "r435", "r436", "r485" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedLoss": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Loss due to change in fair value included in earnings" } } }, "localname": "EquitySecuritiesFvNiRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r236", "r242", "r243", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r338", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE MEASUREMENT" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r236", "r242", "r243", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r338", "r383" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r339", "r343" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r236", "r242", "r243", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "auth_ref": [ "r340", "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Increase resulting from initial issuances of additional convertible notes payable" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r366" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Right-of-use-assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r74", "r88", "r187" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Loss on equity investment", "verboseLabel": "Equity method Loss" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r88", "r244", "r245" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "(Loss) gain on settlement of debt", "verboseLabel": "Gain (loss) on debt settlement" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative", "verboseLabel": "General and Admin Expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r204", "r205", "r378", "r405" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r69", "r102", "r153", "r164", "r168", "r171", "r173", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r346" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Impairment of Investment" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r70", "r89", "r112", "r113", "r114", "r115", "r122", "r125", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net Loss from Operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r103", "r320" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r117", "r118", "r151", "r311", "r319", "r321", "r429" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r60", "r309", "r310", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r85", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.", "label": "Induced Conversion of Convertible Debt Expense", "negatedLabel": "Decreases resulting from conversion or payoff of convertible notes payable" } } }, "localname": "InducedConversionOfConvertibleDebtExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r64", "r147", "r354", "r357", "r412" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r11", "r12", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r52", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r13", "r53", "r97", "r128", "r199", "r200", "r201", "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r192", "r428" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentSecondaryCategorizationAxis": { "auth_ref": [ "r443", "r447", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.", "label": "Investment Secondary Categorization [Axis]" } } }, "localname": "InvestmentSecondaryCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r188", "r190", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Schedule of Investment Roll Forward" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r442", "r444", "r445", "r446", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r442", "r444", "r445", "r446", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments [Default Label]", "periodEndLabel": "Investment, Ending balance", "periodStartLabel": "Investment, Beginning balance" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments and other noncurrent assets.", "label": "INVESTMENTS" } } }, "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsBySecondaryCategorizationDomain": { "auth_ref": [ "r441", "r443", "r447", "r451" ], "lang": { "en-us": { "role": { "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography." } } }, "localname": "InvestmentsBySecondaryCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r102", "r166", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r332", "r333", "r334", "r346", "r376", "r377" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r102", "r194", "r346", "r378", "r408", "r424" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r102", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r332", "r333", "r334", "r346", "r376", "r377", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r19", "r407", "r417" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans payable - acquisition" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans payable PPP Stimulus" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r235", "r240", "r242", "r243", "r407", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Total Debt balance" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r32" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r133", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r82", "r86", "r89" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used cash in operations", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r58", "r59", "r63", "r66", "r89", "r102", "r110", "r112", "r113", "r114", "r115", "r117", "r118", "r122", "r153", "r164", "r168", "r171", "r173", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r337", "r346", "r411", "r427" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non cash financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionDescription": { "auth_ref": [ "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "A textual description of the purchase or acquisition through business combination of an asset or business through a noncash (or part noncash) transaction. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the purchase or business combination, as well as the asset acquired and the noncash consideration given (that is, debt, stock, and so forth). Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Merger description of Sparrowtech, Inc" } } }, "localname": "NoncashOrPartNoncashAcquisitionDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNameDomain": { "auth_ref": [ "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "The name of the sale of an asset or business acquired through a noncash (or part noncash) transaction." } } }, "localname": "NoncashOrPartNoncashAcquisitionNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis": { "auth_ref": [ "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "This table is organized by a unique description of the noncash or part noncash acquisition.", "label": "Noncash or Part Noncash Acquisitions by Unique Description [Axis]" } } }, "localname": "NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncash or Part Noncash Acquisitions [Line Items]" } } }, "localname": "NoncashOrPartNoncashAcquisitionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionsTable": { "auth_ref": [ "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "The process of acquiring assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisitions [Table]" } } }, "localname": "NoncashOrPartNoncashAcquisitionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSES):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r19", "r407", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Note payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r36", "r105", "r372" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable, related parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total Expense", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:", "verboseLabel": "Expense" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r153", "r164", "r168", "r171", "r173" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Net loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r367" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Right-of-use liabilities - current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r217", "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "OPERATING LEASE" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLease" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r361", "r363", "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Monthly rent" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r54", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Total committed amount to raise for joint ventures" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation." } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/OperatingLeaseDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r89" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class B [Member]" } } }, "localname": "PreferredClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r250" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r250" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value, 50,000,000 shares authorized" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r21", "r267" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r7", "r9", "r202", "r203" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r78" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r83" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from PPP loan payable" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r79" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuance of notes payable", "verboseLabel": "Net proceeds from convertible promissory notes" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.", "label": "Depreciation calculation method" } } }, "localname": "PropertyPlantAndEquipmentDepreciationMethods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r214", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY, MACHINERY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r212", "r378", "r414", "r425" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r212", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r209" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimatied useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r179", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r30", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r285", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r285", "r370", "r371", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r285", "r370", "r373", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r371", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r80" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayments of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r80" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayments to related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r273", "r305", "r378", "r423", "r437", "r438" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r107", "r108", "r109", "r111", "r116", "r118", "r197", "r302", "r303", "r304", "r317", "r318", "r336", "r434", "r436" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r68", "r221", "r223", "r224", "r228", "r229", "r230", "r440" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Related party sales" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r65", "r102", "r144", "r145", "r163", "r169", "r170", "r174", "r175", "r176", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r346", "r413" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r67" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Payroll and related" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Summary of Changes in Fair Value of Derivative Liabilities" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r2", "r102", "r193", "r194", "r346" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r73", "r76", "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r35", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/PropertyMachineryAndEquipmentDetails", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r153", "r156", "r167", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Convertible Notes Payable" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r49", "r100", "r130", "r131", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r259", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r274", "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summarizes the Stock Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r55" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r163", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r176", "r215", "r216", "r431" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r157", "r158", "r159", "r160", "r161", "r162", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and marketing", "verboseLabel": "Selling and Marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrants issued for debt as an investment incentive" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable at End of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable at End of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r294", "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at End of Period", "periodStartLabel": "Outstanding at Beginning of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at End of Period", "periodStartLabel": "Outstanding at Beginning of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Exercisable at End of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Outstanding at End of Period", "periodStartLabel": "Outstanding at Beginning of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r290", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation - Employees" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, shares", "periodStartLabel": "Beginning Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetails", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r18", "r409", "r410", "r419" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96", "r106" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r163", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r176", "r206", "r213", "r215", "r216", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r100", "r102", "r119", "r120", "r121", "r123", "r125", "r130", "r131", "r132", "r194", "r218", "r223", "r224", "r225", "r229", "r230", "r250", "r251", "r255", "r259", "r266", "r346", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r51", "r61", "r62", "r63", "r107", "r108", "r109", "r111", "r116", "r118", "r129", "r197", "r266", "r273", "r302", "r303", "r304", "r317", "r318", "r336", "r348", "r349", "r350", "r351", "r352", "r353", "r434", "r435", "r436", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r107", "r108", "r109", "r129", "r392" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r50", "r237", "r266", "r267", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued in settlement of convertible notes payable and accrued interest, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services rendered, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r266", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued in exchange for exercise of warrants on a cashless basis, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit", "http://marijuanacompanyofamerica.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r51", "r266", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued in settlement of convertible notes payable and accrued interest" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Common stock issued in settlement of convertible notes payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services rendered" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r266", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Sale of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued in exchange for exercise of warrants on a cashless basis" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r102", "r182", "r194", "r346", "r378" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets", "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r251", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r273", "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/GoingConcernAndManagementsLiquidityPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss": { "auth_ref": [], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized holding gain (loss) recognized in the income statement for investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.", "label": "Unrealized gain (loss) on trading securities" } } }, "localname": "TradingSecuritiesUnrealizedHoldingGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r88" ], "calculation": { "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Loss (gain) on change in fair value of derivative liability" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r308", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r134", "r135", "r137", "r138", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of common shares outstanding, basic and diluted (after stock-split)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://marijuanacompanyofamerica.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403832&loc=d3e34039-112682" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.2(ii))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r468": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r469": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r471": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r472": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r473": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r474": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r475": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r476": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r477": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r478": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r479": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r481": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r482": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r483": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r484": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 64 0001079973-21-000818-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-21-000818-xbrl.zip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

D9MX9EDX5(LGMI?4)B9L[X"@=\B'1MU@'AL+\7<8#N/"X43;&*\R,M M8D=IB.U "N!A:9O(_[""&C216MY?J#]&AI>P/$3 MUJW$MXX!$9-G.(?+\]RYQ'L#9(UR]OH,L&OBT=B..!1Y'E](X$HZ,^B2/.= M7HE02Q"^USX//B(13KY2CV_06-5G:G+S&A.@)AX>2-IFT!8H!XV:1R2'1CJCW_=!'?M5F MP"XGPK@AEDKUE"C%P0QUS)B#0T7'ZRJ\A1+HX!#FL".^@PY@)25*<>WC-F'! MT&LKE.B(G8?:KY"T,5!M0DWE1C#Z]J,>7$,O5"40P4-%8I;*FE5LX4>NU!J? ME;+]FX[]]3176L*WE:#9/;TN=EE--]L:UT\+Q^/A*/?-,<%VC@&#LAH (C/U MM$DMF/]KQE8K,TM*UZPV'RF,AEM3,]+90/^(2ARFN7GW8;K7A#V(68NNS6S2 MA'B(,&["AU&HJ5Q@2:="_(/MBH0MPHR^[W8LRD^A>.8HQA]X1!+5O9[G#F]Z M/).2M8%3 ^O\AC<'W'P@6%S29B+M+_(= "MKN^[/GXP-1"+['P '3(V1N?XC MQ48F QM$JZ2_>BDGZ&!X+@*AU+2*VF0 _E 7%TX$(8^EU(HJ4G[$0P(X$(/ M\CB2DOW6M3![@ 2XGRS!$455W90,$Y));P!5-8?$"$Q>1TBF=PVB+.V@8M2@#94 MW'D^!]PD3\V2.EOL"$*-\:19I]ASM)C4ZS4*!>G87[DO"YK\GD5U+%*;F +1$QDC@;:@X D M+1QLM'#SLE3U"TN@( )_"Z\[= 50 M)D.8YD8F9\_ @KJV99/Q!%P#<_#>:H<"DHF\&+X"RW<9B^M/M.6N=2^6CFT6 M/\ _T\: ]SCB2PI*&I'' J$$A-,)T'H20$":7TC1\X=$CQZ:DL(P%XG#*--Y M6A/1-@ 47F?BSUZ$B/R>8HGP2D8'ON".8O)] ZTR\A +LY72$\DT5@U[=[7Z[Y9N#XYNZVN+Z#_Q*XVCS"GK,5MIF/)[E71?X$R"BN)R#YJ MDEX5VAFA>6.MK&'/XD>[BBM27)K*',$P]S*4>5PE#%DU2I0XNY_P?#[L\,3D M0%2MA1?6$TEJW T[J9IBM2^W=Z3#5WV;V 6J@:'T17EW:WA4=,R?F3HM/@#R MR^VHK0(L8=KR,GXI>#6W#0#F27-TG:K@$C4SREI\0USP)DOXNQ[C/BRN]2JJ!570T7J(KR'60.Z"Z'%T;ZP80+W+859F'QIKE%%CG7< MD 1K6(HL<%J6$TR!,*9U[>\)*O5# 0]RT.MDBJ]>8HA @#U&M0;7!M=Y[I0 M6226!<:]SO>SP/N;%L^'9"+(H GMFK1]9MW*,A %6V0!G\2Z:9^_A3Y;++>& MV]03=< )>A!Q9S(Y']95=,UZR][JJAX<.%HB*M[GO=?JPY'L, 1)20E][3>_R01Z)W( .>P.;-E [PU?'?(,V%INA MO(M[9J=?9V#(0B8SS]70ML_3:YRB%89^%6'@_AYQ=TTXOY9C[FM.=HZC*7JN MA"F@Y!GTT5@[8"(.$#,<.+^1OET1-$)F).,!].S GLG WFJ7A"Z)1+2_-[&] M,&\#G13)*U*HUX"3 MS4!37Q3^H2*A"'M"6S?,2D+VJ'!'30;-8IQ8\<"@>0N&+3:/R66H1L-AX:)4 MTRU2!TB&*)4+O H%/QU2A2'WGXHZH:PW,.5%V&J@:T@6NAWN:0?-)#&6CY,:TI2.(\L[4FX@B8 MVF5B1L(MBP<=(]:(B6,SV\:O(<,:5)JFQ^9/M0)1IWYD>E MG6$\U>#=<+!F 6T44 T1PTPRXA/>%CKJ,6E$ H3:S0B_ !%_F('$9(H"=4-# MA2R^'N??L);4NS&7Z8:7Q_)$)?)U40")*@CLHP?Z'":1R-I'^'Q_3WPXL;]%7C !070)#/UDJWF>FR.2KJ@! M+R->H]R5>0X1M<%@Z#F4 M4C3[<8%"^0S&Y'RLHT3TB'1&GCXW$I7C;_?W:I.;M%@4V8EAYRPH^])5,@I[ MP]B\-8R@)+!1^F&6ESS0U$8^RBK66%*!B[OA4IH>X4 @0AQ@\TTPGH2/D8I& MT3GQ)(/E<;SY$1&9[,N-R&33B,QO%I$IM<:.';@EMVB,O672T!:,R*PYC>^" MW,>:HU[@?WA;C0(<\S%V?2C T+7.JC<*/H7DC:@ ] MD8]!&G[T.==7*%&:F;/V)!/>HQTI:L.T.A?' 9"-/FRAC4S[,L/.8](-/1<=X M (S\Q?P]([YY_-$*4[L%E1 >QPC,83>N2+"?H>J+%:3C?C9%*F&GN#9)^_$C M"(>0\QA/V7E"N;F_0DRG"FDO^B6E#1R(D/['7M6TXQ:BY=I.P^(=,I MGE\8IC>)F&;DI]<73G1*S/&3O"DT8[P)3Z)#B+N=?/NCT-_6%.ZVA<7U@X^V MQK\NG8S=^-4Q+G98:-LUX]_R1?VS>5.BG'+I?Y2GVEIM>:P@1AB_V!6(44-5 M+.4+ZT 0Q];B?(V":,H?C1N/R<+J6DC>)L7"Z!?B,S:]7\7\'I<-,8>M)IQ$ M2GD+M5]^ZF&H(>K4:8A)D ,XZGJ6Y"..%XX]F'>NS?0%1ZT;WVKU+O'.4&)) ML @7B>QWEGC%.G5\(AZ$'A^'LW">J<.YFQH&#C-W0C!3,RC ?)D*2U( ]#V> MC;VIO,OYP3F,2/'][>]QM(NV*>-M,[R,'"9T\&%@44R%)^O"6<,T=,025)<( ML*K/1=2ZA=%SF?,:RW5.SG-^JUT+P1%6I]'L!BZRJ7Y5U*+-RK9U>1M>*8CB MYZ($G(YA=["/@D@(45.X>.D9X)3K_>1M?+'4S_)Y+6L4.%>+8Y76=(K44_ ' ML5D8!5$REIJHK0C.!S.U_3!56UM/IC;O:_>X5&UM#9G:Z*!^=*KVD_27&9G: M^WM/2-5.U&"2,[47+0K;1FG8?$832X%3BD7I"CA^S+2#@ECYI]HS1#;%E$7P M//1?7!)0 **Y9Y@J9I6E)'&=.CE"OW@Q#:9[S*BFB6RHA C&E.25E4E/*KF@ MA(D'"'DJ/K[^QBK7/COOG@#J(>'ZTQISV$4E_L76N),]JGP(;O\=-*=+W![6E<8G^/UA"CWT3W61IA MP3L5J."C)L-4KBC2M,6A(Z\=Q?5(F5-"D2:3:5G&O8 S-J$*>(L+/GFA;Z , ML) [A?F(OH(%FVS0A/VY:XZ)_SH!!(73/=S]K:2PEX6>;XV;[2^E]K'Y_895 M=I3K@%7^Z\-7/W-3REZ=6V"5PXFV;H9'F0R49LU[V?IR+"%]1BV^A&V&(P?@ MK-Y('7F$MBP4*BFOBN@R#D8"&S#*P\,Y'19EX$>=M\E\QO=N M%$>Q5R\JE7B)EY;_\P@(S KPIPG,K*B8.?NIUCCG#FK#QN7EX=^[VCBLTAK[ MG<;@YOO'9C7_@[Q$T7&(U?+S:'B@!1$UMQV%-PH>J&W^L*6?&G7@.3BN+V(N MO$.S/# ),'Y>,#5_TK<)_0GUY00H7LW!#/\ODC:A5J&3> M#ZB?A[$>H;,>:HW;9]\\-_CVH?AAW5/#GR#C/UY^^?[CQ]?#6@TLW9H4$=&Q MXI)]H\G$5QX6!T8RU1=2U_.L,!T0;2IIMYBR5I//;>$VX5N-+R.$MZ4V#8:7 M\J@%#=/R>V 6'J!O1@0(9([HU#9$T!8%:RAF<5@/?3%!&9#N\TA"1DD%O(\O M;5L*V3#\-#! T18;[X'2[7K"H(_"[L(JM,(NH:J.$Z8:;[;C;@@H @@89^?H M0)2X%?V])NW74]>CP7/=H2V_Q8EICMVWRM>TQI?7/^[/G/+M8<_:75*]/KOQ M?GV_&)PZ75[UR8U_Q"!Y+MGJ=3L^JAH?X.R)M!YRX,>V:8IM/AVH'GMFF;?'+16^TL>CITL/LB30H7Z$C]6=E82.N:KR>CXQ%10)R&2K,_ CN@\.+=K:@#=D<(% MYM%VQ &..,3$W#F<-D>CZ,(Q<[7YVWAHRMRC-A$?-%?SS[NKG/QMA2"4=[/BX$"0ZE+ M <2E-LB8A.-3\)D/T1,:&W[69CSW.&2CI'=2'^4#"T,$]!/V)W]]6C\]?Q/I MH4IV!,H&5$'O>&F8)2^8""Y2A=TV-NWT.XS7.:/XX_LQN!M5/H6"R9;2FL<$ M&.^5K?3_HP-UE:>D+(K>)P[+8R1*&STEF+2_QYNOBQXO)NM+O[%X."J-XXE# M/&HQ]4<"/KF*E4EOV.F#MR,'N?R#YP^WU>0H79EVARXO>10N;!&>OJPXDKG7 M;[7C*&PTU45:GXB+)RZY63>U'YQW%Z@_*,:\U+,>:HVSGMG_^OFZ\>]P5U,9 MJZWQS9?K+Y]^!I=>KHQ.:HZI"?4'&S5=Y3["%&2,!7K4-8HBH?RO4::R:YN8 MC-#Y:=R$,PC"SIKX]8TB4A-41':(-'RDA##/B8K!SJJ37QRDWX5M.,F66DT= MT/7XU5KC3T>6T?F4NR@<)L5''G-)Z(.:T3IDQE#+=YKX[?_EZ#]/P,]B:_SK MQUFG6OA^=5L%JZU)X6$"!F]?)L&A'6@G_8'MCMC"PNTQOK6EX##?+3X-I2MU M'FZHPXF=$QM&6F^X[PYM^^!H30%':7F'2/6"46"KL,A7EKOLRO9Q'^Z.Z M"Q(US,"$!'I&&3@BTPVB.'^L"P7F#OHR[H4Y2.5L!?N;Y#-OM8NAAY.#PU[[ MX9\.2HO$=A:(YTR#6HQOBATZA&-B.RN9&J?T&..&H=(/0AV!C"(P&,7"9+B* MN%;Q4)LCLFPW-)4D,>-]LOW$U/>G7DI;"IO*845O.&3 8Y@M 98GOU$R>A^9 M?+=I-D($HB(@9;H,?9FYH6;-+@X<:I. ?S> "?%)'%$6C4I;L8 MRA$S*=J6*7+-?B('^35T9?890.)GV*L3AV 3;QI;-H4%(KYI^:I=YL1RW&ZP28*H+#2T0\MQ^^BYY]J1=N::S!8O M.,!KP:]%"6!]_'.,^HC#>+RPDF?FA9E\?-KA8"@9.7Y"C2'^W#0@)QA%%!)5 M0Z"3(=)'ZSY*,'3.WD0 &;V=QL '>2M_>D4ATK\"3[Z94I ZABW94> .7LDP M:A26%6\MPCO%[F5GNN+; G(T^:D,\U?4#WG/.OKF8Y4O:G%6BJ1>8,[<7'8% MFU.BR[->4RW\=WK%F6S]L>?]RWI_0I5 *#PQ9C=)C]H,>U,*>A[[B$9 C$T3E1+@"%FHE+2+RC,3.R8^.K2"QEA@ -5.=+&8.O#>RA+%\6"9=3(#)W+G:[ ;RBK#>E5T[8+E@) MLD6!JN@60)H9:N,C0S3B(<[.9Y^0,U#HHFXH#R=P6"@.Y$[%3#3>WUI%3W1Y M"D58Z"+*_. AJ%Z=4$M[!R>*'2G>"#CL/Q!VYQ*C050JXO+9EQIR,!IPP1IB MIB::'Y-ED_@HZ4UA]?=,Z"&V.*YFNPYJ3$\$Y#O<,)P^=GRL1$47<=3IG%^M MDOS.IQR#,66'X!$=R-JHHJ#+=1O'B7O @8+$%)9)ZJ'XK*3C9=FCP6D-;;_:32/#K\/+_[Y ML2H"Q#0^^_C?B^)]X[MK/7;5%V5_/2&=:)QU$#M,S$*+0RC2,D7???$(S\1Y:@+R;MW)8LH2<:KA(.YV4OY@R-\O6]KG!,'T-L4/4NXKG M-U*8I_R^JJMT54Y8[3$^6#+T(DC*JZ.>8G1+_.'88X03Z_/=:LNX;F(#:MF#[H>8X3]K_TWW"^]#!UYL:7\N<0R^5VDE+<1WD=_EG4MG M, MXOWUVR86UE H>R1P%G#_EM',']XN0FVO&$:Z5H_8\V1)Z#;9A6CT!ZD&B.0- M#$'[H5\JGLX2:U9+F3,2#KKLK.Y3'G( >@)-:*?O$(SX3Z!A,!RO3HD72!O< M;2^R#]3R*36FR6^#7Y7:AL. EYIQ%(A"FLZ0TOI1=[JC=JAA/34VQ,'OV*-8 MO !]U:L)WX97\Z@HKF@+(OIAR.9%^WM)%R&["'DF#^D+98XK0"8V-O6I1/PV M6E;@M-*PA&)+LG@E//GZ.UU2NME4ZEW#=<)//HY_? M_JX%/Y(*J=9XKTNGZ.5:X^/,<;:=A+"4->4?M'[,9\I]T,+3/J)CB5WD81 M6B5O#'^7P4HEI[^+\UT2]S'Y?IZ^@D@AY[_PO'\U+*=KE&7EN &E"-*WI7'! M9=G4/L5*0OKM[TGQAZ-7\ E^/^J!)]NTMT4_]%BK<#X=AUJN!IXKZX9XYJ;( M2D5G@-'IQ:-<8B6.MK&WV$D53>O8V]/B M6H67&]YD:]B^^=KTE]'=?+&:9I<)MZATP4%=W^%D\] M6")1-,T-?3ZQ2?'67)H;JE7+.YL;^N="&9CZM-N*Y@#L1@HF:(VKRL'$SWJN M#8^'3N[I+,QYV97[>TNE5TX%%I5@HLRWBL5:']KD_I[>4,I**@#2Y)$TN63@&GQ+G M:HES@1>^U R59YVG\M@,E>QC&Q)-.<_6WRCHQ/ PK.9?,(\"G_/;3A64ID / M/-D:'WVXJ/]C5K*CNKFCO:>.6^/SLOLM?_.]FFF:K][+(R'>\#CP5KK4'8)1 MWJ%14N%F.(+RYLE2<]_?:PN1BW+1832IV042>(WM3-_(X<%2OH4*>I3LD]@L M0YF'U>]C%PN>NZ14!YN3+=7>\LR*7.;=L64/R64SM7D1)9>#E87;S$5]$;W@ M)CX83JSCZBJU)L&ZUJ3=J9D^(FD)MD?S,\-1(V!(X8P2M#'X(&CA$R&;47R1 MF=+%%IV6QW'YEFYEN';FV*#IC5@X&0*^-HP'D@/)Q3A(X_,;R9F/C!C8:M+9 M8ML/W7JC 4[&(YF,V@).A/#Y0*#(:49I7,+\'@R]#MA_+'ZY@G]*!!'M^K@U M,GW9!!Q -1YZ-VR)1J\3>@]*9P =#D/AY.<4Z1OP.G_HAWLRT27K"B;-[0@< M+C-CH)."D=>(HQ]:A+5[$,;"4QL"E* MX5/_;K(V' 8C[[*-7(07/#G ZAY$V)B,%OSO/F4;!$);!%9"*1'*S-=-]IB[ M$.-KL>M;4'-,S&ZA\7L/SF(.9S M=:3WB;L.L)G_2 8NF1RF,^P+[Y+)E"Q6/A*J[U+',C&U3&G%JW3T=L*TF4!M M:4HM0\E+PZ>*XAAE&@U)J_$-6GQ8&V7V=+F_C%1%0?UOM=/8U.DP7P;Y$)X/ M@#M0X+6_%P=8F$DJ0"8&0HI3QOC]9*_FXB*8?ZP [(Q8@2^Z7L-_6ZVP_W7K MX:4.1YCC4;NW_$6^?4:MO<,VT.H^8CXGSI]>++;7Q+@A+['B-HX1).5KJ'J]ID<]6E[7,X)]- M7F&KY7O!P<$EFF/\2?K]S'*L_K OOC.^N9B/:4W 8*UW MC9MKQ?86:_Q] #KO=CO9;/4 M.:N8Q8:Q Q>K[FVU%UN<=;&XXL9FP\<-]D>D#A9?;NI@,4T=?(FI@_.3!X_- MSZ;3_.?"^M1[SB/$ZN'4T_E6S/'$A(;$9UKCSD_[QX?OPU+G?E<'B('98EQ= M>'FC\Z/7Z_$1"6+LZS8'ARD19I'(2"D!_K =4/U#'JXSF]'W]Y3]'HC"F&;D M]I'5&O@L?T3XH=X(^SJ=$1&VW MADYHH-"8'AXOI5E#4\X+&1J2F611L9GVC884).S&XIYMG,A@A+-VU>'T:FE@ M;((IGR!JTTSP6%*&KW;5DR8.K#;TQ7P@;BIA=SJ,@M,?Y(GCQ7@R($W;X+XD M^<773<:TA@LO++W9I,?B.)S3[5_*$>+GW>C3&IJA -@)6E?'%2VZ1&M.DGZE-Y:U;?@^UN)0 M7H2@!C'DF@+"/C5$#J@1HJ!L;= ;^>0?]5D RC#A+Z8,,5 'R <8_YPZ#LI< M.95BB+@-P&'7XOW5<06:_QM?(/H-9Y002>&D%^DD?<1VY#["3!R1!2C.*EB( MR>ZY;U?9[/^*=Y(S>W]O-@SY>'D:W!T-KH^#5)N":-+!7T?%SH;\HBQO0R<. M?G]_CS\0B^&C?Q]9VRT! CW^G$V2VQ]#D;>\3SI%(";N1'7'!IYKOPDO\(9L M=_X>;';O84;4*+P^2O1]\/["006/O+:),C!D]\CQ)>0[81:O%?! 0>2)#_WS MLD2<8$$^. V#I0=1$"9B1,BGF4'"3' D7G,0ZTA_UV.TBB&X,,F;<.FVD&_QUB@.!F-P< 6B8D33W=PAI%G&; 3!X4H]VU1X>>'6NU" M1.1CN*K.!Z0X'$ $1S&JT0='R1J7M="UF20BD*C/A;.4]28>Y0 M0IEEHZ+#XTK[>WP=.1X2 M+,V>ZY'&)B@?)U(BQ#$N-P#5S>*YB^'F^ PLGX8FXLOC:A:./U0+3+GW6#+ MB0/R_O/")QX[%==5XQU-YP 9.7N)-E>\T@IYW:")*>D MX9NHKEB=^P#RCHD*740<&OPFYPT3V[\U+)O(DB,2C\/BN,P.GQJ,#_!QI'([ M"[QGHT.D3@$7OB(FG'=#?5!1!Q/'1JDNU(6>;XW[=X$_' 29T>?\CBK*N=;X MKGEVX1:-ZI/7$0GHR-R^I3:XI<,QQ;+@K0N!ALLXXAVLSSC/3H*Z@4 M."0N-LD*:B8):M0Z<##> ],)8T-IYS_9&G>:_>O/QT>F64BJ.MX%\C]IC:N' M[->'B[[Y*U-^]5XYTM9-8NDWC^AVA 43 M#OF?S+CIDCRY>VH&<3;YND_X\HD1LHF1P\J^<+,/SAB>>LFKA;'\J4.%LZ6* M7JY,CQ;6! XD3FG./PRA3 BAS.8@E F#>YE5P:=0T$O%ZDSPA+,$K7M>0^.C M?@DXAB)C?R\F,_B$<754LTX^BPE8;':P)KM!@1'Z_C@[6SQK=J'G6^-_SLVC MVEGU;@.&40E9\1=;GM,0IMV'B_*X M1#C8F&9^H-O+ZBMOX9L-/1[P##F=>-DU6K#AN;&]H>_./?=46R&-CX86$W&% M9A..KW2P(LZ]\8P!F+*HTACPPO-IZ)!/T\2D8&RY!/O@&9.N([OP&52\P#R: MQ2O>RH(PKC#UF:._0D7(0C2.FP M)5-LHSW+0@MT6' M7C:"LD=J+P(TZ^4@U,3#RXN;]A=CQ6/874K,5:7V)!-W MI(,=T1\TSVJ75T_J)+4DDTKJ(C4OSZ+TQ4O,LYB995%LC;]U&K?M M\[___G?0W9A>L.1 HU;RJ79V7*BU1K' M6K/^73L[;UQ];&HGC>.38^W3=>,D!F]C"/DJC7^3H^9 MP*7.NY.ZNZ+?'H[$'U4;8#'V$^K1E9QJ)RSW5M#$OS:/&L?]'W<-;*$X[ ,< M1_2"/[7C4%G3#K3F]1E@[S^(4LWZAT;]M'Y4 PRK'1V=7S>NZHT/VL7YY_I1 M_:2IO3YF >A+_ILD.JZAOJ!K'YE]2W5(<(&&XQ^(6YS9@&N"?SY09\S%=$*I ML2QZS=-_A/3A%6_XE&TF5,TN0I8AUXN;.H>UUKCI7!9_7/SXEN_8(3RP\L V M1G]B(Q*VD &$@F*#QTBL@X:WXL?_]RH?86&A>MR:\-?D\UDE1[DI395#,4]0 M'-;G&+1 M4<[+]'XIJ4@IT*O%24Q?*="#&_MCIV'^RXYR*= CH&=:$\[.E;*7+]?FSZ!Y M=/N];*= CX!>XJ NQ#S,*P-Z>=3X:-H?QE8FFP)]"NC9]0!]U&O8XY/;'_^, M?VX'Z NTAUE>;9NA]+\\C"DO?GDKA0DEI*:BFI;9+4UBJ2MR1^$YJ,)[9/7PO>"_>5?/,A];K,1L&. MS3*2,\/K]/A^119=-H7JDZ'*$T\(J)D4J"E0=Q>HT_2?2:&Z>E1-@;IVH#Y[ M1653MSIY6/6** R>'C8];'K8]+"_Q6%3L;&+MS+#9W4$[VM[UHS4D*UXKC:V MI=\5 7ZKPZ;8_ELB@"J$PF!OK ;N$GN6#)G?LF05UUQAE32_$M.K27S"ASY3_F#?%9D#;22DP86+^Z+E_3E"WJEG)LJZ9L/M+5>V%P> ME*+I[J%I(=Y"=BUHFBWIQ7PY1=,435? 3=>'IL6L7LA,%TBG:)JBZ4)H&JO9 M7Y_0KV3U2C9%TQ1-ET?30JRUQ)K0-*=7BY4435,T70$W7:=N6M#+Y5U73A?V MKR>Y++[UK( ]Z'A_MFZG!5Q-ZV,;.^'.W%.;/>X.)#!U]MJBL>C&_![6H?7)S8WG3M6951DWO; M5-*M6.RQB;:;(9"G[&J=QG<,9[<9Q,P5]4Q^X2!F DYMZV93=']IZ+Z)8&A> MSV>R*;:GV+YU;-]$3#57T>'@*;JGZ+Y==-]0;#8/NGNFF*)[BNY;1_=-Q'CS M53U;63AVEJ)[BNX;X.[K0_8XK-.X?-&ZF%S0-?+J7HG*+S M!IGS&N.[>3U33M$Y1>%LE[*%E)T3M%Y[>B\B?AL(:^7RPLGFSV? MBTS1>>?0>1/QUVI6SU<6SJ[9\D6^W.AK2I ;(,A5[B3EU"EB[!I(4L1($2-% MC!0Q4L1($2-%C!0QGAA%+RM1]-#H/+D?,,=G?JWM!V@LMJS#UK@P_O7OU?#B MYJB274]LG0X/5JR+FW!A-7B<>;;EL 5F_2P-*7'6-'MDZJTO)'LDOEEII>YU?39@J+X-WN&QPX-GYE';A_585+ 6^-^]MPQ?OU= MO+E80N-?-!2SLJ,W [?S4Z-C\)>JATG1>R'T/O!9Y\"Z/^A9ILG@.X K.>N^ M[=F9:J: [ZKDLCGY,OYF+654S^TFB\DWF5[D<[O(4GJ1NW*^IUUD.;W(73G? MYK*#DM6N;>:]9&=Y/ MID156N/2QV\G[<+7[/>&M9U>M\N;6/Q4FN$($RL\7$JLFR76F>BUU8I#(-CL MPGU^=N'&4HS<'D9NI&JPF-$KE:4S^5.4_+U02&JO>RF:Q>J2[VAY"8\$>6"GB\N71^=8N3OA9&;\4:4P-[> M2;F=[(XX:3$.B(.#"V/DN;8-$+UDMA$P4V9XML8709O],"O]^]/G$.,5!XD< M$.(\&A,'2DEU(Z1Z=G1>^W,F5FW3!U',Z]5"JLKLT/EV%1LWX7\H%O1*:>F^ M&"DV_C[8N G70S93T2O9U!NV0^?;273-6I9T,I28[&ZI*[L,Q&WAP,H,GD5]V:L4S=O_WUV/C MF64[J.?@;TV+1;?A#U3O89NNA:R>KZ;*\PZ=;[=0<"/Y#"D*[M;Y=@L%-Y*_ MH)6"NW2^W4+!3;@(\GH^ M5]E%%'RXX/P#

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end